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1 INTRODUCTION 
_____________________________________________________________________________________________________________ 
Note: The doctoral student has published some aspects of this chapter in the underlisted publications. For details, see pages 109-111.  
• Accuracy of glycosuria, random blood glucose and risk factors as selective screening tools for gestational diabetes mellitus in 
comparison with universal diagnosing. http://dx.doi:10.1136/bmjdrc-2017-000493  
• Gestational diabetes using diverse diagnostic criteria, risk factors including dietary intakes, pregnancy outcomes and postpartum 
glycemic status: a nested case-control study in Ghana. https://doi.org/10.1101/582239  
 
This doctoral research focuses on the prevalence of gestational diabetes, validity of screening 
tests, clinical risk factors and associated maternal and perinatal pregnancy outcomes 
including short-term postpartum glycemic status of women diagnosed. This introductory 
chapter is organized into three sections. The first section gives an overview on the 
epidemiology of gestational diabetes mellitus (GDM) highlighting the global and regional 
trends, challenges with screening, implications of recent updated diagnostic guidelines and 
the effect of GDM on quality of materno-fetal health.  
In the second section, literature on hyperglycemia in pregnancy is reviewed narrowing down 
to gestational diabetes: the disease burden, pathophysiology, risk factors, maternal and 
offspring outcomes, screening and diagnostic tests, management and prevention strategies. 
The third section describes the context-specific rationale for conducting the study, the 
objectives set out to be achieved and the research questions and hypotheses that supports 
these study objectives.  
 
1.1 Epidemiology of Gestational Diabetes Mellitus  
In recent years, gestational diabetes mellitus (GDM) has risen considerably globally and 
Africa is no exception. GDM is a glucose intolerance that affects 1–14% of all pregnancies 
(American Diabetes Association, 2015). In 2017, 16.2% live births experienced 
hyperglycemia in pregnancy of which 86.4% was accountable to GDM, that is, diabetes first 
recognized in pregnancy (Cho et al., 2018). Over 90% of cases occur in low and middle-
income countries (Guariguata et al., 2014). In Africa, prevalence of hyperglycemia in 
pregnancy has increased considerably from negligible levels to almost 30% in some settings 
within the past four decades (Macaulay et al., 2014, Hall et al., 2011, Adam and Rheeder, 
2017). With 14% prevalence in sub-Saharan Africa (Mwanri et al., 2014), health systems in 
many developing settings need restructuring to tackle the surge. However, consideration of 
gross variations in screening and diagnostic procedures and reference criteria used are 
necessary when interpreting these trends.  
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Screening denotes scheduled measurement of blood glucose in all pregnant women whether 
asymptomatic or symptomatic, and whether ‘at risk’ or not, followed by diagnostic testing in 
screen-positive clients. However, specific screening procedures and outcomes that should 
indicate diagnostic testing remain controversial (National Institute for Health and Care 
Excellence, 2015, World Health Organization, 2013, American Diabetes Association, 2015). 
Despite recent diagnostic criteria by various health regulating and advisory bodies, opinions 
are divided on selective verses universal screening, and the diagnostic thresholds (Agarwal, 
2018, Cundy et al., 2014). Selective screening, also known as routine screening, is where only 
pregnant women identified from screening to be at high risk are booked to perform diagnostic 
testing to evaluate their actual glycemic status. Universal screening is where all pregnant 
women are tested irrespective of their risk status. 
In line with evidence from the hyperglycemia and adverse pregnancy outcome study (HAPO) 
(Metzger et al., 2008), and recommendations from the International Association of Diabetes 
and Pregnancy Study Group (IADPSG) (Metzger et al., 2010a), the World Health 
Organization (WHO) updated its clinical guidelines for detecting hyperglycemia in 
pregnancy in 2013 (World Health Organization, 2013). Similarly, the American Diabetes 
Association (ADA) updated its guidelines in 2015 (American Diabetes Association, 2015). 
The WHO recommends one-step diagnosing using fasting plasma glucose (FPG) between 
5.1-6.9 mmol/L (92-125 mg/dl) or 75-gram oral glucose intake followed by 1-hour 
postprandial glucose ≥10.0 mmol/L. However, the 2-hour oral glucose tolerance test (OGTT) 
between 8.5-11.0 mmol/L (153-199 mg/dl) performed ideally between 24-28 weeks is 
preferred by the WHO. Conversely, the National Institute for Health and Care Excellence 
(NICE) considers 2-h 75-g OGTT performed between 24-28 weeks as the ‘gold standard’. 
Compared to the current guidelines by the WHO/IADPSG/ADA, NICE’s criteria for 2-h 
OGTT is 0.7 mmol/L lower (≥7.8 mmol/L) whereas their fasting plasma glucose threshold is 
0.5 mmol/L higher (≥5.6 mmol/L) (National Institute for Health and Care Excellence, 2015). 
Meanwhile, the 1999 WHO diagnostic criteria for FPG was ≥7.0 mmol/L whereas 2-h was 
OGTT ≥7.8 mmol/L, same as the current NICE guideline. There are concerns that lowering 
diagnostic thresholds would unnecessarily increase GDM prevalence and burden weaker 
health systems in low-resource settings (World Health Organization, 2013, Cundy et al., 
2014). Random glucose or 2-h OGTT ≥11.1 mmol/L at any time during pregnancy is 
suggestive of clinical (overt/pre-existing) diabetes (World Health Organization, 2013, 
IADPSG Consensus Panel, 2010).  
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In Ghana, GDM screening entails dipstick glycosuria urinalysis, tested at every antenatal care 
(ANC) visit. Values between 1+ and 2+ on two occasions or 3+ and 4+ on one occasion 
warrant OGTT (Ghana Ministry of Health, 2010). But dipstick (reagent-strip) urine testing 
for glucose is not without challenges. During pregnancy, renal threshold for glomerular 
glucose reabsorption is reduced, leading to increased glycosuria at some point in about 50% 
of all pregnancies (Alto, 2005). However, hyperglycemia without detectable glycosuria is not 
unlikely (Cersosimo et al., 1997). Using glycosuria as routine screening test could result in 
missed (false negative) opportunities for diagnosis and management. Although in Ghana, 
fasting plasma glucose is recommended at the first ANC booking, and at 28-32 weeks, no 
diagnostic cut-offs are provided in the standard treatment guidelines. Adherence to screening 
and diagnostic protocol is not only discretionary on the healthcare provider but also dependent 
on the level of healthcare. Making diagnostic decision based on maternal risk factors is often 
the norm. However, there is no clear guideline on the profile of risk factors or the number of 
risk factors that should indicate diagnostic testing. Macrosomia (birthweight >4.0 kg), a 
cardinal adverse neonatal outcome associated with GDM, identifies 3% (Agbozo et al., 2016) 
pregnant women to be at risk of GDM. 
Predisposing factors like ethnicity, first-degree relatives with diabetes, advanced maternal 
age, short maternal stature, macrosomia and previous bad obstetric history are non-modifiable 
risks. Focusing on modifiable risk factors like obesity, high parity, gestational weight gain, 
sedentary lifestyle, excess carbohydrate intake, abnormal lipid profile and hypertension could 
reduce the incidence (Ashwal and Hod, 2015, Mwanri et al., 2014, Metzger et al., 2008, 
Kampmann et al., 2015, Hod et al., 2015). Amid the nutrition transition, the double burden of 
undernutrition and obesity resulting from lack of dietary counseling, unhealthy dietary intake, 
urbanization and sedentary behaviors is fueling ‘uterine diabetogenic environment’ and 
insulin resistance (Hod et al., 2015).  
Adverse outcomes linked to GDM include preeclampsia, postpartum hemorrhage (PPH), 
obstructed labour, cesarean delivery, macrosomia, birth trauma, birth asphyxia, neonatal 
hypoglycemia and perinatal mortality (Wendland et al., 2012, O’Sullivan et al., 2011, 
Metzger et al., 2008). GDM affects breastfeeding (Hod et al., 2015), increases risk of 
childhood obesity, metabolic dysfunctions and cardiovascular complications in mother-
offspring dyads (Eades et al., 2015, Kampmann et al., 2015, Hod et al., 2015) and leads to 
long-term neuropsychiatric morbidity in the offspring (Sacks et al., 2016). Increasing obesity 
and pre-disposition for diabetes have triggered an inability to withstand the metabolic stress 
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of pregnancy. However, in rural areas in Ghana, prevalence of maternal obesity (4.3%) 
(Agbozo et al., 2018) and type II diabetes (4.0%) (Sarfo et al., 2017) are low. Unlike type II 
diabetes, risk factors and adverse pregnancy outcomes associated with GDM are not well 
established in Ghana. Extrapolated data indicated 0.5% prevalence in 2004 but a decade on, 
the prevalence has risen to 9.3% (Oppong et al., 2015). Given that this study was conducted 
in the national referral hospital, lower prevalence is hypothesized in lower level facilities.  
Many studies in Africa have assessed risk factors, but evidence on short-term outcomes is 
limited. In this doctoral research, a cohort of pregnant women was prospectively followed to 
assess socio-demographic, anthropometric, dietary, obstetric and physiologic factors that 
increased predisposition to GDM, short-term adverse birth outcomes and postpartum 
glycemia. Prevalence of GDM in primary and secondary healthcare settings in Ghana was 
assessed using the current WHO and NICE diagnostic criteria. Accuracy of screening tests 
(dipstick glycosuria, random capillary whole blood glucose, and presence of maternal risk 
factors) were tested and validated against the diagnostic tests (glycated hemoglobin (HbA1c), 
fasting venous plasma glucose, 1-hour and 2-hour postprandial OGTT). Effectiveness of 
universal and selective screening approaches were tested and diagnostic thresholds that 
optimized sensitivity and specificity was evaluated from coordinates of the receiver operating 
characteristic curve.  
 
1.2 Review of Literature on Hyperglycemia in Pregnancy 
Hyperglycemia in pregnancy is the most prevalent metabolic disorder occurring during 
pregnancy. Globally, prevalence is rising due to increasing diabetes mellitus resulting from 
lifestyle changes, shifts from consumption of whole grains to refined and high fat foods, 
increasing obesity, physical inactivity and more pregnancies in older women (National 
Institute for Health and Care Excellence, 2015). Hyperglycemia in pregnancy is divided into 
two broad categories: (1) diabetes in pregnancy and (2) gestational diabetes mellitus.  
Diabetes in pregnancy, also referred to as clinical or overt diabetes, presents in pregnant 
women previously diagnosed with either type I or type II diabetes. GDM which is 
hyperglycemia first detected in pregnancy, is a pregnancy-specific glucose intolerance 
(National Institute for Health and Care Excellence, 2015) considered to be a transient form 
of type II diabetes. The rapid onset is triggered by the metabolic and hormonal changes of 
pregnancy (American Diabetes Association, 2013). GDM is therefore any degree of 
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carbohydrate or glucose intolerance that is not clearly overt diabetes, and results in 
hyperglycemia of variable severity with onset or first recognition during pregnancy 
(American Diabetes Association, 2010, WHO, 2006a). 
 
1.2.1 Prevalence of GDM 
Among all forms of hyperglycemia in pregnancy, gestational diabetes accounts for 87.5%, 
type I diabetes accounts for 7.5% and type II diabetes accounts for 5% (National Institute for 
Health and Care Excellence, 2015). Prevalence depends on the population studied and the 
diagnostic procedures used. Over 90% of all cases of hyperglycemia in pregnancy is estimated 
to occur in low- and middle-income countries (Guariguata et al., 2014). In 2013, the global 
prevalence of hyperglycemia in pregnancy in women aged 20–49 years was 16.9%. South-
East Asia had the highest prevalence (25.0%) while North America and Caribbean had the 
lowest prevalence (10.4%) (Guariguata et al., 2014). In America for instance, 1-14% of all 
pregnancies are complicated by GDM (American Diabetes Association, 2015) but in certain 
populations, the prevalence is much higher. Prevalence in Qatar and India are 16.3% (Bener 
et al., 2011) and 17.9% (Seshiah et al., 2007) respectively. In the Atlantic Diabetes in 
Pregnancy study in Ireland involving 5,500 pregnant women, 12.4% (2010 IADPSG criteria) 
and 9.4% (1999 WHO criteria) were diagnosed with GDM (O’Sullivan et al., 2011). 
On the African region, type II diabetes accounts for over 90% of all diabetes. Systematic 
reviews suggest that GDM prevalence has risen considerably from 0-14% between 1979 and 
2013 (Macaulay et al., 2014, Hall et al., 2011). A systematic review on GDM prevalence in 
Africa showed that in 1991, no GDM case was recorded in Tanzania (Macaulay et al., 2014) 
but this increased to 5.9% in 2013, indicating an emerging public health problem (Mwanri et 
al., 2014). Also, GDM prevalence in Ethiopia in 1999 was 3.7%; prevalence in Mozambique 
in 2002 was 11%; prevalence in South Africa in 2006 was 8.8%; prevalence in Morocco in 
2009 was 7.7%, and prevalence in Nigeria in 2012 was 13.9% (Macaulay et al., 2014). 
However, the wide variations in test procedures, diagnostic criteria, timing of test, rural-urban 
disparities and level of healthcare delivery accounts for much of the differences.  
Although data on GDM from Ghana is limited, the epidemiological and nutrition transitions 
apparent in Ghana suggest rising GDM prevalence. Shifts from consumption of traditional 
foods high in complex carbohydrates and fibre to refine and high fat diets and physical 
inactivity is promoting obesogenic environments (Popkin, 2001). This could contribute to 
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metabolic imbalances. The first study reporting prevalence of GDM in Ghana was conducted 
at the largest national tertiary healthcare facility in 2015. The study was a cross-sectional 
survey involved 399 pregnant women who did 2-h OGTT following intake of 75-g glucose 
between 24-28 weeks. Reported prevalence of GDM was 9.3% (n=37, 95% CI 6.6%-12.5%) 
(Oppong et al., 2015). 
 
1.2.2 Pathophysiology of GDM, Macrosomia and Hypoglycemia  
Maternal hyperglycemia is believed to be caused by excessive hypophyseal production of 
gonadotropins and growth factors in pre-diabetic and diabetic mothers, hypercorticism of 
pregnancy and genetics (Pedersen, 1954). Maternal adipose tissue and the placenta are 
believed to produce large amounts of diabetogenic adipokines with adipokine tumor necrosis 
factor alpha (TNF-α); believed to be the most significant independent predictor of maternal 
insulin sensitivity (Kirwan et al., 2002). Elevated pre-pregnancy insulin resistance observed 
in obese women is supposedly based on the role of diabetogenic adipokines in the insulin 
resistance pathways. Insulin resistance characterizes normal pregnancy and triggers increased 
insulin secretion by the pancreatic β cells. This reduces renal threshold for glucose 
reabsorption from the glomerular filtrate. Placenta hormones contribute to making maternal 
tissues progressively insensitive to insulin. In normal pregnancy, insulin secretion increases 
by 200-250% to make up for the 50% decreases in insulin-mediated whole-body glucose 
disposal needed to maintain a normoglycemic state (Barbour et al., 2007). GDM tends to 
develop when the pregnant woman is unable to produce adequate insulin to compensate for 
this normal insulin resistance.  
Adipose tissue, especially the intra-abdominal omental fat, contribute to the pathophysiology 
of GDM (Harlev and Wiznitzer, 2010). According to the Pedersen hypothesis, maternal 
hyperglycemia results in excess glucose transfer to the fetus leading to fetal hyperglycemia, 
hyperinsulinemia and overgrowth of insulin-sensitive tissues such as adipose tissues 
especially around the chest, shoulders and abdomen (Pedersen, 1954). Fetal hyperglycemia 
triggers hypoxemic state in utero increasing risk of fetal polycythemia, hyperbilirubinemia 
and intrauterine fetal death (Metzger et al., 2008). When placental nutrient supply is 
discontinued at birth, immediate postnatal metabolic changes preserve fuel supplies for vital 
organ function. Plasma insulin levels fall with rapid surge of catecholamine and pancreatic 
glucagon release (Hussain, 2011). Although transient hypoglycemia are reflections of normal 
metabolic adaptation during fetal-to-neonatal transition, the peak of the fluctuations is 2-4 
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hours after birth and should normalize by the fourth day. Newborn who experience 
diabetogenic in-utero conditions face difficulty normalizing this transient hypoglycemia 
(Hawdon, 2012, Metzger et al., 2010b). 
 
 
1.2.3 Risk Factors and Predictors for GDM 
Both current and previous studies have assessed factors associated with increased risk for 
GDM (National Institute for Health and Care Excellence, 2015, Ashwal and Hod, 2015, 
Metzger et al., 2008, Kampmann et al., 2015, Berkowitz et al., 1992). Significant 
demographic and anthropometric risks include maternal age above 25 years, high parity, 
ethnicity (Native Americans, Asians, Hispanics, and African-American women), obesity, 
short maternal stature and high gestational weight gain. High pre-pregnancy body mass index 
(BMI) and the BMI at 28 gestational weeks are strongly correlated to increased insulin 
resistance at 28 weeks (Metzger et al., 2008). Physiologic and genetic risk factors include 
abnormal lipid profile, hypertension in pregnancy, first-degree relatives with diabetes and 
prior GDM. Previous poor obstetric outcomes like previous cesarean delivery, history of 
stillbirth, miscarriage, unexplained perinatal/neonatal death, macrosomic birth and congenital 
malformations have all been found to be independent risks.  
Secondary analysis of data on singleton live births in the US between 1995 and 2003 provides 
some insights on ethnicity and GDM risk among US-born and foreign-born women (Savitz 
et al., 2008). Ghanaian-born women had 6.9% risk for GDM. Peruvians had the least risk 
while Bangladeshi had the highest risk. Data on 2,056 pregnant women in Qatar shows that 
women with GDM were significantly older (35-45 years age group) (Bener, 2012, Bener et 
al., 2011). Others were family history of diabetes, high parity and obesity. Similar risks have 
been reported in sub-Saharan Africa. In Tanzania, GDM prevalence was found to be higher 
for women who had a previous stillbirth, family history of type II diabetes and mid-upper arm 
circumference (MUAC) >28 cm (Mwanri et al., 2014). In Zambia, the predictors were high 
BMI, prior macrosomic birth and history of diabetes (Liu et al., 2013). Studies in Ghana have 
found obesity, stillbirth, first-degree relatives with diabetes, more than two miscarriages, 
previous caesarean delivery and parity above two live children as significant predictors for 
GDM (Oppong et al., 2015, Asare-Anane et al., 2014). Also, low density lipoprotein and total 
cholesterol were significantly higher in women with GDM (Asare-Anane et al., 2013).  
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1.2.4 Maternal and Child Outcomes  
The HAPO study demonstrated that risk for adverse maternal, fetal and perinatal outcomes 
continuously increased as a function of maternal glycemic index between 24–28 weeks of 
gestation (Metzger et al., 2008). Adverse maternal outcomes include pre-eclampsia and 
cesarean deliveries and neonatal effects include macrosomia, large for gestational age and 
shoulder dystocia (O’Sullivan et al., 2011, Wendland et al., 2012, Vambergue and Fajardy, 
2011). A systematic review to assess adverse maternal and perinatal outcomes in 44,829 
untreated pregnant women diagnosed with GDM showed increased risk of adverse outcomes 
such as with macrosomia, large for gestational age, perinatal mortality, pre-eclampsia and 
cesarean delivery (Wendland et al., 2012). Macrosomia, a key adverse outcome, increased 
likelihood for cesarean delivery, fresh stillbirth, low Apgar score and admission to neonatal 
intensive care unit (NICU) in Zambia. (Liu et al., 2013)  
Uncontrolled GDM has implications on long-term risk of type II diabetes. Follow-up between 
6 weeks postpartum to 28 years post-gravidity shows a cumulative incidence of diabetes 
ranging from 2.6-70% (Kim et al., 2002). Adjustment for lengths of follow-up shows similar 
rates of progression. Despite the adjusted odds for diabetes increasing at 3 years (5.4), 3-6 
years (16.6) and 10 years of diagnosis (8.2), the risk is substantially highest during the 3–6 
years after GDM (Song et al., 2018). A Scottish cohort study between 1994-2004 on women 
diagnosed with GDM reported 25% (n=41) prevalence of type II diabetes from 4 months to 
16 years between diagnosis of GDM and follow up (Eades et al., 2015). To determine the 
long-term implications of GDM, women diagnosed in the UK from 1995-2003 were followed 
up till 2009. Risk of developing diabetes was 6.9% at 5 years and increased to 21.1% at 10 
years following the initial diagnosis of GDM (Sivaraman et al., 2013). Significant 
associations were found between fasting and post-prandial glucose levels during pregnancy 
and future risk of diabetes. However, it was not associated with age, gestational age at 
diagnosis, numbers of previous and subsequent pregnancies.  
Likewise, offspring of women diagnosed with diabetes during pregnancy are at higher risk 
for long-term metabolic outcomes, cardiovascular diseases and increased adiposity at a 
younger age. Epigenetic mechanisms are thought to play a role (Ma et al., 2015, Landon et 
al., 2015). A clinical trial in Germany analyzed differences in offspring anthropometrics 
among pregnant obese women with or without GDM and normoglycemic lean women. 
Findings show that pre-pregnancy obesity combined with GDM was associated with newborn 
hyperinsulinemia and increased offspring fat mass (Uebel et al., 2014). Not only does GDM 
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predisposes mother-offspring to type II diabetes, it also increases adiposity and lipidemia. A 
cohort study assessed impact of GDM on longitudinal changes in adiposity and metabolic 
variables in overweight Latino offspring between age 8-20 years (Davis et al., 2013). Results 
showed that compared with the non-GDM offspring, the GDM offspring had greater increases 
in total body fat, steeper declines in acute insulin response and disposition index across the 
Tanner stages. The associations were independent of ethnicity, sex, breastfeeding status, 
family history of diabetes, and changes in body composition. 
 
1.3 Detection of GDM 
1.3.1 Universal Versus Selective Screening for GDM  
A 3-pronged approach has been proposed for screening GDM; (1) selective screening, (2) 
risk stratification and (3) universal screening (Ashwal and Hod, 2015). Screening denotes 
scheduled assessment of GDM risk and measurement of blood glucose in asymptomatic 
pregnant women followed by diagnostic testing of screen-positive women. Universal 
screening is screening of all pregnant women irrespective of symptoms and glycemic status 
and booking all for diagnostic testing to assess likelihood for GDM (Tieu et al., 2014). 
Selective (risk factor-based) screening is the assessment done at the first prenatal visit. 
History is taken on pre-pregnancy or first trimester body mass index (BMI), parity, previous 
pregnancies and outcomes, family history of diabetes, etc. Screening tests include glycosuria, 
random blood glucose, fasting blood glucose, 50-g glucose challenge test and glycated 
hemoglobin (HbA1c) (NICE, 2015). Whether to screen for GDM or not, and the screening 
approach to use remain controversial.  
The risk factor-based screening approach shown in Table 1 stratifies risks as low, average 
and high (Ashwal and Hod, 2015). Some have proposed selective screening where risk is 
stratified according to severity and only the high-risk group selectively booked for diagnostic 
testing (Ashwal and Hod, 2015, National Institute for Health and Care Excellence, 2015). 
Depending on the woman’s risk level, an appropriate diagnostic action is taken. Indications 
for OGTT based on independent risk factors and clinical measurements include the following 
(National Institute for Health and Care Excellence, 2015): 
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• Glycosuria ≥ 1+ on more than one occasion or ≥ 2+ on one occasion  
• Macrosomia in current pregnancy  
• Previous macrosomia (<4.5 kg, or above the 95th percentile for gestational age)  
• Previous gestational diabetes  
• First-degree relative with diabetes  
• Asian ethnic background  
• Previous unexpected perinatal death  
• History of polycystic ovary syndrome  
• Obesity (BMI >30 kg/m²) or booking or weight above 100 kg  
• Polyhydramnios  
• Fasting blood glucose > 6.0 mmol/L or random blood glucose >7.0 mmol/L  
 
 
Table 1. Screening for gestational diabetes using the risk stratification approach 
 Low risk Average risk High risk 
Risks 
groups  
1. Normal pre-pregnancy and 
pregnancy weight (not overweight) 
2. Age <25 years 
3. No T2D in first-degree relatives 
4. No history of abnormal glucose 
metabolism 
5. No prior poor obstetric outcome 
6. Not from high risk ethnic group 
1. Not classified 
as low/high risk 
2. Detected as 
high risk at early 
pregnancy but 
did not have 
GDM in early 
pregnancy 
1. Obesity 
2. First degree family 
with T2D  
3. Prior history of GDM 
4. Known glucose 
intolerance outside of 
pregnancy 
5. Glycosuria 
Diagn-
ostic 
action  
No challenge test is required for 
screening or diagnosis of diabetes 
Challenge test is 
required at 24–
28 weeks 
Single OGTT or 2 stage 
GCT & OGTT in early 
pregnancy. If negative, 
repeat at 24–28 weeks  
GDM: oral glucose tolerance test; GCT: glucose challenge test; T2D: type II diabetes  
 
 
In the midst of the epidemiological transition, WHO cautions the use of selective screening 
as there is possibility of under-diagnosis thereby missing the opportunity to manage women 
who might need treatment (World Health Organization, 2013). Essence of universal screening 
has been reaffirmed in an observational study in Nigeria where selective versus universal 
screening was assessed. Singleton pregnant women (n=1059) were screened for GDM 
between 24-32 weeks using the 2010 IADPSG criteria. If selective screening were used, about 
20% of the GDM cases would have been missed (Olagbuji et al., 2015). In the US, the 
screening universal group was found to be less likely of being diagnosed with GDM (RR 
[relative risk]: 0.44 95%  CI [confidence interval]: 0.26-0.75) than the selective screening 
group (Tieu et al., 2014). Low-risk women are less likely to benefit from universal screening 
(Tieu et al., 2014). This has generated concerns about the economic burden universal 
screening will put on health systems. The new criterion is expected to increase the number of 
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women identified with GDM (World Health Organization, 2013) and health systems need to 
be prepared to manage the implications of the high prevalence. 
 
1.3.2 Global Guidelines on GDM Screening and Diagnosis 
Until the landmark HAPO study in 2008, which was a large-scale multinational prospective 
observational study involving 25,000 pregnant women, GDM did not receive much global 
policy attention. GDM detection is attributed to Matthews Duncan. In 1882, Duncan observed 
a possibility of hyperglycemia during pregnancy, which did not normalize after delivery 
(Coustan, 2013). In 1964, OGTT was identified as a diagnostic test to detect GDM. Pregnant 
women (n=752) were tested for GDM through intake of 100-g glucose and the 3-hour 
postprandial glucose measured (O’Sullivan and Mahan, 1964). Thereafter, various guidelines 
for detecting GDM evolved. 
Notable were the National Diabetes Data Group (NDDG) in 1979 (National Diabetes Data 
Group, 1979), the criteria by Carpenter and Coustan in 1982 (Carpenter and Coustan, 1982) 
and the 1999 WHO consultation report on the definition, diagnosis and classification of 
diabetes mellitus (WHO, 1999). In the past decade, these guidelines were updated to bring 
global uniformity in the diagnosing and improve sensitivity and specificity of the diagnostic 
tests. Example is the ‘clinical guideline on the management of diabetes and its complications 
in pregnancy from pre-conception to the postnatal period’ by NICE in 2008 (NICE, 2008). 
The Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study formed basis for the 
current globally endorsed criteria on the definition, diagnosis and classification of diabetes in 
pregnancy and GDM (Metzger et al., 2008). Based on the HAPO study, the International 
Association of Diabetes and Pregnancy Study Groups (IADPSG) developed 
recommendations for the diagnosis and classification of Hyperglycemia in Pregnancy 
(IADPSG Consensus Panel, 2010). It was adopted by WHO in 2013 as the ‘Diagnostic 
Criteria and Classification of Hyperglycemia First Detected in Pregnancy”. Similarly, the 
American Diabetes Association (ADA) updated its diagnostic guidelines based on IADPSG 
recommendations (American Diabetes Association, 2015). It is expected that with the new 
diagnostic criteria, more women would be diagnosed with GDM as a reflection of the 
increasing prevalence of type II diabetes (World Health Organization, 2013).  
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Presented in Table 2 are some common diagnostic criteria and thresholds. The NICE 
guideline considers 75-g OGTT conducted at 24–28 weeks as the ‘gold standard’ test for 
GDM (National Institute for Health and Care Excellence, 2015). The WHO guideline focuses 
on prognostic accuracy rather than diagnostic accuracy (World Health Organization, 2013) 
and hence does not endorse any gold standard test per se. Most guidelines recommend 24-28 
weeks as the optimum timing for diagnostic testing using fasting plasma glucose (FPG), 1-
hour and 2-hour OGTT. Cut-offs are based on mean glucose values at which odds of adverse 
pregnancy outcomes reach 1.75 times (IADPSG Consensus Panel, 2010). 
 
Table 2. Global guidelines for diagnosing gestational and overt diabetes 
 
Diagnostic 
criteria  
Random plasma 
glucose 
Fasting plasma 
glucose 
1-hour 75g post 
prandial OGTT 
2-hours 75g post 
prandial OGTT 
 
Test time 
(weeks) mmol/L mg/dl mmol/L mg/dl mmol/L mg/dl mmol/L mg/dl 
Gestational diabetes   
ADA 
2015a 
  ≥5.1 ≥ 92 ≥10.0 ≥ 180 ≥8.5 ≥153 24-28 
IADPSG 
2010  
  ≥5.1 ≥92 ≥10.0 ≥180 ≥8.5 ≥153 24-28 
NICE 
2015 
  ≥5.6 ≥100   ≥7.8 ≥140 24-28 
WHO 
2013 
  5.1-6.9 92- 
125 
≥10.0b 180b 8.5-
11.0 
153-
199 
20-28 
preferred  
Clinical diabetes 
IADPSG 
2010  
11.1c 200c 7.0 126     Early 
prenatal 
WHO  
2013 
≥ 11.1d 200d ≥ 7.0 126   ≥ 11.1 200 Anytime 
Tests with blank spaces imply that no diagnostic cut-offs have been recommended.  a This criterion is according 
to the one-step strategy.  The two-step” approach is 50-g OGTT screening followed by 100-g OGTT for those 
who screen positive  (American Diabetes Association, 2015). bThere is no established WHO criterion for the 
diagnosis of GDM based on 1-hour post-load value (World Health Organization, 2013). c When random 
plasma glucose test is used, diagnosis should be confirmed using fasting plasma glucose or glycosylated 
haemoglobin (IADPSG Consensus Panel, 2010). d Diagnosis based on random plasma glucose test results 
should be made in the presence of diabetes symptoms (World Health Organization, 2013). 
 
1.4 Management and Prevention of GDM 
Gestational diabetes is associated with adverse maternal and neonatal consequences (Metzger 
et al., 2008, Wendland et al., 2012) including long-term metabolic risks (National Institute 
for Health and Care Excellence, 2015). Testing and management using non-pharmacological 
and pharmacological methods could improve outcomes (Landon et al., 2009). Although 
evidence on the clinical importance of non-pharmacological management is not so strong 
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(Hartling et al., 2013, Colberg et al., 2013), management is shown to improve glycemic 
control. Treatment may consist of lowering blood glucose concentration alone or in adjunct 
with special obstetric care. Treatment options include lifestyle modifications (dietary 
changes, physical activity), use of oral hypoglycemic agents (metformin or glibenclamide) 
and insulin therapy. Likewise, WHO recommends GDM management with interventions 
which promote lifestyle changes like nutritional counseling and exercise and cautions the use 
of insulin therapy unless clinically indicated (World Health Organization, 2013). The 
recommendation is that in mild cases of GDM where glucose values overlap with the 
thresholds recommended, 80–90% of these women could be managed with lifestyle therapy 
alone (American Diabetes Association, 2013). 
 
1.4.1 Biomarkers for GDM  
Research is ongoing to understand the role of maternal serum biomarkers in predicting the 
risk of gestational diabetes (Nanda et al., 2011, Nagalla et al., 2015, Zhu et al., 2015, Rasanen 
et al., 2013, Singh et al., 2015). Aside known maternal risk factors, serum biomarkers like 
adiponectin, follistatin-like-3, sex hormone binding globulin, oxidative stress associated with 
levels of high-sensitivity C reactive protein (hs-CRP) and high fluorescence reticulocytes at 
fasting, and hs-CRP in 1-h OGTT, proteomic and glycosylated fibronectin are significantly 
associated with GDM.  
In recent times, gut microbiota of both GDM women and their newborns is shown to alter 
with more metabolic and inflammatory taxa, suggesting a potential effect on metabolic health 
in later stages in life (Su et al., 2018, Ferrocino et al., 2018). The current epidemiological 
transition necessitates that screening for GDM be combined with maternal characteristics and 
serum biomarkers as it will provide a holistic approach to understanding the pathophysiology 
of GDM and interventions needed to reduce the incidence and ameliorate materno-fetal 
complications. However, many of these biomarkers are expensive and difficult to perform in 
low-income settings.  
 
1.5 Conceptual Framework and Current State on GDM  
Except for GDM detection using biomarkers and the management strategies, all other aspects 
related to GDM conceptualized in Figure 1 were directly investigated in the study. The 
literature review has shown a global rising prevalence of GDM. High prevalence in some 
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low-income settings are worrying considering the low investments in healthcare and 
inadequate preparedness to respond to the condition. Although the increasing prevalence has 
been attributed to rising diabetes mellitus, obesity, physical inactivity and more pregnancies 
in older women, lowering of diagnostic cut-offs in recent guidelines is largely accountable.  
The screening procedure is chaotic, because the screening tests are not clearly defined and 
there is no global non-consensus on the approaches to use. Opinions are divided on whether 
to test all pregnant women (universal screening) or screen all pregnant and test the ‘at risk’ 
group (selective screening). The argument of the universal screening proponents is based on 
not missing any pregnant women who might need management and specialized care to avert 
pregnancy complications. The argument of the selective screening proponents is based on 
cost implications of testing all pregnant women some of whom have no risk factor whatsoever 
and the associated over-medicalization of obstetric care. Evidence is not strong on the 
pregnancy outcomes, but a trajectory of GDM to type II diabetes has been established in the 
long term. Pharmacological treatment is initiated when glycemic control is not achieved from 
non-pharmacological management.  
The first gaps identified in the literature are the dearth of evidence on the prevalence of GDM 
in lower level facilities and among rural and peri-urban dwellers in low-income settings; 
diagnostic validity of some screening tests as well as the birth outcomes and glycemic status 
in the short and long-term postpartum period. Also missing is lack of evidence on the cost 
effectiveness of universal versus selective screening; effectiveness of interventions to prevent 
and manage GDM during pregnancy and during postpartum in low-income settings; low-cost 
biomarker tests for early prediction of GDM and gut microbiome profile of GDM-affected 
mother-offspring pairs. This study attempts to fill the first gaps identified.  
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Figure 1. Conceptual framework on the public health spectrum of GDM 
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1.6 Problem Statement  
1.6.1 Background of Ghana – the Study Context   
Ghana is a lower middle-income West African country sharing borders with Togo to the East, 
Cote d’Ivoire to the West and Burkina Faso to the North. It is bordered to the South by the 
Atlantic Ocean, covering a coastline of 539 km while the country covers a total land area of 
227,540 km2. The median age of the 24,658,823 population is 20.5 years and about 55% is in 
urban centers (Ghana Statistical Service, 2013). Per the population density, Ghana has 10 
administrative regions sub-divided into 6 metropolitan, 49 municipalities and 261 districts. 
Life expectancy is 60 years for among males and 63 years among females (Ghana Statistical 
Service, 2015). Presented in Table 3 are the key economic and health indicators for Ghana.  
 
Table 3. Key economic and health indicators for Ghana 
Economic or Health Indicator  Results  
Gross domestic product 24.6% 
Gross domestic product growth 8.5% 
Inflation 9.8% 
Average lending interest rates  16.2% 
Main economic activity - agriculture 45% 
Women in reproductive age (15-49 years) 45.3% 
Mean size of households 3.5 
Females educated above secondary level 6.3% 
Females currently employed  73.4 
Median age at first birth for women age 15-49 (years) 21.4 
Total fertility rate (children per woman) 4.2 
Mean no. of children ever born to women age 40-49 4.8 
General fertility rate (per 1,000 women age 15-44) 143 
Crude birth rate (per 1,000 population) 30.6 
Women age 15-49 currently pregnant 7.1% 
Teenage pregnancy (15-19 years)  11.3% 
Use of any modern contraceptive method 31.7% 
Unmet need for family planning 29.9% 
Antenatal care from a skilled provider 97% 
Births attended by a skilled provider 74% 
Four or more antenatal care visits  87% 
Median pregnancy duration at first antenatal visit (months) 3.6 
Perinatal mortality rate (per 1,000 pregnancies) 38 
Neonatal mortality rate (per 1,000 live births) 29 
Infant mortality rate (per 1,000 live births) 41 
Under-5 mortality (per 1,000 live births) 60 
Maternal mortality ratio (per 100,000 live births) 310 
Lifetime risk of maternal death 1% 
Percentage of maternal deaths 7% 
Source: (Ghana Statistical Service, 2015, Ghana Statistical Service, 2018, African Development Bank, 2019) 
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1.6.2 GDM in Ghana and the Diagnostic Procedure  
GDM screening and diagnosis is not uniform in Ghana but based primarily on glycosuria  
Selective screening for GDM is a risk assessment strategy routinely used in Ghana Health 
Service facilities. The procedure used in screening and diagnosing GDM in Ghana is 
presented in Figure 2. At the first antenatal visit, the pregnant woman is interviewed to 
determine the risk for GDM by assessing age, body weight at first ANC visit, previous 
pregnancies, previous diagnosis of GDM, and family history of diabetes. In addition, at every 
antenatal visit, glycosuria is tested using a qualitative rapid urine dipstick test to detect the 
presence of glucose in urine. Corresponding colour changes represent negative, trace, +1, +2, 
+3 and +4 urine glucose. Clients in the high-risk category are identified based on risk factors 
and/or +1 glycosuria test result on one or two screening occasions. These clients usually 
perform a GDM confirmatory test. However, type of diagnostic test depends on level of 
healthcare and could be fasting or random glucose using capillary whole blood or venous 
plasma and OGTT.  
 
 
Figure 2. Procedure for screening and diagnosing gestational diabetes in Ghana 
Health Service hierarchy of facilities.  
Note: *The standard treatment guideline currently used in Ghana does not indicate what monitoring entails. 
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Glycosuria testing is unreliable during pregnancy, yet it is used  
During pregnancy, renal threshold for glucose reabsorption from the glomerular filtrate 
reduces leading to increased glycosuria at some point in about 50% of all pregnancies (Alto, 
2005). The renal threshold for glucose is highly variable with a reduction in glycemic 
thresholds needed for the GDM diagnosis. This may lead to a positive glycosuria despite 
normal blood glucose (that is, glycosuria without hyperglycemia).  
Glycosuria test, aside being cheap and convenient, is useful in identifying patients with 
uncontrolled diabetes. However, it has low specificity due to the lower renal threshold that 
occurs with gestation (Hanna and Peters, 2002). Yet, there is possibility of symptomatic 
hyperglycemia without detectable glucose in the urine (that is, hyperglycemia without 
glycosuria) (Cersosimo et al., 1997). Cases could be missed should glycosuria be the only 
screening test thereby missing the opportunity to manage the condition and prevent adverse 
materno-fetal complications. Glycosuria screening for GDM has been discredited (National 
Institute for Health and Care Excellence, 2015), but remains the only option in primary 
facilities in Ghana. Some studies have suggested removal of routine urine dipstick screening 
for glycosuria during pregnancy (Alto, 2005) while others have suggested a re-evaluation of 
the test as it is a routine ANC practice (National Institute for Health and Care Excellence, 
2015).  
 
Global guidelines on GDM screening are inconsistent and Ghana has no clear policy  
Currently, there are controversies regarding screening tests for GDM that should form the 
basis to perform a diagnostic test. Also, whether the procedure should be done for all pregnant 
women (universal screening) or on a selected number based on their risk levels (selective 
screening) is yet another issue with no international consensus. On the contrary, guidelines 
for diagnosing GDM and overt diabetes are clear (Table 2). Key guidelines include that by 
the International Association of Diabetes in Pregnancy Study Groups Consensus Panel 
(2010), World Health Organization (2013), American Diabetes Association (2015), and the 
National Institute for Health and Clinical Excellence (2015). These guidelines are based on 
the outcomes obtained from random plasma glucose, fasting plasma glucose, 1-h and 2-h post 
75-g OGTT. Clinicians in Ghana rely on outcomes of routine glycosuria testing and history 
taking for risk assessment as indicators for diagnostic testing. Maternal history though taken 
at first ANC visit, is seldom used to evaluate GDM risk level. The WHO guideline on 
diagnosis and management of GDM is used as there is no clear policy guideline in Ghana. A 
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study in the US assessed glycemic status of 324 pregnant women to evaluate effects of using 
fasting blood glucose as screening test, and 1-h and 2-h OGTT as diagnostic tests (Herrera et 
al., 2015). Seven percent tested positive using fasting glucose, 37% using 1-h and 22% using 
2-h OGTT. But for the screening, the 7% would have been missed.  
 
 
GDM situation in Ghana is not well established  
Literature consistently points macrosomia as one of the most important adverse neonatal 
outcomes of diabetes in pregnancy (Metzger et al., 2008, Wendland et al., 2012, Vambergue 
and Fajardy, 2011). Secondary data was analyzed on 4262 singleton newborns from January 
2012 to December 2013 to get an overview of the magnitude of GDM in the study location. 
Macrosomic deliveries (birthweight ≥4 kg) was found to be 3.03% (n=129) (Agbozo et al., 
2016). Analysis of antenatal records from the same health facility for 2013 showed that out 
of 2234 pregnant women who did dipstick urinalysis, over half (n=1175) tested positive for 
protein in urine whereas only 1.8% (n=40) tested positive for dipstick glycosuria. Findings 
from this secondary analysis of data are inconclusive making it difficult to draw any 
meaningful conclusion.  
Until 2015, there was no published data on prevalence of GDM in Ghana. Using the 2012 
diagnostic criteria of the American Diabetes Association, prevalence of GDM by 2-h OGTT 
was 9.3% in the largest referral hospital in Ghana (Oppong et al., 2015). As this study was 
conducted in a tertiary facility, generalizing findings as the true population prevalence must 
be done with caution. Meanwhile, prevalence of type II diabetes among adults age 18-80 
years seeking outpatients services at the same hospital was 6.5% (Nelson et al., 2015). Thus, 
this pregnancy-related metabolic condition is emerging as a maternal problem that could pose 
challenges to already over-stretched health systems. Considering the lack of consensus on 
universal verses selective screening, GDM is hypothesized to be under-diagnosed in Ghana.  
 
Summary of the rationale for the study   
In summary, despite the recommendation to checking the fasting blood glucose of all 
pregnant women in Ghana as stipulated in the standard treatment guideline, GDM screening 
and diagnostic procedures are not uniform in Ghana and the diagnostic decision is at the 
discretion of the provider. Dipstick glycosuria remains the most used screening test despite 
its non-reliability during pregnancy. Moreover, the actual GDM situation that is 
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representative of the true population is not well established in Ghana, neither is there any 
evidence on the associated birth outcomes and postpartum glycemia. On the global front, 
current GDM screening and diagnostic guidelines are inconsistent leading to application of 
diverse tools and cut-off.  
 
1.6.3 Study Objectives 
The overall objective is to validate the diagnostic accuracy of screening tests for gestational 
diabetes, assess prevalence, risk factors and associated maternal and neonatal birth outcomes 
including short-term postpartum glycemia status.  
Specific objectives  
1. To estimate the prevalence of GDM using various cut-offs including WHO and 
NICE diagnostic criteria 
2. To validate the diagnostic accuracy of glycosuria and random blood glucose 
compared to fasting plasma glucose and OGTT 
3. To assess the risk factors for GDM using socio-demographic, anthropometric and 
dietary data; obstetric and medical history and macrosomia as proxy for GDM 
4. To assess association of GDM with adverse maternal and newborn birth outcomes 
5. To examine extent of attainment of euglycemia among GDM mothers at 12 weeks 
postpartum  
 
1.6.4 Hypothesis and Research Questions  
Hypothesis: The current screening tests for GDM in Ghana (urine dipstick for glucose and 
history taking) is missing majority of cases. 
Research questions that this study intend to answer include the following: 
1. What is the prevalence of GDM and overt diabetes in Ghana? 
2. How accurate are the screening tools used to detect GDM?  
3. Which diagnostic criteria will be most applicable in primary level facilities? 
4. Is there difference in prevalence using universal and selective screening approaches? 
5. What proportion of cases are missed if selective screening is applied? 
6. Which maternal characteristics (adiposity, dietary, obstetric and physiologic risk 
factors) predict the likelihood for developing GDM? 
7. What is the effect of GDM on maternal and newborn health outcomes? 
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8. To what extent do women diagnosed with GDM attain euglycemia during 
postpartum? 
 
 
1.6.5 Purpose of the Study  
In order to develop a national protocol on GDM screening and diagnosis and design evidence-
based interventions for prevention and management, empirical evidence is needed on validity 
of screening tests that is applicable within the Ghanaian context, prevalence, risk factors and 
birth outcomes. This study aims to generate this knowledge following current global 
diagnostic criteria and provide background for future intervention studies.
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2 MATERIALS AND METHODS 
_______________________________________________________________________________________________________________ 
Note: The doctoral student has published some aspects of this chapter in the underlisted publications. For details, see pages 109-111. 
• Prevalence of low birth weight, macrosomia and stillbirth and their relationship to associated maternal risk factors in Hohoe 
Municipality, Ghana http://dx.doi.org/10.1016/j.midw.2016.06.016  
• Accuracy of glycosuria, random blood glucose and risk factors as selective screening tools for gestational diabetes mellitus in 
comparison with universal diagnosing. http://dx.doi:10.1136/bmjdrc-2017-000493  
• Gestational diabetes using diverse diagnostic criteria, risk factors including dietary intakes, pregnancy outcomes and postpartum 
glycemic status: a nested case-control study in Ghana. https://doi.org/10.1101/582239  
 
This methods chapter is organized into six main sections. The first section describes the 
geographic and health context of the study. The second and third sections describe the four 
observational study designs used and how the sample size of approximately 800 was obtained. 
The fourth and fifth sections describe the procedures used in obtaining data in the prenatal, 
intrapartum and postpartum phases of the study and the statistical analyses applied in 
interpreting the raw data generated. In the final section, the ethical considerations are 
highlighted. Overview of the methodology is presented in Figure 3.  
 
 
2.1 Study Setting   
2.1.1 Maternal Health Indicators of the Study Setting  
The study was conducted at the maternal health departments of five state-own hospitals in the 
Volta region administered through the Ghana Health Service and regulated by the Ministry 
of Health. Data was collected from the antenatal clinic, labour ward and postnatal clinic of 
the study facilities. Generally, in Ghana, antenatal care (ANC), delivery and postnatal 
services are provided at secondary level facilities. Therefore, participants were 
proportionately recruited from one primary-level facility serving mainly rural communities, 
three secondary-level facilities serving rural and peri-urban communities, and the largest 
referral hospital in the region, also a secondary facility. 
The facilities comprised the Jasikan district hospital, a primary level facility; three secondary 
facilities (district hospitals) comprising the Hohoe and Ho municipal hospitals, and the 
Margaret Marquart Catholic hospital. The largest of the secondary facilities was the Volta 
regional hospital, a 240-bed capacity hospital situated in Ho, the Volta regional capital. It 
serves as the regional referral facility and has now been upgraded to a tertiary facility to serve 
as a Teaching Hospital for the University of health and Allied Sciences.   
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Figure 3. Summary of the study methodology highlighting the designs, sample size, eligibility criteria, follow-up, statistical analyses and 
outcome measures 
Note: GDM, gestational diabetes mellitus; CS, cesarean section; BMI, body mass index; LGA, large for gestational age; MUAC, mid-upper arm circumference; HPT, hypertension  
Materials & Methods 
 
24 
 
These study facilities were purposively selected because of their peculiar diverse 
characteristics (Table 4), which aided in providing an overview of the maternal and newborn 
healthcare situation in the region. Therefore, findings obtained were most likely to be 
generalizable to the national situation as it gives a representation of rural-urban differences 
and provides empirical data for comparing healthcare systems in urban and rural areas of 
Ghana. Also crucial in the selection of the study facilities was the ease and proximity of 
transporting samples to the research laboratory located in the Hohoe municipality (see section 
2.4.1) where the biochemistry and hematological analyses were done.  
Shown in Table 4 is the maternal and child health profile of the study facilities and the 
demographic and health indicators of the region, three municipalities and one district where 
the study facilities are located. The primary facility is somewhat resourced to deliver the 
seven basic Emergency Obstetric and Newborn Care (EmONC) signal functions while the 
higher-level facilities provide both basic and comprehensive EmONC services and have at 
least one resident obstetrician. But all the facilities have skilled birth attendants particularly 
midwives and other crucial support staff.  
 
Table 4. Demographic and health indicators of the Volta region and the facilities 
where the study was conducted  
 Profile  Volta 
Region  
Ho 
Municipality   
Hohoe 
Municipality 
Kpando 
Municipality  
Jasikan 
District  
Total population 2,118,252 177,281 167,016 93,649 59,181 
Rural inhabitants (%) 66.3 55.7 59.7 68.4 72.4 
Women in reproductive 
years (15-49 years) (%) 
24.4 28.1 25.2 25.1 23.5 
Total fertility rate (15-49 
years) 
3.4 2.7 3.3 3.0 3.4 
General fertility rate  
(1000 women 15-49 years) 
99.2 74.4 96.0 87.1 98.5 
Crude birth rate  
(per 1000 population) 
24.2 20.9 24.3 21.9 22.5 
Crude death rate (per 1000 
population) 
8.8 8.3 8.7 8.9 9.6 
Infant mortality 
(per 1,000 live births) 
57 58 51 50 53 
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Major health facility  
Volta 
Regional 
Hospitala 
Ho 
Municipal 
Hospitala 
Hohoe 
Municipal 
Hospitala 
Margret 
Marquart 
Hospitala 
Jasikan 
District 
Hospitala 
Bed capacity 240 130 178 152 45 
ANC registrants 1,359 1,160 1,417 902 832 
ANC attendance 12,128 6,256 7,073 5,290 4,236 
1st trimester registrants  730 621 628 354 385 
2nd trimester registrants  446 395 550 447 348 
3rd trimester registrants  183 144 123 101 99 
No. making 4 ANC visits 572 568 1071 794 509 
No. of deliveries 1,989 1,699 2,016 1,396 669 
Live births 1,972 1,687 2,030 1,407 667 
Source: Ghana Statistical Service, 2013 and Ghana Health Service 2015 District Health Information Management 
System (DHIMS II) Data for the Volta region.  
a These secondary facilities provide both basic and comprehensive Emergency Obstetric and Newborn Care (EmONC) 
signal functions and b the primary facility provides only basic EmONC signal functions. 
Basic EmONC signal functions:  
(1) parenteral antibiotics;  
(2) parenteral anticonvulsants;  
(3) parenteral oxtyocics;  
(4) manual removal of placenta;  
(5) removal of retained products (manual vacuum aspiration);  
(6) assisted vaginal delivery (with vacuum extractor or forceps);  
(7) neonatal resuscitation with bag and mask 
Comprehensive EmONC signal functions:  
(8) blood transfusion and  
(9) cesarean section 
 
 
 
2.1.2 General Information about the Volta Region   
Volta Region is the third least populated region in Ghana and has 20 districts and 5 
municipalities. It is located between latitudes 5° 45’N and 8° 45’N along the southern half of 
the eastern border of Ghana. The region lies on the eastern side of Ghana and shares 
boundaries with the republic of Togo. It shares boundaries with Greater Accra, Eastern and 
Brong Ahafo regions to the west, Northern Region to the north and the Gulf of Guinea to the 
south. The region is the longest of all the regions in Ghana covering about 500 km in length 
from south to north. Map of the study site is shown in Figure 4. It occupies 20,570 square 
km representing 8.7% of the total land area of Ghana. The vegetation includes costal 
grassland, mangrove swamps, guinea savannah, semi-deciduous forests, Sahel-savannah and 
mountainous wooded savannah in the north. Apart from the ecological diversity of the region, 
almost all ethnic groups in Ghana live in the region as indigenes. Although Ewes constitute 
the largest ethnic group in the region, there are seven other major ethnic groups speaking 56 
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different dialects. As a result of this uniqueness, the region is described as a “microcosm” of 
the country (Ghana Statistical Service, 2013).  
The region has a total of 326 health institutions out of which 242 are administered by the 
Ghana Health Service. The doctor to population ratio in the region is one doctor to 35,871 
inhabitants and the nurse to population ratio is one nurse per 1,327 inhabitants. The region 
has a population of 2,118,252 inhabitants with 66.3% resident in rural areas. Out of the 
1,098,854 females, 45.2% are women in their reproductive years aged 15-49 years. The 
regional total fertility rate is 3.2 children per woman age 15-49 years while the average 
completed family size for women aged 12-54 years is 5.1 children per woman. Fertility rates 
of rural dwellers is relatively higher but there is little difference in teenage fertility in urban 
and rural areas. Infant mortality and under-five mortality (per 1,000 live births) for the region 
are 57 and 87 respectively (Ghana Statistical Service, 2013). On the other hand, the national 
crude birth rate (per 1,000) is 30.6 (Ghana Statistical Service, 2015). Data from the Ghana 
Health Service District Health Information Management System (DHIMS II) reveals that in 
2014, 72,003 pregnant women registered at antenatal clinics in the Volta region. First, second 
and third trimester registrant were 33,149 (47%), 27,694 (39%) and 8,742 (12%) respectively. 
Mothers making four ANC visits were 48,007 (67%) while 48,096 live births were recorded.  
 
 
Figure 4 a: Map of Ghana in relation to West Africa (source: Google map) 
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Figure 4 b. Map of the Volta region showing the specific study sites 
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2.2 Study Design  
The study was observational and employed four main designs; cross-sectional survey; 
diagnostic accuracy study design, prospective longitudinal study design and unmatched 
nested case-control study design. The diagnostic accuracy study and the case-control study 
were nested in the prospective cohort study. Synopsis of the study designs used, and the 
corresponding number of participants enrolled is shown in Figure 5.  
 
 
Figure 5. Synopsis of the study designs and corresponding number of participants 
enrolled  
Note: *Case definition used in this present was fasting plasma glucose ≥5.6 mmol/L (National Institute for 
Health and Care Excellence, 2015) and/or 2-h OGTT ≥8.5 mmol/L (World Health Organization, 2013) 
 
Cross-sectional design: To obtain information on the magnitude of GDM in the study area 
using newborn macrosomia as a proxy, a baseline cross-sectional survey was conducted in 
the Hohoe municipality between January 2013 to December 2014. Secondary medical records 
of 4477 deliveries documented in the labour and gynecological theatre of the Hohoe 
municipal hospital were reviewed, extracted and analyzed. 
Blind comparison to a gold standard design: For the diagnostic accuracy study, the 
prospective blind comparison to a gold standard design was used. This design compares 
accuracy of different diagnostic tests in the same individual. The index screening tests 
evaluated were dipstick glycosuria test, random blood glucose (RBG) and presence of 
maternal risk factors. The index diagnostic tests evaluated were 1-h OGTT and HbA1c. 
Performance of each test within the same individual was validated against the 2-h OGTT and 
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fasting glucose. Findings were reported according to the Standards for Reporting Diagnostic 
Accuracy (STARD) guidelines (Bossuyt et al., 2015).  
Longitudinal cohort design: The longitudinal cohort study involved a cohort of pregnant 
women who were followed through the prenatal (antenatal), intrapartum (during delivery) 
and postpartum periods of pregnancy. Prevalence of GDM was assessed as well as the 
association with maternal, fetal and newborn outcomes. Participants were tested for GDM in 
the second to third trimesters of pregnancy and the postpartum changes in glycemic status 
repeated at 12 weeks postpartum. Physiologic measurements such as glycosuria, proteinuria, 
blood pressure and weight were assessed at each ANC visit while birth outcomes were 
extracted from facilities’ delivery records. 
Case-control design: The unmatched nested case-control design was used to assess the risk 
factors that decreased or increased a pregnant women’s likelihood for GDM. At enrolment, 
data was obtained on socio-demographic characteristics. Dietary intake, medical and obstetric 
history were assessed retrospectively, whereas weight, height, random blood glucose and 
Hb1Ac were measured at ANC registration to assess the risk for GDM. 
 
2.3 Sample and Sampling  
2.3.1 Study Population   
The study population was pregnant women who attended and received antenatal care, delivery 
and postnatal care services at the Volta regional hospital, Hohoe and Ho municipal hospitals 
and the Jasikan district hospitals between May 2016 and April 2017. Pregnant women who 
were found at the antenatal care clinic in any of the study facilities during the data collection 
period who met the inclusion criteria and were willing to participate in the study were 
enrolled. 
 
2.3.2 Sample Size Estimation  
Due to the variability of the study designs used, two approaches were employed to calculate 
the required sample size. First, the sample size formula proposed by Cochran which accounts 
for finite population corrections and prevalence in a randomly-selected population was used 
to determine the minimum sample size (n) (Cochran, 1977). To assume normality of the 
Gaussian distribution for the study population of 516,461 (Ghana Statistical Service, 2013) 
women in their reproductive age (15-49 years) in the region, a confidence level of 95% 
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corresponding to 1.96 z-score (Z) statistics and permitted error margin (e) of 5% were used. 
Even though the reported prevalence of GDM in an urban tertiary teaching hospital in Ghana 
was 9.3% (Oppong et al., 2015), the study was conducted among peri-urban and rural dwellers 
where GDM prevalence was unknown. Besides, other factors such as hypertensive disorders 
in pregnancy, dyslipidemia, obesity, dietary patterns and micronutrient deficiencies, also 
known to affect pregnancy outcomes were assessed. Therefore, using estimation of risk 
associations as the basis, default population proportion (p) of 50% (Cochran, 1977) was used 
in determining the required sample size (n) as shown below.  
n = [
𝑍𝛼
2  × 𝑝(1−𝑝)
𝑒2
1+( 
𝑍𝛼
2  × 𝑝(1−𝑝)
𝑒2𝑁
)
] × d  =  [
1.962 × 0.1(1−0.1)
0.052
1+( 
1.962 × 0.1(1−0.1)
0.052 × 516,461
)
]        
n  = 130 × 3.2    =  416 
Where n = Sample size  
Zα = Z score of the Gaussian distribution  
N = Study population  
p = Percentage proportion or prevalence  
e = Margin of error (precision level) 
d = Design effect  
The primary and secondary facilities were each treated as separate clusters. Clustering 
ensured that participants in the same cluster were somewhat similar to one another. To 
account for variability of health service provision at each level, the effect of clustering was 
adjusted for, ensuring maximize statistical accuracy of GDM estimate that was nationally 
representative. Aided by the G*Power software (version 3.1.9.2) (Faul et al., 2007), a design 
effect of 3.2 was determined based on a two-tail t-test statistic with an alpha error probability 
of 0.05, 1-β error probability of 0.95 and an intra-cluster correlation of 0.16 derived from 0.03 
coefficient of determination. This was to allow for comparison of differences among cases 
and controls without increasing the error margin. This way, the 5% pre-determined error 
margin used in calculating the sample size was evenly distributed across the two comparison 
groups without introducing biases. This generated a sample size of 130. The sample size was 
multiplied by the design effect resulting in an effective sample size of 416. An a priori 
statistical power analysis yielded 91%, an indication that the sample size was adequately 
powered. The sample size was doubled (100% increase) to approximately 800 participants to 
account for attrition and loss to follow-up.  
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In all, 807 participants were recruited in their first trimester of pregnancy. As ANC and 
delivery services are mainly provided at the secondary level in Ghana, 75% of the participants 
were proportionately recruited from secondary facilities while about 15% were each recruited 
from the primary and referral (tertiary) facilities. Breakdown of the sample size (n=807) per 
study facility is as shown below.  
• One primary facility 
o Jasikan district hospital – 13.4% (n=108) 
• Three secondary facilities – 73.8% (n=598) 
o Ho municipal hospital – 30.2% (244)  
o Margaret Marquart Catholic hospital – 24.1% (n=195) 
o Hohoe municipal hospital – 19.7% (n=159)  
• One referral facility (currently being upgraded to a teaching hospital) 
o Volta regional hospital – 12.5% (n=101) 
 
 
2.2.3 Sampling Technique 
The consecutive sampling method was used in recruiting participants onto the study. This 
implied that every pregnant woman who visited any of the five facilities during the study 
period who met the inclusion criteria was enrolled. This process was sustained until the 
required sample size was obtained. Regarding the nested case-cohort component, all pregnant 
women tested for GDM and were disease-free per the case definition were purposively 
selected to act as controls. The case to control ratio was about 1:5, that is 70 cases to 376 
controls. At delivery and 12 weeks postpartum, GDM outcomes all participants and their 
index offspring were purposively followed.  
  
 
2.2.4 Eligibility Criteria  
Any pregnant woman identified at the ANC of any of the study health facilities was 
approached, screened for eligibility and enrolled onto the study if she met the following 
criteria: 
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Inclusion criteria  
• At recrement, gestational age of the pregnancy was supposed to be in the first trimester 
(up to 13 weeks) as evidenced by last menstrual period adjusted to either 
ultrasonography or fundal height measurement.  
• The woman did not have pre-existing diabetes. 
• Permanent residency within any of the study districts and intention to deliver in any 
of the study facilities. 
• Willingness to partake in the study by signing or thumb-printing the consent form. 
 
Exclusion criteria  
• Verbal confirmation of having pre-existing diabetes. If the woman was unaware of 
her diabetes status, random glucose and Hb1Ac were done in the first trimester.  
o Random glucose value ≥11.1 mmol/L and HbA1c value ≥6.5% was an 
indication of pre-existing diabetes. 
o HbA1c is useful indicator of glycemic control and is used to determine quality 
of glycemic intolerance the preceding 10-12 weeks and hence is a useful test 
to differentiate GDM from pre-existing diabetes. 
o Pregnant women with multiple gestation. 
 
Note:  
Age was not an exclusion criterion due to evidence of increasing incidence of non-
communicable diseases including metabolic disorders in both younger and older 
populations. Pregnant women who were teenagers were included because they were 
regarded as emancipated adults. Similarly, chronic ill-health was not an exclusion 
criterion because of the possibility of concomitant presence of GDM in immune-
suppressed women.  
 
 
2.4 Data Collection Instruments and Procedures  
This section describes how the raw data was obtained. Administrative and clinical managers 
of the hospitals where the study was conducted were sensitized on the study objectives and 
data collection procedures and their support elicited. Obstetrics and gynecology specialists, 
midwives, nurses, laboratory technicians and health assistants working in the maternal and 
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child health unit of the study facilities were trained on the study protocol. Fifteen research 
assistants with academic backgrounds in Health and Allied Sciences who were conversant 
with the local terrain were trained and engaged on the project to assist with participant 
recruitment and face-to-face interviews. Three research assistants were stationed in each of 
the five study facilities. Data was collected concurrently from the five study sites between 
April 2016 to April 2017. 
 
Phases of the study: The study was conducted in three interrelated phases; antenatal 
(prenatal), intrapartum (delivery) and post- postpartum (post-delivery) phases. Presented in 
Figure 6 are the specific type of data collected at each phase of the study. The data collection 
tools used included structured questionnaires, validated food frequency questionnaire, 
validated Edinburgh Postnatal Depression Scale (EPDS) and data extraction sheets. The 
questionnaires were designed and, in some cases, adopted from the Ghana Health Service 
Maternal Health Records Booklet and the delivery records book. The data collection tools are 
found in Appendix 8.1.  
 
 
 
 
Figure 6. Phases of the study and the types of data collected 
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2.4.1 Prenatal Care Phase 
One-on-one interviews were conducted with the 807 participants at enrolment. During the 
prenatal phase, the following data were collected directly from the participants.   
2.4.1.1 Socio-demographic and health indictors   
• Socio-demographic data: The women’s age, place of residence, ethnicity, marital 
status, educational level and occupation of the couple, and household size.   
• Obstetric history: Last menstrual period, parity (number of live births), gravida 
(number of pregnancies in her life-time) including spontaneous and induced abortions, 
and outcome of previous pregnancies (sex, mode of delivery, whether alive or dead, 
single or multiple delivery and any complications encountered). 
• Medical history: physical assessments using glycosuria, proteinuria, blood pressure 
measurements, probing for known individual and family history of diabetes, previous 
GDM, hypertension and other cardiovascular diseases. 
2.4.1.2 Maternal and fetal adiposity  
Maternal anthropometry: To assess adiposity, pre-pregnancy body weight was recorded if 
known. Weight and height were measured in the first trimester and used to determine the 
body mass index (BMI). Weight at first trimester is a good proxy for pre-pregnancy weight 
since no substantial weight changes are expected in the first trimester (Institute of Medicine, 
2009). Pregnancy weight change was monitored monthly. Pregnancy weight change was 
calculated by subtracting weight measurement when the woman reported at the health facility 
for delivery from the weight at the first ANC visit in the first trimester. BMI was estimated 
using weight (kg) divided by height squared (meter squared) and classified using WHO 
classification (WHO, 2006b). In accordance with recommendations from the Institute of 
Medicine on appropriate pregnancy weight gain based on a woman’s BMI, the expected 
weight gain for each BMI group was identified as shown below. Weight gain above the 
threshold was considered as a GDM risk (Institute of Medicine, 2009).  
    BMI       Pregnancy weight gain (kg) 
1. underweight (<18.5)    12.5-18.0  
2. normal weight (18.5-24.9)   11.5-16.0 
3. overweight (25.0-29.9)  7.0-11.5  
4. obese (≥30)     5.0-9.0  
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Mid-upper arm circumference (MUAC) was measured in the first, second and third trimesters 
of pregnancy and the average of two or the three closest values taken as MUAC measurement 
is fairly stable throughout pregnancy (Institute of Medicine, 2009). Since no optimal MUAC 
cutoff is currently available, measurements above the population specific cut-off values for 
the median MUAC value was used to estimate adiposity.  
Fetal growth: To determine fetal adiposity, ultrasound scans taken in the first, second and 
third trimesters of pregnancy were reviewed for fetal growth parameters such as estimated 
fetal weight, head circumference, crown rump length and femur length. Symphysio-fundal 
height was measured between 20-36 weeks gestation. Excess fetal growth was suspected 
when the symphysio-fundal height was larger than the gestational age by ultrasound scan. 
Fetal and newborn growth was assessed using guidelines from the International Fetal and 
Newborn Growth Consortium for the 21st Century study (Papageorghiou et al., 2014, Villar 
et al., 2014). 
 
2.4.1.3 Habitual dietary intakes  
A validated food frequency questionnaire (FFQ) modified based on habitually consumed 
foods in Ghana was used to assess the dietary patterns and intakes of the participants. Dietary 
patterns were derived a priori. The foods were classified into nine groups according to major 
nutrient contribution: (1) cereals and grains; (2) roots, tubers and plantain; (3) legumes and 
peas; (4) nuts and seeds; (5) animal source foods; (6) green leafy vegetables; (7) other 
vegetables; (8) fruits; and (9) fats and oils. Information was also taken on less consumed 
foods and snacks, confectionaries, fizzy drinks, fruit juices, alcohol, smoking, non-nutritive 
pica, supplements as well as food cravings, aversions and taboos.  
The FFQ had seven frequency of consumption categories ranging from (1) at least once daily; 
(2) 3-6 times per week; (3) 1-2 times per week; (4) 2-3 times per month; (5) once monthly, 
(6) rarely to (7) never. The dietary data was modified into a ten-food-group FFQ according 
to the FAO Minimum Dietary Diversity for Women (MDD-W) designed by the Food and 
Agriculture Organization (FAO, 2014). Consumption of at least five out of the ten defined 
food groups the previous day indicated micronutrient adequacy (FAO, 2014). The ten food 
groups are: 
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(1) staple foods (grains, white roots and tubers, and plantains);  
(2) pulses (beans, peas and lentils);  
(3) nuts and seeds;  
(4) dairy;  
(5) fleshy foods (meat, poultry and fish);  
(6) eggs;  
(7) dark green leafy vegetables;  
(8) other vitamin A-rich fruits and vegetables;  
(9) other vegetables; and  
(10) other fruits 
The dietary data was validated by a non-quantitative 24-hour call of foods eaten the previous 
day/night. Qualitative data on intake of high glycemic index (GI) foods including snacks and 
beverages during the day prior to the interview was obtained. Each carbohydrate-containing 
food consumed that contributed above 70% of the GI value was assigned a score of one. 
Example of these foods included white bread, polished rice, processed cassava and corn 
foods, ripe plantain, table sugar, pasta, pineapple, watermelons and soda drinks. To determine 
excess intake of high glycemic index foods, cumulative scores obtained from the high 
glycemic index foods consumed during the previous day were classified into three groups as 
follows: 
1. adequate (intake of high GI foods 1-2 times per day),  
2. moderate (intake of high GI foods 3-4 times per day) and  
3. excess (intake of high GI foods ≥5 times per day)  
 
 
2.4.1.4 Measurement of glycemic status  
The one-step universal strategy recommended by the IADPSG for diagnosing GDM was 
followed whereby all the study participants did all the screening and diagnostic tests for 
GDM. (Metzger et al., 2010a). The screening and diagnostic procedures is simplified in 
Figure 7. Glycosuria, random glucose and maternal history taking for GDM risk factor 
assessment were considered as screening tests whereas HbA1c, and 1-hour OGTT were 
diagnostic. Each screening test was evaluated reference to fasting plasma glucose and the 
‘gold standard’ 2-hour OGTT. Where thresholds for 2 out of these 4 test results were obtained, 
it was considered as a case of pre-existing diabetes first detected in pregnancy:  
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1. random blood glucose ≥11.1 mmol/L,  
2. 2-h OGTT ≥11.1 mmol/L,  
3. HbA1c ≥6.5% (7.8 mmol/L) or  
4. Fasting plasma glucose ≥7.0 mmol/L 
 
Screening for GDM 
Dipstick glycosuria: Glycosuria urinalysis was tested at every ANC visit as a qualitative urine 
dipstick test using the ‘Urit 5V’ urine reagent strips to detect the presence of glucose in about 
10 ml of urine. A colour change corresponding to trace test result or above (1+ to 4+) at any 
one point during pregnancy was considered to be screen positive for GDM. To be eligible for 
inclusion in the analysis, the woman should have performed at least one dipstick urine test 
each in the first, second and third trimesters.  
Random capillary glucose: Between 10-20 weeks, participants were screened for GDM 
through random capillary blood glucose. About 0.8ul capillary blood was drawn from the 
middle fingertip prick and measured on the point-of-care testing devise called ‘On Call Plus 
Blood Glucose Meter’. Random blood glucose >7.0 mmol/L was considered to be screen-
positive for GDM (National Institute for Health and Care Excellence, 2015). 
 
 
Figure 7. Screening and diagnostic procedures for GDM 
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Diagnosis of GDM  
All participants were scheduled for diagnostic testing between 20-28 gestational weeks. 
Participants who failed to turn-up were rescheduled for testing between 30-34 weeks. The 
evening prior to the test, participants were called and reminded to fast overnight for ten to 
twelve hours. Upon arrival at the laboratory in the morning of the test, they were made to rest 
for about 15 minutes before the tests were conducted.  
Fasting plasma glucose: Three millilitres of pre-prandial venous blood was drawn from the 
antecubital fossa. One ml of the blood was used to measure the fasting plasma glucose on a 
fully-automated ‘Selectra ProM’ clinical chemistry analyzer operating on kinetic enzymatic 
peroxidase-antiperoxidase principle. In accordance with the WHO (World Health 
Organization, 2013) and the NICE (National Institute for Health and Care Excellence, 2015) 
diagnostic criteria, fasting plasma glucose ≥5.1 mmol/L and ≥5.6 mmol/L were considered to 
be GDM diagnostic positive.  
Glycated hemoglobin: HbA1c was checked irrespective of clients’ fasting status using two 
ml of the venous blood. It was analyzed on an automated HA-8160 ADAMS analyzer 
operating on the ion exchange HPLC principle. Results were aligned to the Diabetes Control 
and Complications Trial (DCCT) method. HbA1c results ≥6.5% (7.8 mmol/L) was suggestive 
of GDM (National Institute for Health and Care Excellence, 2015).  
Oral glucose tolerance test: After drawing the pre-prandial blood, participants were 
supervised to drink within three minutes 75-gram anhydrous glucose dissolved in 300 ml of 
water at room temperature. Post-prandial venous blood was collected at one- and two-hour 
intervals and plasma glucose levels checked following similar biochemical procedure as for 
the FPG. As per the WHO diagnostic criteria, 1-hour OGTT ≥10.0 mmol/L and 2-hour OGTT 
≥8.5 mmol/L were indicative of GDM (World Health Organization, 2013). Also, the NICE 
diagnostic criterion based on 2-hour OGTT ≥7.8 mmol/L was indicative of GDM (National 
Institute for Health and Care Excellence, 2015).  
 
2.4.1.5 GDM case definition 
Diagnosis of gestational diabetes using fasting plasma glucose was in line with the NICE 
(National Institute for Health and Care Excellence, 2015) guideline while diagnosis using 2-
h OGTT was in line with the IADPSG/WHO guidelines (World Health Organization, 2013, 
IADPSG Consensus Panel, 2010). Since only one abnormal value is needed for GDM 
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diagnosis to be made (World Health Organization, 2013, Hod et al., 2015, National Institute 
for Health and Care Excellence, 2015), the case definition and diagnosis of GDM was done 
as follows:  
1. Fasting plasma glucose ≥5.6 mmol/L (National Institute for Health and Care 
Excellence, 2015) and/or 
2. 2-hour OGTT (≥8.5 mmol/L) (World Health Organization, 2013) 
Basis for choosing these thresholds is the result of a previous study where fasting plasma 
glucose ≥5.6 mmol/L and 2-h OGTT ≥8.5 mmol/L were found to have higher diagnostic 
validity including higher disease prediction compared to the lower thresholds recommended 
by WHO for fasting glucose (≥5.1 mmol/L) and the lower threshold recommended by NICE 
for 2-hour (≥7.8 mmol/L) required to make a diagnosis of GDM (Agbozo et al., 2018).  
Also, the recent updated guidelines whereby lower thresholds have been recommended by 
some health regularly bodies for GDM diagnosis has spark concerns of overdiagnosis of 
GDM and the resultant over medicalization of obstetric care (Cundy et al., 2014, Twohig et 
al., 2018, Glasziou, 2017, Moynihan, 2016, Moynihan et al., 2015, Bolognesi, 2015, 
Naaktgeboren et al., 2018). These informed the decision to limit to using higher and restrictive 
diagnostic thresholds for both fasting glucose (≥5.6 mmol/L) and 2-h OGTT (≥8.5 mmol/L) 
as the case definition for GDM in this study.  
 
2.4.1.6 Other tests performed  
Tests such as lipid profile (total cholesterol, triglycerides; high, low and very low-density 
lipoproteins), hemoglobin levels as proxy for iron status, full blood count, and blood film for 
malaria parasites were measured to assess the general health of the woman. Other routine 
tests conducted during ANC were extracted from the medical records. These included tests 
for hemoglobin Electrophoresis, glucose-6-phosphate dehydrogenase (G6PD) deficiency, 
blood group, rhesus factor, urine and stool routine examination, Venereal Disease Research 
Laboratory test for syphilis, Hepatitis B Virus Surface Antigen and HIV status. 
 
2.4.1.7 Quality control 
Blood samples were collected and analyzed by qualified laboratory scientists. On-the-spot 
tests were analyzed by midwives engaged on the project. To ensure comparability of the test 
results, the same brands of urine dipsticks and glucometers were used across all the study 
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facilities. The urine dip-stick brand was Urit Series 5V Urine Reagent Strips (Manual) 
manufactured by Urit Medical Electronic Group and supplied by the Ghana Health Service. 
The glucometer brand was On Call® Advanced Blood Glucose Monitoring System 
manufactured by Medical Device Safety System GmbH in Hannover, Germany. All the 
laboratory analyses were conducted at a central point, that is the research laboratory of the 
University of Health Allied Sciences located in the School of Public Health within the 
premises of the Hohoe municipal hospital. On-the-spot sample collection and analysis was 
done for random and fasting blood glucose using glucometer as well as for glycosuria and 
proteinuria using test trips. In cases where laboratory analysis was required (e.g. fasting 
plasma glucose, OGTT, lipid profile), samples were collected from participants at the 
respective study facilities, emptied into sodium fluoride or anticoagulant test tubes, stored in 
cold boxes and transported to the laboratory within a maximum of three hours for immediate 
analysis. Analysis of blood chemistries were done using the Selectra Pro M fully-automated 
Clinical Chemistry Analyzer manufactured by ‘EliTechGroup’. Standard operating 
procedures relating to calibration, client preparation, sample collection, specimen handling 
and preparation, reagents, materials and equipment needed, and analysis procedures were 
duly followed. Test quality was ensured by running controls after every 20th test and/or in the 
morning of each field visit as the case might be.  
 
2.4.2 Intrapartum Phase  
At delivery, the following information were extracted from the delivery records. 
Maternal information: Mode of delivery (spontaneous vaginal delivery, instrumentation, 
cesarean section); perineal injury; labour complications (prolong, obstructed labour, 
hemorrhage); pre-eclampsia and/or eclampsia.  
Newborn’s information: Gestational age at birth (preterm birth: below 37 weeks; term birth: 
37-42 weeks; and post-term birth: above 42 weeks); newborn’s anthropometry (birth-weight, 
length, head and chest circumferences); APGAR score at birth and after five minutes to 
determine respiratory distress; birth trauma especially shoulder dystocia; neonatal glucose 
status to assess hypoglycemia; congenital malformation; admission to intensive care and 
stillbirth.  
• Apgar score  
In relation to the newborn’s appearance, pulse, grimace, activity and respiration, 
cumulative Apgar scores at 1 and 5 minutes after birth  
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(1) ≥7 was considered as normal; 
(2) 4 to 6 implied fairly low Apgar;  
(3) ≤3 was considered as critically low and necessitated resuscitative efforts.  
 
• Diagnosis of neonatal hypoglycemia     
Hypoglycemia was assessed by taking capillary heel prick blood between 1-2 hours after 
birth into sodium fluoride micro-tube, placed immediately in a cold box and transferred 
to the research laboratory for analysis. Neonatal hypoglycemia was defined as glucose 
levels of <10th percentile, that is 2.2 mmol/L (Metzger et al., 2010b). It is recommended 
that intervention to increase blood glucose in newborns diagnosed with neonatal 
hypoglycemia should be considered if two consecutive blood glucose levels are below 2 
mmol/L or a single blood glucose level is below one mmol/L (Hawdon, 2012). Hence 
categorization based on severity was done as follows (Tin, 2014): 
o Mild: blood glucose 2.2–2.8 mmol/L (40–50 mg/dl); 
o Moderate: 1.1–2.2 mmol/L (20–40 mg/dl); 
o Extreme: <1.1 mmol/L (20 mg/dl)  
 
2.4.3 Postpartum phase  
Twelve 12 weeks after delivery, the study participants were contacted in their homes to 
monitor glycemic status especially for women diagnosed with GDM. Postpartum 
anthropometric changes and general health of the mother-infant pairs were also assessed. 
• Maternal information: Weight; height, MUAC; fasting plasm glucose; and assessment 
for postpartum depression using the validated Edinburgh Postnatal Depression Scale. 
• Infant information: Body weight, length, head/chest circumferences and MUAC; 
infant feeding including breastfeeding; immunizations; infections (jaundice, sepsis, 
pneumonia, diarrhoea, malaria); and general wellbeing. 
 
2.4.4 Baseline Study of the Context  
The cross-sectional survey was conducted as the first step to investigate all deliveries over a 
2-year period from January 2013 to December 2014 to assess the prevalence of macrosomic 
births. The data covered 4,359 pregnant women between the ages of 12-51 years who 
delivered 4,477 newborns in the Hohoe municipal hospital. All women with documented 
delivery record in the delivery register were reviewed. After excluding multiple births, 4262 
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infant-mother pairs were included in the analysis. Maternal information extracted included 
age at delivery, gravidity (number of pregnancies in her lifetime), parity (number of live 
children), number of doses of sulfadoxine–pyrimethamine taken for Intermittent Preventive 
Treatment (IPT) for Malaria in Pregnancy, HIV status, partner involvement during labour and 
the mode of delivery. Newborn information extracted included birthweight, sex and whether 
alive or dead at birth.  
 
2.5 Exposure and Outcome Measures   
Main exposure of interest was diagnosis of gestational diabetes in line with the case 
definition.  
Maternal outcomes: Primary maternal outcomes were cesarean delivery and perineal trauma 
while the secondary outcomes were preeclampsia (defined as concomitant hypertension and 
proteinuria with/without edema) and post-partum hemorrhage (defined as estimated blood 
loss above 500 ml). 
Fetal outcomes: Primary outcomes were fetal adiposity and survival. Secondary newborn 
outcomes were gestational age at birth and hypoglycemia. 
Fetal adiposity was assessed using 3 indicators:  
(1) macrosomia defined as birth weight ≥4 kg regardless of gestational age at birth;  
(2) large for gestational age defined as birth weight >90th percentile per the 
InterGrowth study standards accounting for gestational age at birth and sex of the 
newborn; and  
(3) Ponderal Index (PI) defined as newborn weight (g)/length (cm3) ×100 and 
classified as small for gestational age (<2.0), marginal (2.0-2.5), normal (2.5-3.0.) 
and large for gestational age (≥3.0). 
Newborn survival was assessed using 4 indicators:  
(1) Apgar score at one and five minutes,  
(2) newborn resuscitation,  
(3) admission to neonatal intensive care unit (NICU) and  
(4) perinatal death (that is, death before discharge home)  
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2.6 Statistical Analyses  
Described in this section is how the raw data generated through the various data collection 
procedures were processed and analysed. Data was entered into Statistical Package for the 
Social Sciences (SPSS version 24) for preliminary data cleaning and management. Data 
analysis was conducted in STATA (version 14.2). To ensure that errors were reduced, 
consistency and plausibility checks were done; multicollinearity and singularity among 
independent variables checked; and residual scatter plots visualized to check for normality, 
linearity, and homoscedasticity. Also, correlation matrix was computed to identify 
collinearity and possible confounders while interaction terms were considered in final model 
selections. The data was summarized using descriptive statistics including frequencies and 
percentage distributions for categorical variables. Interquartile values, ranges, means (x̄) and 
standard deviations (SD) were used to report continuous variables.  
To make inferences from the analysis of continuous variables, paired samples t-test was used 
for repeated measures, one sample t-test was used to compare means of two unrelated groups 
whereas one-way analysis of variance (ANOVA) was used to determine whether there were 
any statistically significant differences between the means of more than two independent 
groups. To test differences between two or more groups, the inferential statistics used was 
Fisher’s exact test for 2×2 contingency tables (pairwise comparisons). For tables with more 
than two rows and/or columns, Pearson's Chi-square test (χ2) was used for multiple 
comparisons.  
Post-hoc tests using Bonferroni-corrected pairwise technique or least significant difference 
(LSD) was used for categorical variables with more than two response levels to adjust for the 
effect of multiple comparisons and determine specific variables that generated significant 
differences. McNemar's test aided in reducing inter-subject variability in polychotomous 
variables obtained at different time points. Results were statistically significant when 
confidence intervals (CI) excluded one and the P-value was <0.05 at 95% confidence level 
and 5% margin of error. A detail description of the analysis conducted is presented below.  
 
2.6.1 Validation of diagnostic accuracy  
In the exception of results from dipstick glycosuria, all the tests yielded continuous scale 
values. Diagnostic thresholds aided in defining positive and negative results. Changing the 
threshold changed the proportion of false positive and false negative diagnoses. The formulae 
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used in estimating the diagnostic measures is presented in Table 5. Number of true positive, 
true negative, false positive, and false negative were estimated reference to the diagnostic 
criteria for 2-h OGTT based on the WHO (≥8.5 mmol/L) and NICE (≥7.8 mmol/L) 
guidelines. Similar measures were calculated for fasting plasma glucose in accordance with 
the WHO (≥5.1 mmol/L) and NICE (≥5.6 mmol/L) diagnostic criteria. This was done by 
designing a 2 x 2 table with participants grouped according to the reference test in columns, 
and the categorization of disease status in rows.  
Paired diagnostic accuracy was estimated using standard formulas for disease measurement 
to evaluate the discriminative, predictive and diagnostic properties of each test. 
Discriminatory and predictive abilities were determined by test sensitivity (true positive rate), 
specificity (true negative rate), positive and negative predictive values, and positive and 
negative likelihood ratios (LR). Likelihood ratios for instance compares probabilities that a 
person with a particular disease will have a specified test result versus the probability that a 
person without that disease will have the same test results. Positive and negative predictive 
values are measures of test performance that are used in interpreting patients' results (Raslich 
et al., 2007). Other predictive measures used to validate diagnostic accuracy included 
Youden's index, diagnostic effectiveness and diagnostic odds ratio (DOR). Except for 
negative LR where lower values indicate more discriminatory ability of the test, for all the 
disease measures estimated, higher values were indicative of more discriminatory and 
predictive diagnostic accuracy.  
To determine overall test performance, receiver operating characteristic (ROC) curve and 
coordinates of the curve was obtained for each continuous glucose measurements. Test 
performance was evaluated based on the area under the curve (AUC). The closer the curve 
was to the left-hand upper border of the ROC space, the more accurate the test. Rating ranged 
from excellent (AUC = 0.9 to 1.0), very good (0.8 to <0.9), good (0.70 to <0.80), sufficient 
(0.60 to <0.70), poor (0.50 to <0.60) to invaluable (AUC <0.5) (Raslich et al., 2007) (Mallett 
et al., 2012). The p-value for each variable tested the null hypothesis that the true area under 
the ROC curve equal to 0.5 (no effect). This is the diagonal where the true positive rate equals 
the false positive rate. A p-value <0.05 indicated that the null hypothesis could be rejected, 
meaning the test was clinically relevant (Raslich et al., 2007). The lower the p-value, the 
better the test performance. Reference cut-offs for each test that provided analogous and 
clinically useful sensitivity and specificity for the study population was estimated from the 
coordinates of the ROC curve. 
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Table 5. Diagnostic validity, basic definitions and method of estimation 
Diagnostic 
measure  
Basic definition Estimation 
True positive 
(TP)a  
Actual GDM cases correctly identified as having 
GDM 
 GDM No 
GDM 
Test 
+ 
TP FP 
Test 
- 
FN TN 
 
False negative 
(FN)a 
Actual GDM cases wrongly identified as not having 
GDM 
False positive 
(FP)a 
Those without GDM wrongly identified as having 
GDM 
True negative 
(TN)a 
Those without GDM correctly identified as not having 
GDM 
Sensitivity  The proportion of actual GDM positives that are 
correctly identified as such. Probability that a person 
with the target disease will test positive  
=  
TP
TP + FN
 
Specificity  The proportion of actual GDM negatives that are 
correctly identified as such. Probability that a person 
without the target disease will test negative 
=  
TN
TN + FP
 
Positive 
predictive 
value  
Probability of having the state/disease of interest in a 
subject with positive result. Percent with positive 
result having the disease. 
=  
TP
TP + FP
 
Negative 
predictive 
value  
Probability of not having a disease in a subject with a 
negative test result. Percent with negative result not 
having the disease. 
=  
TN
TN + FN
 
Positive 
likelihood 
ratiob 
Ratio of probability that a positive test result occurs in 
subjects with the disease compared to those without 
disease. Useful for ruling-in diagnosis 
=  
Sensitivity 
1 − Specificity 
 
Negative 
likelihood 
ratiob 
Probability that a negative result occurs in subjects 
with the disease to probability that same result occurs 
in subjects without the disease. Useful for ruling-out 
diagnosis 
=  
1 −  Sensitivity 
Specificity 
 
Diagnostic 
accuracy 
Discriminative ability of a diagnostic test that gives 
the probability that an individual will be correctly 
classified by a test 
 
TP + TN
TP + TN + FP + FN
 
Diagnostic 
odds ratioc 
It is the ratio of the odds of positivity in subjects with 
disease relative to the odds in subjects without disease  
=  
TP + FN
FP + TN
 
Youden's 
indexd 
Measure of a test performance used to evaluate overall 
discriminative power of a diagnostic procedure and to 
compare test with other tests 
= (Sensitivity
+ Specificity) − 1  
ROC curve & 
area under the 
curve 
Global measure of diagnostic accuracy that helps to 
estimate the discriminative power of a test. The closer 
the curve to the upper left-hand corner and the larger 
the area, the better the discrimination between those 
with and without the disease.  
0.9-1.0: Excellent; 0.8-
0.9: Very good; 0.7-0.8: 
Good; 0.6-0.7: 
Sufficient; 0.5-0.6: Bad; 
<0.5: Not useful  
a Number of true positive, false negative, false positive and true negative estimated with the aid of the inserted 
two-by-two table.  
b Good diagnostic tests have positive likelihood ratio >10 and negative likelihood ratio <0.1 and  
c Higher discriminatory and predictive values indicate more diagnostic accuracy. Diagnostic odds ratio ranges 
from 0 to infinity with higher values indicating more discriminatory properties.  
d Youden's index values ranges from -1 to 1  
Source: (Raslich et al., 2007, Mallett et al., 2012).  
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2.6.2 Determinants of GDM  
To assess the significant determinants for GDM, the case-control component was analyzed 
using the dichotomous outcome (GDM present or absent) tabulated in a two-by-two table 
with the predictor variables. GDM present was defined as 2-h OGTT ≥8.5 mmol/L and/or 
fasting glucose ≥5.6 mmol/L whereas GDM was absent when thresholds lower than this were 
obtained. To run the model, all the predictor variables were recategorized into dichotomous 
forms. For instance, formal educational was recategorized into primary level versus 
secondary level and above; BMI into overweight/obese versus normal/underweight, parity 
into more than 3 children versus 3 children and below; glycemic intake into excess versus 
moderate/adequate (Table 15), etc. Statistical differences between the cases and controls were 
tested using the Cochran-Mantel-Haenszel statistic. Unconditional univariate logistic 
regression model was run to generate the crude estimates of association between the predictor 
variables and GDM as the outcome. This regression model was used because the cases and 
controls were unmatched. Then correlation analysis was conducted using variables known 
from literature and clinical practice to increase or decrease likelihood for GDM. Variables 
with p-value ≤ 0.3 and factors demonstrated from literature to be associated with GDM were 
selected into the final regression model. Confounding factors were adjusted for by stratifying 
the exposure variables into sub-groups and computing the multivariate binary logistic 
regression to obtain the adjusted odds ratios (AOR). Fit of the logistic regression models were 
evaluated using Goodness-of-fit whereas R-squared (coefficient of determination) was used 
to determine the percent of variance explained by the regression model.  
 
2.6.3 Associated Birth Outcomes  
First, the continuous scale measurements for 2-h OGTT and fasting glucose were used as the 
predictor scale variables and simple linear regression analysis with the outcome variables to 
estimate the regression coefficients and identify the direction of a unit increase in 2-h OGTT 
and fasting glucose on each maternal and newborn outcome. After computing a correlation 
matrix to identify collinearity and noting the possible confounding factors and interaction 
terms, the predictor variable was categorized as binary, that is, GDM present defined as 2-h 
OGTT ≥8.5 mmol/L and/or fasting plasma glucose ≥5.6 mmol/L and GDM absent when 2-h 
OGTT and FPG fell below these thresholds. To estimate the pregnancy outcomes associated 
with GDM, a multivariate binary logistic regression model was run to estimate the relative 
risk (RR) association of GDM with pregnancy outcomes. To ensure that the final model was 
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significant, the model summary had a Prob > Chi2 = 0.0000 and the Hausman test showed no 
evidence of violation of the independent of irrelevant alternative assumption. A p-value of 
<0.05 and CI excluding one were considered as statistically significant.  
 
2.6.4 Postpartum Glycemia   
Differences in the prenatal and postpartum scale fasting glucose measurements was tested 
using paired-comparisons t-test to analyze for significant change. To determine the extent of 
attainment of euglycemia at 12 weeks postpartum, postpartum glycemic outcome was 
categorized into a binary variable. GDM was considered to be resolved when fasting glucose 
at 12 weeks postpartum was less than <5.6 mmol/L whereas GDM was considered to persist 
when fasting glucose measurement was ≥5.6 mmol/L at 12 weeks postpartum. The binary 
outcome (GDM resolved and GDM unresolved) were analyzed using a two-by-two table and 
the difference in the two groups tested using McNemar’s test.  
 
2.7 Ethical Consideration and Consenting 
All procedures pertaining to human research ethics was adhered to in accordance to the 
Helsinki declaration. The study was approved by the Ghana Health Service Ethics Review 
Committee (GHS-ERC-GM 04/02/16) and the Institutional Review Board of Heidelberg 
University Medical Faculty (S-042/2016). All participants including minors (less than 18 
years) provided written informed consent after verbal explanation of the study protocol to 
every potential participant who met the inclusion criteria. Voluntary willingness to participate 
in the study was obtained by either signing or thumb-printing the consent form. Pregnant 
teenagers were included in this study but were not required to provide assent because they 
were considered by the ethical review committee as emancipated adults. Permission was 
granted by heads of the respective study facilities and the Volta regional health directorate. 
To ensure that quality of care for all women who sought ANC care in the study facilities was 
not compromised, a woman’s status as a study participant was known only to the research 
team. Personal details of participants were taken only for the purpose of addressing them 
appropriately and facilitating follow-up at all phases of the study. In Appendix 8.2 is the 
participant information and consent form used. 
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2.7.1 Unintended Treatment Effect of the Study   
During the study period, when a participant was identified to have any physical, social or 
mental health condition either through the interviews, physical assessment or diagnostic 
procedures that affected the wellbeing and optimum pregnancy experience, a clinical staff 
was notified immediately for appropriate action to be taken. Particularly at the prenatal stage 
of the study, a chain of communication was instituted from the research assistants to the 
midwife in-charge at the antenatal clinic. Through this chain, participants who were 
diagnosed with gestational diabetes or any other health problem were referred to the 
appropriate specialist for treatment. Consequently, although provision of an intervention to 
GDM cases was not a direct objective of this study, referral and subsequent management of 
diagnosed cases was expected to have a positive effect on the materno-fetal outcomes. The 
referral procedures instituted in provided in Appendix 8.3.  
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3 RESULTS 
_______________________________________________________________________________________________________________ 
Note: The doctoral student has published some aspects of this chapter in the underlisted publications. For details, see pages 109-111. 
• Prevalence of low birth weight, macrosomia and stillbirth and their relationship to associated maternal risk factors in Hohoe 
Municipality, Ghana. Midwifery Journal; http://dx.doi.org/10.1016/j.midw.2016.06.016  
• Accuracy of glycosuria, random blood glucose and risk factors as selective screening tools for gestational diabetes mellitus in 
comparison with universal diagnosing. BMJ Diabetes Research & Care http://dx.doi:10.1136/bmjdrc-2017-000493  
• Gestational diabetes using diverse diagnostic criteria, risk factors including dietary intakes, pregnancy outcomes and postpartum 
glycemic status: a nested case-control study in Ghana. bioRxiv 582239 https://doi.org/10.1101/582239  
 
This results chapter is organized into five sections according to the study objectives. Results 
on the prevalence of gestational diabetes and diagnostic validity of the test instruments are 
described in the first and second sections respectively. Results on the associated risk factors 
and birth outcomes are described in the third and fourth sections respectively. The chapter 
closes with results on the postpartum glycemic status of cases. Number of participants 
enrolled in each stage of the study is shown in Figure 8. 
Overall, 807 participants were booked for GDM testing of which 490 representing 55% 
reported for diagnostic testing but 446 and 435 participants performed the fasting plasma 
glucose test and 2-hour OGTT respectively. Also, 402 were traced at delivery and 100 
followed-up at 12 weeks postpartum.  
 
3.1 Prevalence of GDM Per Diverse Diagnostic Criteria  
3.1.1 Description of Blood Glucose Values  
In Figure 9 is the comparison of interquartile glucose values for each test among primary 
(n=78) and secondary/referral (n=357) facility users. In comparison to secondary/referral 
facility users, primary facility users had significantly higher mean fasting plasma glucose 
(4.44±0.98 vs 5.12±0.85 mmol/L), 1-h (6.70±1.88 vs 7.20±1.83 mmol/L) and 2-h 
postprandial glucose (6.24±1.71 vs 6.74±1.72 mmol/L). However, no statistical differences 
were observed for RBG and HbA1c. Overall, mean 1-h OGTT (7.2±1.8 mmol/L) was 0.5 
mmol/L higher than 2-h OGTT (6.7±1.7 mmol/L). Also, mean RBG (5.4±1.1 mmol/L) was 
0.3 mmol/L higher than the fasting plasma glucose (5.1±0.9 mmol/L). Fairly strong 
correlation was observed between 2-h OGTT and 1-h OGTT values (r=0.764, p<0.001) and 
also between 2-h OGTT and fasting plasma glucose values (r=0.643 (p<0.0001) but 
correlation the between 2-h OGTT and random glucose values (r=0.240, p<0.0001) and 
HbA1c were weak.  
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Figure 8. Number of participants followed-up at each stage of the follow-up 
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Figure 9. Box and whisker plots comparing interquartile and mean glucose values among users of primary and secondary/referral facilities  
Note: The Solid line represents the WHO diagnostic criteria and dotted lines represent the NICE diagnostic criteria. The referral facility is the Regional hospital in the process 
of upgrade to a teaching hospital 
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3.1.2 Prevalence According to Common Diagnostic Criteria  
The main diagnostic criteria used in diagnosing and classifying GDM were the guideline by 
IADPSG adopted by the WHO, International Federation of Gynecology and Obstetrics and 
American Diabetes Association; and the guideline by the NICE. 
Fasting glucose of 446 participants and 2-hour OGTT of 435 participants were obtained. 
Prevalence of gestational diabetes per 2-h OGTT ≥8.5 mmol/L was 9.0% (n=39, 95% CI; 6.3-
11.6) and prevalence per fasting plasma glucose ≥5.6 mmol/L was 10.8% (n=49, 95% CI; 
8.1-13.9). Participants who met the case definition of 2-h OGTT ≥8.5 mmol/L and/or fasting 
plasma glucose ≥5.6 mmol/L were 15.9% (n=70/446; 95% CI; 12.5-19.3). Only 3.9% 
(n=17/433; 95% CI; 2.1-5.8) were positive for both 2-h OGTT ≥8.5 mmol/L and fasting 
plasma glucose ≥5.6 mmol/L whereas 15.9% (n=70/466, 95% CI; 12.5-19.3) had either FPG 
≥5.6 mmol/L or 2-h OGTT ≥8.5 mmol/L being positive. Presented in Table 6 is the 
prevalence of gestational diabetes according to the common diagnostic criteria.  
 
Table 6. Prevalence of GDM according to common diagnostic criteria 
 
Diagnostic 
criteria 
Fasting plasma 
glucose positive 
(N=446) 
 2-hour OGTT 
positive  
(N=435) 
 Fasting glucose 
and/or 2-h OGTT 
positive e (n=446) 
Cut-off 
mmol/L 
Prevalence 
% 
 Cut-off 
mmol/L 
Prevalence 
% 
 Prevalence  
% 
IADPSGa/WHO/ 
FIGO/ADA 
≥5.1 23.8  ≥8.5 9.0  26.5 
NICEb ≥5.6 10.8  ≥7.8b 14.3  20.3 
CDA ≥5.3 16.9  ≥9.0 5.1  18.9 
ACOG/Carpenter 
& Coustanc 
≥5.3 16.9  ≥8.6 7.8  20.0 
ACOG/NDDGc ≥5.8 8.3  ≥9.2 4.4  10.6 
1999 WHO ≥7.0 2.7  ≥7.8 14.3  14.9 
This studyd ≥5.6 10.8  ≥8.5 9.0  15.9 
IADPSG: International Association of Diabetes in Pregnancy Study Groups (IADPSG Consensus Panel, 2010); 
WHO: World Health Organization (World Health Organization, 2013); FIGO: International Federation of 
Gynecology and Obstetrics (Hod et al., 2015); ADA: American Diabetes Association (American Diabetes 
Association, 2015); NICE: National Institute for Health and Care Excellence (National Institute for Health and 
Care Excellence, 2015); CDA: Canadian Diabetes Association (Diabetes Canada Clinical Practice Guidelines 
Expert Committee, 2018a); ACOG: American Congress of Obstetricians and Gynecologists (Committee on 
Practice Bulletins—Obstetrics, 2018). 
a IADPSG criteria is adopted by WHO, FIGO, ADA, Australian Diabetes in Pregnancy Society and Brazilian 
Society of Diabetes. GDM is diagnosed made when one or both glucose values is abnormal. 
b NICE cut-off for 2-h OGTT is used by the Diabetes in Pregnancy Study group in India but 2-h OGTT is done 
irrespective of the woman’s fasting state. 
c ACOG recommends 2-step screening. Diagnosis requires two or more elevated values on the 3-h OGTT. 
d This study used a case definition of fasting plasma glucose (≥5.6 mmol/L) and 2-h OGTT (≥8.5 mmol/L). 
e GDM is diagnosed made when one or both of the diagnostic cut-off values is exceeded 
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3.1.3 Prevalence Per Diverse Fasting Glucose and 2-h OGTT Combinations  
Using the case definition of 2-h OGTT ≥8.5 mmol/L and fasting plasma glucose ≥5.6 mmol/L 
to determine the prevalence of gestational diabetes, varied GDM prevalence were 
investigated using combinations of 2-h OGTT and fasting plasma glucose. As shown in Table 
7, it was observed, for instance that 6.7% of participants were positive for GDM based 
exclusively on fasting plasma glucose ≥5.6 mmol/L while the 2-h OGTT was negative (that 
is below the 8.5 mmol/L cut-off). Likewise, 5.0% had positive 2-h OGTT while the fasting 
plasma glucose was negative. 
 
Table 7. Prevalence using diverse fasting glucose and 2-h OGTT combinations  
 Combinations of 2-h OGTT and fasting glucose N n % 
1.  Either fasting positive and/or 2-h OGTT positive a  446 70 15.9 
2.  All fasting glucose positive  
(irrespective of 2-h OGTT results) 
446 48 10.8 
3.  All 2-h OGTT positive (irrespective of fasting results) 435 39 9.0 
4.  Only fasting glucose positive but 2-h OGTT negative 
(both positive cases excluded) 
416 28 6.7 
5.  Only 2-h OGTT positive but fasting glucose negative  
(both positive cases excluded) 
416 21 5.0 
6.  Both fasting and 2-h OGTT positive  433 17 3.9 
7.  Either fasting glucose positive or 2-h OGTT positive  
(but not both being positive)  
416 49 11.8 
N: sample size; n: number of observations. a The NICE cut-off for fasting plasma glucose (≥5.6 mmol/L) was 
used to define GDM (National Institute for Health and Care Excellence, 2015) while the IADPSG/WHO cut-
off for 2-hour OGTT ≥8.5 mmol /L was used to define GDM (World Health Organization, 2013).  
 
 
 
3.1.4 Proportion of Pre-Existing Diabetes and Screen-Positive Cases  
Pre-existing diabetes first detected in pregnancy was 2.0% (n=10, 95% 95% CI: 1.0-3.5). Per 
WHO diagnostic criteria, prevalence based on fasting plasma glucose ≥5.1 mmol/L was 
23.8% (n=106, 95% CI: 19.8-27.9) while based on 1-h OGTT ≥10.0 mmol/L was 4.5% (n=20, 
95% CI: 2.7-6.7). Regarding screening outcomes, almost one third (29.1%, n=130, 95% CI: 
24.7-32.6) of participants had at least one risk factor for GDM, 9.1% had two risk factors 
while only 1.3% had three risk factors. Positive dipstick glycosuria including trace results 
was 31% while random blood glucose ≥ 7.0 mmol/L was 4.7%. Figure 10 shows the 
prevalence based on screening and other diagnostic tests. If the WHO 1999 criteria for fasting 
glucose ≥7.0 mmol/L was in use, the prevalence of GDM would have been 2.7% (n=12, 95% 
CI: 1.1-4.3). 
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Figure 10. Percentage of participants who tested positive to the screening and 
diagnostic tests and the proportion who had pre-existing diabetes  
Note: GDM diagnosis from 2-h OGTT (≥8.5 mmol/L) using WHO and NICE (≥7.8 mmol/L) guidelines; fasting 
plasma glucose using WHO (≥5.1 mmol/L) and NICE (≥5.6 mmol/l); 1-h OGTT using WHO (≥ 10.0 mmol/L); 
HbA1c using NICE (≥6.5% [7.8 mmol/L]).  
Source: WHO guideline (World Health Organization, 2013) and NICE guideline (National Institute for Health 
and Care Excellence, 2015) 
 
 
3.2 Diagnostic Accuracy of Test Instruments 
3.2.1 Blood/Urine Glucose and Risk Per Facility Type 
Presented in Table 8 is the breakdown of diagnostic-, screen-, and risk factor-positive 
proportions among primary and secondary/referral facility users. Even though GDM tended 
to be more prevalent among primary healthcare users, no significant differences existed 
except for the prevalence based on fasting glucose from the WHO (48.7% vs 18.7%) and 
NICE cut-offs (23.4% vs 8.2%) and HbA1c (11.7% vs 5.2%). However, compared to primary 
facility users, significantly higher proportion of secondary facilities users were obese per the 
first trimester BMI (4.3% vs 13.5%) and had higher triglycerides (35.0% vs 64.4%).   
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Table 8. Comparison of blood/urine glucose and GDM risk profile among participants 
accessing antenatal care from primary and secondary facilities  
Test and reference cut-off 
values 
Mean±SD % (n) 
 
95% CIe Facility (%) P-value g 
Primary Secondf  
    (n=77) (n=369)  
Diagnostic tests       
2-h OGTT ≥8.5 mmol/L a 6.7±1.7 9.0 (39) 6.5-12.0 10.3 8.7 0.663 
2-h OGTT ≥7.8 mmol/l b 6.7±1.7 14.3 (63) 11.0-17.5 20.5 12.9 0.106 
1-h OGTT ≥10.0 mmol/L a 7.2±1.8 4.5 (20) 2.7-6.7 6.4 4.1 0.368 
Fasting glucose ≥5.1 mmol/La 5.1±0.9 23.8 (106) 19.8-27.9 48.7 18.7 <0.0001* 
Fasting glucose ≥5.6 mmol/Lb 5.1±0.9 10.8 (48) 7.9-13.7 23.4 8.2 <0.0001* 
HbA1c ≥ 6.5% b 5.5±0.9 6.3 (30) 4.2-8.5 11.7 5.2 0.040* 
Screening tests d      
Random glucose >7.0mmol/Lb 5.4±1.1 4.7 (23) 2.9-6.7 6.2 4.4 0.562 
Glycosuria ≥ trace  d 3.1 (15) 1.6-4.7 1.2 3.4 0.484 
Risk factors       
Maternal age >35 years 28.4±6.3 13.8 (62) 10.5-17.2 13.3 13.9 >0.999 
Gravidity above 5  2.7±1.5 5.4 (24) 3.4-7.7 6.7 5.1 0.577 
Parity above 3 children  1.5±1.3 7.1 (30) 4.8-9.7 5.8 7.4 0.801 
Body weight >90 kg c 63.0±13.1 3.4 (15) 1.8-5.3 1.4 3.8 0.483 
Height <150 cm 161.8±8.2 4.2 (19) 2.4-6.2 5.9 3.9 0.509 
BMI ≥29.9 kg/m2 24.7±4.9 12.0 (52) 9.0-15.0 4.3 13.5 0.027* 
MUAC >30 cm c 28.3±3.9 23.3 (103) 19.5-27.6 16.9 24.5 0.220 
Family history of diabetes  d 6.4 (29) 4.2-8.6 8.0 6.1 0.604 
Systolic BP >140 mmHg 106.6±12.4 2.0 (9) 0.7-3.3 1.4 2.1 >0.999 
Diastolic BP >90 mmHg 66.2±9.4 1.8 (8) 0.7-3.1 1.4 1.9 >0.999 
Proteinuria ≥1+  d 4.2 (19) 2.4-6.0 1.3 4.8 0.338 
Triglycerides >2.25 mmol/L 3.0±1.7 59.5 (290) 55.0-63.9 35.0 64.4 <0.0001* 
OGTT: oral glucose tolerance test; BMI: body mass index; MUAC: mid-upper arm circumference; BP: blood 
pressure.  
a, b Same tests but different diagnostic criteria based on aWHO and bNICE guidelines.  
c Maternal weight, height and mid-upper arm circumference were measured in the first trimester.  
d The blank spaces represent categorical variables that do not have mean values.  
e Represents the 95% CI for the positive proportions [% (n)].  
f  Included in the secondary facilities was the largest referral facility in the region (Volta regional hospital) now 
upgraded to a teaching hospital.  
g Differences among primary and secondary facility estimated by Chi-square test 
 
 
3.2.2 Flow of Participants through the Study   
In reporting findings from the diagnostic accuracy study, the 2015 STARD guidelines 
(standards for reporting diagnostic accuracy studies) (Bossuyt et al., 2015) was followed. 
Overall, 807 pregnant women aged 15-54 years were booked for GDM screening between 
12-20 gestational weeks. Even though all participants performed dipstick urine testing, 797 
participants had the urine dipstick test results documented for at least three times during the 
pregnancy (one in each trimester) while random blood glucose was performed by 732 
participants. Concerning diagnostic tests, between 20-34 weeks, fasting plasma glucose of 
446 participants were tested while 436 and 435 completed the 1-hour and 2-hour OGTT 
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respectively. The over 300 participants missed in the follow-up diagnostic testing were as 
result of logistical constraints; difficulty establishing contact; relocation outside the study 
area; lack of interest in doing the test, spontaneous termination of the pregnancy, inability to 
fast overnight and difficulty tolerating the OGTT. Participants’ flow through the study, 
proportions performing each screening and diagnostic test and the main reasons for 
withdrawal is shown in Figure 11.  
 
 
Figure 11. Flow of participants through the study and the proportions who tested 
positive and negative to each screening and diagnostic test 
Note: TP: true positive; FN: false negative; FP: false positive; FN: false negative; RBG: random blood glucose; 
FPG: fasting plasma glucose: HbA1c: glycated hemoglobin; OGTT; the ‘goal standard’ oral glucose tolerance 
test   
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3.2.3 Validation of Test Instruments  
3.2.3.1 Sensitivity, specificity, predictive and other diagnostic measures   
Presented in Table 9 and Table 10 are the diagnostic measures of the test instruments 
reference to the ‘gold standard’ 2-h OGTT and fasting plasma glucose estimated based on 
WHO and NICE cut-offs. Generally, the screening tests had low sensitivity and positive 
predictive value whereas their specificity and negative predictive values were relatively high. 
Using the WHO diagnostic criteria for 2-h OGTT as reference, fasting plasma glucose ≥5.1 
mmol/L had the highest sensitivity (68%) and negative predictive value (96%). However, 1-
h OGTT had the highest specificity, positive predictive value (75%) and diagnostic odds ratio. 
Glycosuria, HbA1c and RBG were the least sensitive (<15%) and hence yielded a clinically 
irrelevant specificity above 95%. Although presence of at least one risk factor was 54% 
sensitive, its accuracy was the least among the test instruments (≈70%).  
Similar pattern was observed when the NICE diagnostic criteria for 2-h OGTT (≥7.8 mmol/L) 
was used as the reference cut-off. But here, the test instruments had relatively lower 
sensitivity and DOR. Using the WHO diagnostic criteria for fasting plasma glucose (≥5.1 
mmol/L) as the reference yielded generally lower diagnostic measures. Two-hour OGTT ≥7.8 
mmol/L had the highest sensitivity and negative predictive value. This was followed by risk 
factors with a sensitivity of 32%. However, the 1-h OGTT ≥10.0 mmol/L had the highest 
positive predictive value and diagnostic odds ratio. When the NICE diagnostic criteria for 
fasting plasma glucose (using ≥5.6 mmol/L cut-off) was the reference test, sensitivity of the 
test instruments were slightly higher. 
If selective screening based on glycosuria test result of trace and above were used, only 3.2% 
would have been booked to perform a diagnostic test for GDM. Out of this total, only 2.6% 
would be positive if the test of choice was 2-h OGTT. Should the glycosuria cut-off be 
changed to 1+ and above, the proportion of screen-positive cases would further have declined 
to less than one percent and none of the participants would have needed a diagnostic test. If 
selective diagnostic testing based on random blood glucose >7.0 mmol/L were used, only 
4.8% would have performed a diagnostic test for GDM out of which 12.8% would have tested 
positive. If selective diagnostic testing based on the presence of at least one risk factor was 
as basis to inform diagnostic testing, 29.1% would have performed a diagnostic test out of 
which 53.4% would be positive. 
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Table 9. Diagnostic measure of test instruments using two-hour OGTT ≥8.5 mmol/L (WHO) and ≥7.8 mmol/L as (NICE) diagnostic 
criteria 
 
Diagnostic 
measure 
WHO reference cut-offs (≥8.5 mmol/L) NICE reference cut-offs (≥7.8 mmol/L) 
Risk 
factorsa 
Glyco
suriab 
RBGc HbA1cd FPGe FPGf 1-h 
OGTTg 
Risk 
factorsa 
Glyco
suriab 
RBGc HbA1cd FPGe FPGf 1-h OGTTg 
True positive  19 1 5 1 26 16 15 23 3 6 2 38 21 17 
False negative 16 38 33 37 12 21 23 35 59 56 59 22 39 44 
False positive 97 13 16 26 77 29 5 93 11 15 25 65 24 3 
True negative 267 383 381 364 318 367 391 248 362 358 342 308 349 370 
Sensitivity (%) 54.3 2·56 13·16 2·63 68·42 43·24 39·47 39.7 4·84 9·68 3·28 63·33 35·00 27·87 
Specificity (%) 73.4 96·72 95·97 93·33 80·51 92·68 98·74 72.7 97·05 95·98 93·19 82·57 93·57 99·20 
PPV (%) 16.4 7·14 23·81 3·70 25·24 35·56 75·00 19.8 21.43 28·57 7·41 36·89 46·67 85·00 
NPV (%) 94.4 90·97 92·03 90·77 96·36 94·59 94·44 87.6 85·99 86·47 85·29 90·91 89·95 89·37 
LR + 2.04 0·78 3·26 0·39 3·51 5·90 31·26 1.45 1·64 2·41 0·48 3·63 5·44 34·65 
LR - 0.62 1·01 0·90 1·04 0·39 0·61 0·61 0.83 0·98 0·94 1·04 0·44 0·69 0·73 
Accuracy (%) 71.1 88·28 88·74 85·28 79·45 88·45 93·55 67.9 83·91 83·68 80·37 79·91 85·45 89·17 
DOR 3.3 0·78 3·61 0·38 8·95 9·64 51·00 1.8 1·67 2·56 0·46 8·18 7·83 47·65 
Youden's index 0.28 -0·01 0·09 -0·04 0·49 0·36 0·38 0.12 0·02 0·06 -0·04 0·46 0·29 0·27 
PPV: positive predictive value; NPV: negative predictive value; LR +: positive likelihood ratio; LR –: negative likelihood ratio; DOR: Diagnostic odds ratio; RBG: random blood 
glucose; HbA1c: glycated hemoglobin; FPG: fasting plasma glucose; OGTT: oral glucose tolerance test.  
Indicators of increased discriminatory and predictive properties of a test are concurrently high values for test sensitivity and specificity, positive likelihood ratio, positive and 
negative predictive values, diagnostic odds ratio (DOR), accuracy and Youden's index. Lower negative likelihood ratio is more discriminatory. DOR values ranges from 0 to infinity 
whilst the Youden's index values ranges from -1 to 1 (Glas et al., 2003). 
Screen-positive based on a presence of ≥1 risk factors, b reagent-strip glycosuria result of trace and above and c capillary random blood glucose >7·0 mmol/L. Diagnostic-positive 
derived from d HbA1c ≥6·5% (National Institute for Health and Care Excellence, 2015); fasting venous plasma glucose e ≥5·1 mmol/L (World Health Organization, 2013) and f ≥5·6 
mmol/L (National Institute for Health and Care Excellence, 2015) as per WHO and NICE guidelines and one-hour postprandial OGTT g  ≥10·0 mmol/L (World Health Organization, 
2013).. 
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Table 10. Diagnostic measure of test instruments using fasting glucose ≥5.1 mmol/l (WHO) and ≥5.6 mmol/l as (NICE) diagnostic criteria 
 
Diagnostic 
measure 
WHO reference cut-offs (≥5.1 mmol/L) NICE reference cut-offs (≥5.6 mmol/L) 
Risk 
factorsa 
Glyco
suriab 
RBGc HbA1cd 1-h 
OGTTe 
2-h 
OGTTf 
2-h 
OGTTg 
Risk 
factorsa 
Glyco
suriab 
RBGc HbA1cd 1-h 
OGTTd 
2-h 
OGTTf 
2-h 
OGTTg 
True positive  31 5 11 10 17 27 38 18 4 8 6 13 17 21 
False negative 67 101 95 93 89 76 65 27 44 40 41 35 28 24 
False positive 83 9 10 18 3 12 22 98 10 13 22 7 21 39 
True negative 217 330 329 317 334 318 308 265 387 384 369 388 367 349 
Sensitivity (%) 31.6 4.7 10.4 9.7 16.0 26.2 36.9 40.0 8.3 16.7 12.8 27.1 37.8 46.7 
Specificity (%) 72.3 97.3 97.1 94.6 99.1 96.4 93.3 73.0 97.5 96.7 94.4 98.2 94.6 89.9 
PPV (%) 27.2 35.7 52.4 35.7 85.0 69.2 63.3 15.5 28.6 38.1 21.4 65.0 44.7 35.0 
NPV (%) 76.4 76.6 77.6 77.3 79.0 80.7 82.6 90.8 89.8 90.6 90.0 91.7 92.9 93.6 
LR + 1.14 1.74 3.59 1. 79 17.77 7.27 5.51 1.48 3.32 5.06 2.28 15.05 7.00 4.62 
LR - 0.95 0.98 0.92 0.95 0.84 0.76 0.67 0.82 0.94 0.86 0.92 0.74 0.65 0.59 
Accuracy (%) 62.3 75.3 72.2 70.3 75.2 79.7 79.9 69.4 87.9 88.1 85.6 90.5 88.7 85.5 
DOR 1.2 1.8 3.8 1.9 21.3 9.4 8.2 1.8 3.5 5.9 2.5 20.6 10.6 7.8 
Youden's index 0.04 0.02 0.08 0.04 0.15 0.23 0.30 0.13 0.06 0.13 0.07 0.25 0.32 0.37 
PPV: positive predictive value; NPV: negative predictive value; LR +: positive likelihood ratio; LR –: negative likelihood ratio; DOR: Diagnostic odds ratio; RBG: random blood 
glucose; HbA1c: glycated hemoglobin; FPG: fasting plasma glucose; OGTT: oral glucose tolerance test.  
Indicators of increased discriminatory and predictive properties of a test are concurrently high values for test sensitivity and specificity, positive likelihood ratio, positive and 
negative predictive values, diagnostic odds ratio (DOR), accuracy and Youden's index. Lower negative likelihood ratio is more discriminatory. DOR values ranges from 0 to 
infinity whilst the Youden's index values ranges from -1 to 1 (Glas et al., 2003). 
Screen-positive based on a presence of ≥1 risk factors, b reagent-strip glycosuria result of trace and above and c capillary random blood glucose >7·0 mmol/L. Diagnostic-positive 
derived from d HbA1c ≥6·5% (National Institute for Health and Care Excellence, 2015); e one-hour postprandial OGTT g ≥10·0 mmol/L (World Health Organization, 2013) and 
two-hour postprandial OGTT f  ≥8.5 mmol/L (World Health Organization, 2013) and g ≥7.8 mmol/L (National Institute for Health and Care Excellence, 2015) as per WHO and 
NICE guidelines. 
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3.2.3.2 Diagnostic performance based on area under the curve    
In Figure 12 is the receiver operating characteristic (ROC) curves showing the area under the 
curve (AUC) as indication of test performance. Interpretation of the ROC curves is presented 
in Table 11. In Figure 12 a and b, the reference test was 2-h OGTT based on the WHO (≥8.5 
mmol/L) and NICE (≥7.8 mmol/L) diagnostic cut-offs. One-hour OGTT and fasting glucose 
were very good tests as the AUC was between 0.86-0.88. Random blood glucose was a poor 
test for detecting GDM (AUC≈0.6) whereas HbA1c was not a useful test because the AUC 
was <0.5 and the CI of the AUC was statistically insignificant (p=0.686). In Figure 12 c and 
d, FPG ≥5.1 mmol/L and ≥5.6 mmol/L were used as the reference cut-offs based on the WHO 
and NICE guidelines respectively. One-hour and 2-h OGTT were found to be ‘good’ test 
because the AUC was between 0.76-0.78. Although AUC values for random glucose and 
HbA1c were slightly higher compared to Figure 12 a and b, the test rating was similar as 
when the 2-h OGTT was used as the reference.  
 
Table 11. Area under the curve showing test performance for 2-h OGTT and fasting 
glucose using WHO and NICE cut-offs as reference   
Reference 
criteria 
 Test assessed AUCc 95% CI p-valued 
2-h OGTT ≥8.5 
mmol/La 
 1-hour OGTT  0.88 0.81-0.94 <0.0001 
 Fasting glucose  0.86 0.80-0.91 <0.0001 
 Random glucose 0.60 0.51-0.69 0.035 
 HbA1c 0.48 0.40-0.57 0.686 
2-h OGTT ≥7.8 
mmol/Lb 
 1-hour OGTT  0.85 0.80-0.91 <0.0001 
 Fasting glucose  0.83 0.78-0.88 <0.0001 
 Random glucose 0.62 0.55-0.69 0.002 
 HbA1c 0.48 0.40-0.55 0.567 
Fasting glucose 
≥5.1 mmol/La  
 1-hour OGTT  0.77 0.71-0.82 <0.0001 
 2-hour OGTT  0.78 0.72-0.83 <0.0001 
 Random glucose 0.63 0.57-0.69 <0.0001 
 HbA1c 0.51 0.44-0.57 0.880 
Fasting glucose 
≥5.6 mmol/Lb 
 1-hour OGTT  0.76 0.68-0.84 <0.0001 
 2-hour OGTT  0.78 0.70-0.86 <0.0001 
 Random glucose 0.65 0.56-0.74 0.001 
 HbA1c 0.51 0.41-0.60 0.867 
aWHO and bNICE diagnostic criteria. cArea under the curve under the null hypothesis = 0.5. Test rated 
excellent for AUC 0.9-1.0; very good (0.8-0.9); good (0.70-0.80); sufficient (0.60-0.70), poor (0.50-0.60) 
and invaluable (AUC<0.5) if p<0.05 (Mallett et al., 2012, Raslich et al., 2007). The lower the p-value, the 
higher the clinical relevance of the test  
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    Figure 12. Receiver operating characteristic curves showing the area under the curve reference to two-hour OGTT (a/b)    
    and fasting plasma glucose (c/d)
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3.2.3.3 Cut-offs for the study population using coordinates of the curve  
Using the coordinates of the ROC curve where 2-h OGTT ≥8.5 mmol/L was the reference 
cut-off, diagnostic thresholds for the study population that provided optimized and clinically 
relevant sensitivity and specificity were estimated. Random glucose value of 5.2 mmol/L 
corresponded to sensitivity of 60% and specificity of 54%. Similar sensitivity and specificity 
(62% vs. 41%) were obtained for HbA1c threshold of 5.2%. Increasing the sensitivity of both 
random glucose and HbA1c to 70% corresponded to threshold values of 5.0 mmol/L and 5.0% 
respectively but the specificity of both were not clinically relevant (38% vs. 25%). Regarding 
fasting glucose, 90% sensitivity and 72% specificity corresponded to 4.8 mmol/L glucose. At 
the same threshold, the NICE cut-off for 2-h OGTT (≥7.8 mmol/L) yielded 80% sensitivity 
and 74% specificity. In the case of 1-h OGTT, 7.8 mmol/L threshold corresponded to 82% 
sensitivity and 81% specificity. 
 
 
3.3 Risk Factors for Gestational Diabetes  
3.3.1 Background Characteristics of Study Participants  
Table 12 shows the socio-demographic characteristics of the 445 pregnant women who did 
the diagnostic testing for GDM and subsequently participated in most phases of the study. 
Fifteen percent were each recruited from the primary and referral facilities and the remining 
70% recruited from secondary facilities. A third of the study participants were residing in 
rural setting and the remaining were peri-urban dwellers. Half (n=223) were aged 20-29 years, 
29.8% (n=131) were primiparous women whereas 12.8% (n=57) have had more than five 
pregnancies in their lifetime.  
Two-thirds (63.8%, n=286) had little formal education compared to 41.9% (n=186) of their 
male partners. An equal proportion of the women (64.9%, n=286) and their partners (65.3%, 
n=290) were informal sector workers engaged mainly in trading, handiwork and menial jobs. 
Students constituted 4.5% (n=20) of the 22.0% women (n=97) who were not engaged in any 
economic venture at the time of the study while 5.6% of their partners were unemployed. The 
index pregnancy of 37.1% (n=149) of the women were unintended.  
 
  
Results 
63 
 
Table 12. Socio-demographic characteristic of study participants 
Variable   Sub-scale  N = 445 % 
Level of facility 
   
 
 Primary facility  
Secondary facility  
Referral facility   
69 
309 
68 
15.4 
69.4 
15.2 
Residency   Rural dweller 133 32.8 
Age groups   <20 years  32 7.2 
  20-29 years  223 50.0 
  30-39 years  174 39.2 
  ≥40 years  16 3.6 
Marital status   Married 316 72.0 
  Cohabitating 68 15.5 
 Single 55 12.5 
Woman’s educational 
level  
 None/primary 62 13.8 
 Junior secondary  224 50.0 
 Senior secondary  92 20.5 
 College/university  70 15.2 
Partner’s educational 
level  
 None/primary 33 7.4 
 Junior secondary  153 34.5 
 Senior secondary  133 30.0 
 College/university   124 28.0 
Woman’s 
employment status 
 Unemployed 97 22.0 
 Informal sector 286 64.9 
 Formal sector 58 13.2 
Partner’s employment   Unemployed 25 5.6 
 Informal sector 290 65.3 
 Formal sector 129 29.1 
Gravidity   1-2 pregnancies  229 51.6 
 3-4 pregnancies   158 35.6 
 ≥5 pregnancies  57 12.8 
Parity   No children  131 29.8 
 1-2 children 230 52.2 
 3-4 children 66 15.1 
 ≥5 children  13 2.9 
Pregnancy intention   Unintended 149 37.1 
Religious affiliation    Christian  410 91.3 
 Moslem  39 8.7 
Note: students constituted 4.5% (n=20) of the unemployed group  
 
 
3.3.2 Health Profile of Study Participants  
Reading the health, anthropometry and dietary profile of the women presented in Table 13, 
4.0% (n=18) had pre-existing hypertension, 17.7% (n=80) had a family history of 
hypertension while first-degree relatives of 7.1% (n=32) had diabetes. Apart from malaria 
(10.3%, n=26), prevalence of infectious diseases among the study population was generally 
low but reflective of population rates. HIV, Hepatitis B and status syphilis were 2.1%, 4.2% 
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and 3.4% respectively. An equal proportion of woman were underweight (9.6%) and obese 
(9.4%). Half 51.7% (n=256) of the women received dietary counseling, but fewer received 
counseling on iron-folic acid supplementation 28.8% (n=130). 
 
Table 13. Health, anthropometric and dietary intake profile of participants 
Variable   Sub-categories   n % 
History of hypertension   Yes  18 4.0 
Hypertension in family    Yes  80 17.7 
Diabetes in family    Yes  32 7.1 
HIV status   Positive 22 2.1 
Hepatitis B  Positive 11 4.2 
VDRL for syphilis   Reactive 14 3.4 
Malaria   Positive 26 10.3 
Infestations   Intestinal flagellates 7 4.0 
Sickling    Positive 56 14.0 
Blood group 
   
 
  A 
 B 
 AB 
 O 
103 
106 
19 
206 
19.7 
24.6 
4.8 
50.9 
Rhesus status    Negative 31 6.6 
BMI category 
   
 
  Underweight 
 Normal weight 
 Overweight 
 Obese 
39 
232 
97 
38 
9.6 
57.1 
23.9 
9.4 
MUAC    <24 cm 24 8.2 
Dietary counselling    Given 256 51.7 
Advised on IFA    Yes 130 28.8 
Iron-folic acid    Daily supplements  445 96.8 
Has food taboos    Yes 73 17.7 
Has food aversions   Yes 78 18.8 
Has food cravings     Yes 99 24.0 
VDRL, Venereal Disease Research Laboratory test for syphilis; BMI, body mass index; MUAC, mid-upper 
arm circumference; IFA, Iron-folic acid 
 
3.3.3 Habitual Dietary Intakes of Study Participants  
Figure 13 shows the habitual foods consumed and the frequency of consumption. Daily 
intake was largely from staple foods (90.6%), other vegetables (85.4%), fleshy foods (84.9%) 
and fruits and vegetable rich in vitamin A (78.8%). Detailed description of the habitual intake 
from each food group is found in the supplementary Figure 16 found in the appendix. Corn 
(90.6%) and rice (41.2%) were the most daily consumed staple. Fish (84.9%) and poultry 
(21.6%) were the most consumed fleshy food. Egg and milk were consumed by 20.5% and 
17.6%. Groundnut was the most daily consumed (21.6%) nuts/seeds. Pulses was the least 
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consumed group with black eye beans (11.0%) being the most consumed in that group. About 
one-fourth of the participants took dark green leafy vegetables daily. The main varieties were 
‘kontomire’ (cocoyam/taro leaves), ‘gboma’ (African eggplant leaves) and ayoyo (corchorus 
leaves). Intake of other vitamin A-rich vegetables particularly chilli pepper (83.4%) and 
tomatoes (74.2%) followed the pattern as for staple foods because they are habitual 
accompaniments. Banana and orange which were the most consumed fruits, were eaten by 
about a third daily. While smoking and intake of alcohol were rare, daily intake of sweetened 
foods (35.7%) and beverages (21.1%) was relatively high.  
 
 
Figure 13. Frequency of consumption of the 10 main food groups  
 
 
Foods tabooed were mainly fleshy foods (pork, mutton, mudfish, catfish, crab, snail, beef) 
and okra. Foods averted were beans, cassava flour, fermented corn products, eggs, fresh fish, 
oily foods (particularly groundnuts and palm nuts) and alcohol. Aside one case of white clay 
intake, all the foods craved for were healthy. Diets of 58.6% (n=243, 95% CI: 54.2-63.4) 
contained at least five of the 10 food groups and were thus rated as micronutrient adequate. 
Mean daily intake of high glycemic index (GI) foods was 2.6 high GI foods. The cases tended 
to consume more high GI foods than the controls (mean: 2.9 vs 2.6) but the difference was 
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not significant. Daily glycemic intake of 56.7% (n=212) was adequate (i.e. intake of high GI 
foods 1-2 times per day), 22.7% (n=85) was moderate (i.e. intake of high GI foods 3-4 times 
per day) while the remaining (20.6%, n=77) consumed excess calories (i.e. intake of high GI 
foods above 5 times per day). Shown in Figure 14 is a comparison of the daily glycemic 
intake among the cases and controls. The cases tended to consume high GI foods in excess, 
but the difference was insignificant compared to the control group.  
 
 
Figure 14. Comparison of daily intake of high glycemic 
index foods among the cases and controls  
Note: The difference is not statistically significant (p=0.181). Adequate caloric intake implies (intake of high 
GI foods 1-2 times per day); moderate caloric intake implies (intake of high GI foods 3-4 times per day) and 
excess caloric intake implies (intake of high GI foods ≥5 times per day) 
 
3.3.4 Maternal Health Profile of Cases and Controls   
Seventy participants met the GDM case definition and the remaining 376 served as controls, 
representing one case to about approximately five controls. Mean maternal age was 28.44 
years (SD=6.13); the minimum and maximum ages were 15 and 54 years respectively. Five 
(1.8%) participants were between 15-17 years while only one participant was above 49 years. 
As presented in Table 14, participants who were classified as cases were comparable with 
controls in many regards except that the cases were significantly older (29.8 vs 28.2 years), 
had higher gravidity (3.2 vs 2.7 pregnancies), parity (1.8 vs 1.3 children), first trimester 
weight (66.4 vs 62.4 kg), BMI (24.8 vs 23.2 kg/m2) and MUAC (29.5 vs 28.1 cm). 
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Table 14. T-test comparing the health and anthropometric profile of the GDM cases 
and controls for continuous variables 
Continuous variables  Mean (standard deviation) P-value  
 Total  
(N=446) 
GDM present a 
(n=70)  
GDM absent 
(n=376) 
Fasting glucosea 4.56 (0.99) 5.70 (0.79) 4.28 (0.69) d 
2-h OGTT a 6.33 (1.72) 7.82 (1.73) 5.90 (1.14) d 
Maternal age (years) 28.44 (6.13) 29.82 (6.80) 28.19 (5.99) 0.036* 
Gravida 2.73 (1.49) 3.17 (1.57) 2.66 (1.47) 0.010* 
Parity (live children) 1.35 (1.31) 1.75 (1.45) 1.28 (1.27) 0.007* 
Weight (kg) 62.98 (13.06) 66.38 (14.32) 62.37 (12.75) 0.020* 
Height (cm) 162.36 (9.33) 162.93 (7.94) 162.26 (9.54) 0.604 
BMI (kg/m2) 23.48 (4.43) 24.77 (4.82) 23.21 (4.30) 0.026* 
MUAC (cm) 28.33 (3.69) 29.51 (4.40) 28.08 (3.48) 0.016* 
Weight changeb 11.16 (5.18) 11.67 (5.21) 11.06 (5.18) 0.445 
Systolic BP (mmHg) 108.06 (11.49) 109.88 (11.91) 107.74 (11.40) 0.154 
Diastolic BP (mmHg) 65.39 (9.37) 65.58 (10.23) 65.36 (9.22) 0.859 
Total cholesterol (mmol/L) 5.50 (1.28) 5.32 (1.37) 5.54 (1.27) 0.189 
Triglycerides (mmol/L) 3.05 (1.65) 2.88 (1.23) 3.08 (1.71) 0.331 
HDL cholesterol (mmol/L) 1.47 (0.44) 1.49 (0.49) 1.47 (0.43) 0.596 
LDL cholesterol (mmol/L) 2.66 (1.07) 2.51 (1.04) 2.68 (1.08) 0.201 
VLDL cholesterol (mg/dl) 1.35 (0.76) 1.30 (0.60) 1.36 (0.78) 0.542 
Coronary risk 4.14 (2.37) 3.80 (1.20) 4.20 (2.52) 0.180 
Intake of high GI foodsc 2.62 (1.14) 2.87 (1.24) 2.56 (1.12) 0.242 
*Statistically significant at *p<0.05. BMI, body mass index; MUAC, mid-upper arm circumference; BP, blood 
pressure; HDL, high density lipoprotein; VLDL, very low-density lipoprotein; GI, glycemic index. Apart from 
the lipid profile, all other assessments were taken in the first trimester.  
a The case definition is 2-hour OGTT ≥8.5 mmol/L and/or the fasting plasma glucose ≥5.6 mmol/L. 
b Pregnancy weight change was estimated by subtracting weight at delivery from the weight in the first 
trimester.  
c This is the number of high glycemic index foods consumed the day prior to the survey.   
d No p-values were reported because the cases and controls were estimated from this scale variable.  
 
 
 
3.3.5 GDM and Macrosomia  
As GDM is often associated with macrosomia, secondary data on 4,262 singleton mother-
newborn pairs was analyzed to assess macrosomia (defined as birth weights ≥4.0 kg). 
Macrosomia was 3.03% (n=120, 95% CI: 2.6-3.6). Mean birthweight was 2.98 kg (SD=0.50). 
Significantly higher macrosomic births were observed in infants who were born through 
cesarean section, who had birth order beyond second, and the maternal age was 31-40 years. 
Table 15 shows the predictors for a macrosomic birth. Newborns delivered by cesarean 
section (14.4%) has the highest mean birth weight (3.12±0.54 kg). proportion of stillbirth 
among macrosomic newborns was 6.8%. Risk of macrosomia for a fifth born was 2.66 times 
higher compared to a second or third born. Likewise, macrosomia newborns were 2.56 times 
more likely for cesarean delivery.  
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Table 15. Risk factors for delivery a macrosomic baby (birth weigh >2.5kg) 
Maternal and 
infant factors 
Sub-categories   Prevalence 
[n/N (%)] 
RRR P>z 95% CI 
Parity   1-2 60/1997 (3.0) Ref.   
   3-4 37/755 (4.9) 1.53 0.068** 0.96-2.40 
   >4 19/204 (9.3) 2.66 0.002* 1.43-4.95 
   Nulliparous 14/1342 (1.0) 0.45 0.011* 0.24-0.83 
Sex of baby   Male 79/2182 (3.6) Ref.   
   Female 50/2115 (2.4) 0.65 0.023* 0.45-0.94 
HIV status   Negative  127/4235 (3.0) Ref.   
   Positive 3/63 (4.8) 1.75 0.360 0.53-5.77 
Maternal age    21-30 65/2461 (2.6) Ref.   
   <20 2/574 (0.4) 0.22 0.044* 0.05-1.000 
   31-40 49/1097(4.5) 1.08 0.713 0.70-1.670 
   >40 14/164 (8.5) 1.75 0.123 00.86-3.57 
IPT taken    3 doses 70/2175 (3.2) Ref.   
   1 dose 9/241 (3.7) 1.37 0.386 0.67-2.83 
   2 doses 12/535 (2.2) 0.69 0.259 0.37-1.31 
   None taken 39/1347 (2.9) 0.87 0.500 0.58-1.31 
Delivery mode    SVD 81/3123 (26.0) Ref.   
   C/S 37/614 (6.0) 2.56 <0.0001* 1.69-3.86 
   Forceps  2/70 (2.9) 1.41 0.645 0.33-6.10 
   VD & episiotomy  9/468 (1.9) 1.35 0.425 0.65-2.79 
Statistically significant at *p<0.05 and **p<0.10. 
Data presented as % (n/N) unless otherwise indicated. Macrosomia is defined as >4.0 kg. RRR= relative risk 
ratio; CI= confidence interval. Estimates based on maximum-likelihood multinomial logistic regression models. 
IPT: intermittent preventive treatment for malaria; SVD: spontaneous vaginal delivery; C/S: cesarean section  
 
 
3.3.6 Risk Factors for Gestational Diabetes  
Overall, 8.3% of the participants were underweight whereas 22.9% were overweight and 
8.3% obese. Comparing the cases and control, the column adjustments showed that the 
proportions who were underweight (6.3% vs 7.4%) and obese (8.3% vs 7.8%) groups were 
statistically the same but a significant proportion of those who were overweight were 
diagnosed with GDM (35.4% vs 20.9%). On the day prior to the survey, 28.6% of the GDM 
group consumed more than five high glycemic index foods while it was 18.5% in the non-
GDM group (p=0.080). Comparing the lipid profile indices of cases and controls, no 
significant differences were noted in the mean total cholesterol (5.32 vs 5.54 mmol/L), 
triglycerides (2.88 vs 3.08 mmol/L), high density lipoprotein cholesterol (1.49 vs 1.47 
mmol/L) and low density lipoprotein cholesterol (2.51 vs 2.68 mmol/L).  
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Presented in Table 16 is the Chi-square test comparing dichotomous characteristics of cases 
and controls and the crude and adjusted binary logistic regressions showing the significant 
risk factors for GDM. It was observed that double the proportion of cases were primary 
facility users (case: 31.4% vs control: 15.1%, p=0.009). Significantly higher proportion were 
above age 35 years (23.9% vs 12.0%) and their partners had very little formal education 
(16.7% vs 6.7%). Also, more cases were overweight/obese (20.0% vs 10.7%), had mid-upper 
arm circumference (MUAC) above 30 cm and had history of spontaneous abortions (50.0% 
vs 32.0%) and preeclampsia (9.1% vs 1.6%). No significant differences were observed in 
pregnancy weight change, number of lifetime pregnancies, and other socio-demographic, 
anthropometric, obstetric, medical and dietary indicators assessed (Table 16). 
In both the crude and adjusted models, spousal education below secondary level, ANC in a 
primary facility, adiposity (overweight/obesity, high MUAC) and intake of high glycemic 
index foods more than five times per day were significant risk factors for GDM. In addition, 
maternal age above 30 years, previous spontaneous abortion and preeclampsia in the current 
pregnancy were significant independent risk factors in the crude model. In the adjusted model, 
previous cesarean section was an additional significant risk factor (Table 16). For instance, 
women whose MUAC was above 30 cm were 199% (95% CI: 1.12-3.52) more likely to 
develop GDM than women with MUAC below 30 cm. Adjusting for other covariates, the risk 
increased to 297% (95% CI: 1.31-5.58). Also, women who consumed above 5 high glycemic 
index food per day had 176% risk (95% CI: 1.95-3.28) whereas in the adjusted model, the 
risk increased to 291% (95% CI: 1.05-8.07). 
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Table 16. Comparison of cases and controls and binary logistic regression showing crude and adjusted odds for GDM  
Dichotomous predictor variables  GDM 
present 
(n=70) 
GDM 
absent 
(n=376) 
P-value Unconditional binary logistic regression 
Univariate  Multivariate 
Predictor value  Reference value Crude 
OR 
95% CI Adj 
OR 
95% CI 
Socio-demography         
Maternal age >35 years Maternal age ≤35 years 16 (23.9) 46 (12.0) 0.019* 2.29 1.21-4.36* 4.06 0.58-8.73 
Unmarried Married/cohabitating  13 (28.3) 65 (27.3) 0.859 1.05 0.52-2.12   
Rural residence Urban/peri-urban residence 14 (28.6) 71 (29.1) 0.941 0.98 0.49-1.92   
Primary maternal education a Higher maternal education a 11 (21.6) 30 (12.0) 0.077** 2.01 0.931-4.33**   
Primary partner education a Higher partner education a 8 (16.7) 16 (6.7) 0.039* 2.80 1.12-6.97* 3.36 1.271- 8.89* 
Primary facility Secondary/referral facility 16 (31.4) 38 (15.1) 0.009* 2.56 1.29-5.08* 4.95 1.87-3.76* 
Anthropometry         
Overweight/obese b Normal/underweight b 13 (20.0) 39 (10.7) 0.041* 2.08 1.04-4.16* 2.13 1.13-4.03* 
1st trimester weight >90kg b Weight ≤90 kg b 4 (6.1) 11 (3.0) 0.182 2.08 0.64-6.75   
Height <150cmb Height ≥150 cm 7 (13.7) 26 (10.4) 0.466 1.37 0.56-3.35   
Weight gain >threshold c Weight gain <threshold c 12 (24.0) 51 (20.6) 0.574 1.21 0.59-2.49   
MUAC >30cm d MUAC ≤30 cm 22 (34.9) 80 (21.3) 0.024* 1.99 1.12-3.52* 2.97 1.31-5.58* 
Obstetric history         
Parity >3 children Parity ≤3 children 8 (12.9) 22 (6.2) 0.066** 2.25 0.95-5.31** 2.42 0.39-14.75 
Gravida >5 pregnancies  Gravida ≤5 pregnancies  5 (7.9) 19 (5.0) 0.365 1.63 0.58-4.53   
Prior macrosomia No macrosomia history 1 (16.7) 8 (18.6) 0.909 2.87 0.09-8.56   
Prior cesarean section No cesarean section history  10 (20.0) 43 (16.3) 0.539 1.28 0.59-2.75 4.01 1.09-14.76* 
Prior neonatal death No neonatal death history 5 (10.2) 21 (8.0) 0.576 1.32 0.47-3.67 4.06 0.88-18.87** 
Spontaneous abortion No spontaneous abortion 18 (50.0) 62 (32.0) 0.040* 2.13 1.04-4.37* 1.15 0.33-4.03 
Multiple pregnancies No multiple pregnancies 2 (4.0) 7 (2.7) 0.439 1.51 0.31-7.49   
Medical examinations         
Diabetes in family No family diabetes history  5 (7.5) 24 (6.3) 0.787 1.20 0.44-3.26 1.50 0.31-7.31 
Family hypertension No hypertension in family 7 (13.7) 22 (8.8) 0.296 1.65 0.67-4.11 1.21 0.34-4.36 
Trace glycosuria & above e No glycosuria e 4 (5.5) 11 (2.6) 0.171 2.14 0.66-6.91 3.65 0.76-17.42 
Hypertensive Non-hypertensive 9 (17.6) 47 (18.7) 0.989 1.93 0.42-2.04 3.98 0.50-31.42 
Prior preeclampsia  No preeclampsia history  6 (9.1) 6 (1.6) 0.004* 6.23 1.15-19.96*   
Dyslipidemia f Normolipidemia f 8 (15.7) 63 (25.3) 0.153 0.55 0.25-1.23 0.91 0.16-5.11 
HIV positive  HIV negative  2 (5.1) 2 (0.9) 0.082** 5.84 0.797-42.74   
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Nutrition         
Excess high GI foods g Adequate/moderate GI foodsg 18 (28.6) 56 (18.5) 0.080** 1.76 1.95-3.28* 2.91 1.05-8.07* 
Mid/moderate/severe  
anemia h 
Non-anemic h 24 (60.0) 130 (55.6) 0.365 1.20 0.61-2.37   
Statistically significant at *p<0.05 and **p<0.10. 
The blank spaces are the variables that were omitted from the final regression model.  
The GDM case definition was 2-hour OGTT ≥8.5 mmol /L and/or the fasting plasma glucose ≥5.6 mmol/L. 
Model summary: number of observations = 358; Prob > Chi2 = 0.0116; Log likelihood = -87.904; Pseudo R2 = 0.2438. 
BMI, body mass index; MUAC, mid-upper arm circumference.  
a Education up to the primary level was considered low.  
b Weight and height were measured at ANC booking in the first trimester to assess BMI. Underweight (<18.5); normal weight (18.5-24.9); overweight (25.0-29.9) and 
obese (≥30) 
c Weight was measured at each antenatal care visit. Per Institute of Medicine’s recommendations on pregnancy weight gain based on BMI, a high GDM risk was 
considered if the woman’s weight gain was above the threshold for her the BMI group. Underweight: 12.5-18.0 kg; normal weight: 11.5-16.0 kg; overweight: 7.0-11.5 
kg; and obese: 5.0-9.0 kg 
d MUAC was measured once in each trimester. 
and weight was measured monthly.  
e Glycosuria includes trace 1+ to 5+ dipstick glucose at any one time point in pregnancy.  
f Dyslipidemia refers to total cholesterol >7.73 mmol/L, high-density lipoprotein cholesterol <1.34 mmol/L, low-density lipoprotein cholesterol >4.76 mmol/L and 
triglycerides >4.31 mmol/L.  
g High caloric intake defined as excess intake of high glycemic index foods ≥5 per day on the day prior to the survey.  
h Anemia is classified as hemoglobin <11 g/dl. Anemia severity was classified as mild (10.0-10.9 g/dl), moderate (7.0-9.9 g/dl) and severe (<7.0 g/dl) 
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3.4 Pregnancy Outcomes Associated with GDM  
3.4.1 Maternal and Newborn Outcomes Per Glycemic Status 
Records of 63 GDM cases and 340 controls were traced at birth. Maternal and newborn 
outcomes are presented in Table 17 for continuous variables. Mean birth weight was 3.12 kg 
(SD=0.46) and was 0.26 kg higher among the cases (p=0.035). Similarly, estimated blood 
loss was 183.93 ml (SD=103.98) and was 50 ml higher among the women diagnosed with 
GDM (p=0.001). No other significant differences were observed for the other variables 
including birth anthropometries, gestational age at birth and newborns’ blood glucose.  
 
 
Table 17. T-test comparing maternal and newborn birth outcomes among cases and 
controls for continuous variables  
 
Continuous outcomes  
GDM present 
(n=63) 
GDM absent 
(n=340) 
 
P-value b 
Mean ± standard 
deviation  
Mean ± standard 
deviation  
Blood loss (ml) 228.42 ± 123.48 178.54 ± 105.89 0.010* 
Gestational age at birth (weeks) 38.84 ± 2.19 38.80 ± 2.18 0.906 
Birth weight (kg) 3.23 ± 0.49 3.06 ± 0.45 0.035* 
Birth length (cm) 49.59 ± 2.74 48.87 ± 3.34 0.212 
Head circumference (cm) 34.38 ± 1.71 33.97 ± 2.04 0.253 
Ponderal index (g/cm3)a 2.70 ± 0.49 2.69 ± 0.61 0.913 
Newborn glucose (mmol/L) 3.924 ± 1.31 4.74 ± 0.90 0.193 
b Statistically significant at *p<0.05. Difference estimated by unpaired t-test  
a Ponderal Index calculated as newborn’s weight (g)/ length (cm3) x 100 
 
 
 
Key birth outcomes among primary and secondary facility users 
Interquartile ranges for birth weight, birth length, gestational age at birth and the newborn’s 
blood glucose among primary and secondary/referral facility users is shown in Figure 15. 
Birth length of newborns delivered in the secondary facilities (49.16±3.25 cm) were lengthier 
than that of newborns delivered in primary facilities (47.78±3.39 cm) (p=0.028). However, 
among the secondary and primary facility users, significantly differences were found for birth 
weight (3.11±0.47 vs 3.04±0.41 kg), gestational age at birth (38.92±2.02 vs 38.63±2.64 
weeks) and newborns’ blood glucose (4.09±1.30 vs 4.40±0.71 mmol/L).  
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Figure 15. Comparison of birth weight, birth length, gestational age at birth and 
newborns blood glucose among primary and secondary facility users  
Note: *Birth length was the only variable that was statistically significantly (p=0.028)  
 
 
Categorical birth outcomes  
Presented in Table 18 are maternal and newborn outcomes for categorical variables. 
Deliveries of 21.5% (n=65) were by cesarean; it was 11.9% significantly higher among the 
cases. Although adverse outcomes tended to be higher among women diagnosed with 
gestational diabetes, no other significant differences were observed in the categorical 
variables assessed other than the cesarean section rate where the differences was very 
marginal (p=0.049) for the cases (31.4%) and controls (19.5%). Among the GDM group, 
majority (64.3%) of the cesarean section was elective. 
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Table 18. Chi-square test comparing maternal and newborn birth outcomes among 
cases and controls for categorical variables 
Outcomes Sub-categories  GDM present  GDM absent  P-valued 
n (%) n (%) 
Mode of delivery    Cesarean section 16 (31.4) 49 (19.5) 0.049* 
Type of cesarean   Emergency  5 (35.7) 25 (58.1) 0.125 
   Elective  9 (64.3) 18 (41.9)  
Perineum   Intact  25 (69.4) 136 (75.2) 0.369 
   Episiotomy 4 (11.2) 25 (13.8)  
   Tear  7 (19.4) 20 (11.0)  
Pre/eclampsia   Yes  7 (13.7) 22 (8.8) 0.197 
Postpartum hemorrhagea   Yes  3 (7.9) 7 (3.3) 0.180 
Prolong/obstructed labor   Yes  7 (15.6) 26 (11.1) 0.787 
Sex of newborn    Male 28 (60.9) 116 (52.5) 0.332 
   Female  18 (39.1) 105 (47.5)  
Birth weight    Low birth weight  2 (4.3) 17 (7.6) 0.675 
   Normal  43 (91.4) 200 (89.3)  
   Macrosomia (≥4 kg) 2 (4.3) 7 (3.1)  
Gestational age at birth   Preterm <37 weeks 3 (8.1) 15 (8.7) 0.985 
   Term 37-42 weeks  33 (89.2) 154 (89.0)  
   Post-term >42 weeks  1 (2.7) 4 (2.3)  
Growth for gestational 
age (GA)b 
   
  Small for GA 2 (5.4) 13 (6.2) 0.870 
  Marginal 13 (35.1) 82 (38.9)  
  Large for GA 6 (16.2) 40 (19.0)  
Resuscitation   Resuscitated 15 (34.1) 60 (27.0) 0.219 
Intensive care admission    Admitted  1 (2.0) 13 (5.3) 0.289 
Perinatal deathc   Died by dischargec 1 (2.0) 3 (1.2) 0.525 
Statistically significant at *p<0.05. a Postpartum hemorrhage is defined as estimated blood loss >500ml. b 
Growth in relation to gestational age was estimated from Ponderal Index calculated as newborn weight (g)/ 
length (cm3) expressed as a percentage and categorized as small for gestational age (<2.0), marginal (2.0-2.5), 
normal (2.5-3.0.) and large for gestational age (≥3.0). c Perinatal death includes both macerated and fresh cases 
 
 
3.4.2 Adverse Pregnancy Outcomes  
As observed from the simple logistic regression in Table 19, a unit increases in fasting plasma 
glucose and 2-hour OGTT were associated with a significant increase in birth weight and 
estimated blood loss. For every one mmol/L rise in fasting glucose, there was 0.251 kg 
increased in birth weight whereas for every one mmol/L rise in 2-h OGTT there was 0.562 
kg increased in birth weight. Fasting glucose and 2-h OGTT values have overlap effect on 
birth outcome but appears to have some distinctive outcome profiles as well. For instance, for 
every one mmol/L rise in fasting glucose, there was an associated increase in gestational age 
at delivery and newborns head circumference. However, this association was observed only 
for fasting glucose and not 2-h OGTT. 
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Table 19. Simple linear regression showing the coefficients for maternal and perinatal 
outcomes per unit rise in fasting plasma glucose and 2-hour OGTT 
 
Outcomes 
Continuous blood glucose measurements  
Fasting plasma glucose  2-hour OGTT values 
Coef. 95% CI  P- value   Coef. 95% CI  P-
value 
Cesarean sectiona 0.185 -0.087, 0.457 0.183  0.330 -0.140, 0.801 0.168 
Episiotomya 
Perineal teara 
-0.235 
0.204 
-0.601, 0.130 
-0.168, 0.575 
0.207     
0.281      
 -0.490 
0.143 
-1.121, 0.140 
-0.506, 0.793 
0.127 
0.664      
Pre-eclampsiaa  0.087 -0.193, 0.368 0.541      0.149 -0.339, 0.637 0.548     
Prolong labor 0.028 -0.098, 0.155 0.660  0.077 -0.026, 0.122 0.200 
Est. blood loss (ml) 0.196    0.087, -0.306 0.001*       0.290     0.010-0.482 0.003* 
Hemoglobin (g/dl) 0.024 -0.065, 0.114 0.592      0.043 -0.105, 0.193 0.563     
Gestational age (wks) 0.056 -0.004, 0.116 0.067**  0.034 -0.072, 0.140 0.529 
Birth weight (kg) 0.251 0.008, 0.494 0.043*  0.562 0.141, 0.983 0.009*     
Birth length (cm) 0.001 -0.034, 0.036 0.969       0.003 -0.059, 0.065 0.923     
Head circumference  0.058 -0.001, 0.114 0.056**      0.043 -0.059, 0.147 0.405 
Apgar at 5min  -0.036 -0.119, 0.064 0.558  -0.064 -0.236, 0.072 0.296 
Ponderal indexb 0.159 -0.030, 0.349 0.100      0.273 -0.060, 0.607 0.108     
Newborn glucose 0.058   -0.156, 0.273 0.583  0.029    -0.420, 0.478 0.897 
Resuscitationa 0.172 -0.081, 0.426 0.181  0.272 -0.142, 0.687 0.197 
Intensive carea -0.286 -.0881, 0.307 0.343  -0.734 -1.757, 0.288 0.158 
Birth asphyxiaa 0.850 -0.461, 2.163 0.203      0.457    -1.792, 2.706 0.690      
Perinatal deathac 0.719 -0.353, 1.792 0.188      0.645 -1.193, 2.484  0.490     
Statistically significant at *p<0.05 and **p<0.10. a These are categorical variables while the rest are continuous 
variables. bPonderal Index derived from as fetal weight (g)/length (cm3). c Perinatal death includes both 
macerated and fresh cases 
 
As shown in the multivariate binary logistic regression in Table 20 where GDM was 
classified as present and absent, GDM per the case definition significantly increased the 
likelihood for perineal tear by 2.91 times (95% CI: 1.081-5.566) whereas cesarean section 
was a significant outcome at the 10%-level. Regarding newborn outcomes, GDM increased 
the likelihood for birth asphyxia by 3.24 times (95% CI: 1.006-10.449) whereas large for 
gestational age (LGA) and neonatal resuscitation were associated the outcomes at the 10% 
significant level. Using specifically 2-h OGTT ≥8.5 mmol/L and fasting glucose ≥5.6 mmol/L 
as individual exposures yielded slightly varied but overlapping outcomes. For instance, 2-h 
OGTT ≥8.5 mmol/L was found to increase likelihood for LGA by 5.56 times (95% CI: 1.396-
12.772, p=0.023) whereas cesarean section and birth asphyxia were associated outcomes at 
the 10% significant level. Fasting glucose ≥5.6 mmol/L increased the likelihood for perineum 
tear by 3.87 times (95% CI: 1.183-9.109, p=0.047) and neonatal resuscitation by 5.72 times 
(95% CI: 1.370-23.845, p=0.017) whereas LGA was an associated outcome at the 10% 
significant level (Table 20).
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Table 20. Binary logistic regression showing the adjusted odds ratios for adverse pregnancy outcomes associated with GDM per 
diverse diagnostic criteria  
Outcomes  Sub-categories  
GDM positive per case  
definition a (n = 446) 
GDM positive per NICE criteria for 
fasting glucose ≥5.6 mmol/L b (n = 446) 
GDM positive per WHO criteria for 2-
h OGTT ≥8.5 mmol/l c (n = 435) 
RR 95% CI P value  RR 95% CI P value  RR 95% CI P value  
Preeclampsia  No  Ref    Ref    Ref    
 Yes  1.198 0.162-8.809 0.859 1.038 0.360-5.533 0.157 1.280 0.053-3.076 0.879 
Perineum  Intact  Ref    Ref    Ref    
 Tear  2.909 1.081-5.566 0.043* 3.869 1.183-9.109 0.047* 1.717 0.069-7.375 0.780 
Delivery mode  Vaginal  Ref    Ref    Ref    
 Cesarean 1.884 0.965-3.678 0.063** 1.244 0.007-9.058 0.445 1.490 0.829-7.227 0.098** 
PPH No Ref    Ref    Ref    
Yes  4.652 0.311-69.586 0.265 1.196 0.141-10.144 0.869 3.722 0.699-19.800 0.123      
Birth weight  <4 kg  Ref    Ref    Ref    
 Macrosomia >4 1.914 0.489-7.484 0.350       2.175 0.432-10.941 0.346       2.809 0.552-14.290 0.213      
GA at birth  37-42 weeks  Ref    Ref    Ref    
 
<37 weeks   
>42 weeks 
0.736 
1.227 
0.207-2.619 
0.133-11.330 
0.637 
0.856 
0.898 
1.909 
0.194-4.153 
0.204-17.859 
0.891      
0.571 
0.459 
1.952 
0.058-3.630 
0.208-18.301 
0.461      
0.558 
GA for growth Normal  Ref    Ref    Ref    
 
SGAd 
LGAd 
0.116 
2.661 
0.010-1.313 
0.863-5.048 
0.589 
0.082** 
0.169 
2.302 
0.01082.652 
0.751-5.048 
0.206 
0.090** 
1.134 
5.563 
0.1740-7.391 
1.396-12.772 
0.895 
0.023* 
Birth Asphyxia Apgar >3 Ref    Ref    Ref    
 Apgar ≤3  3.243 1.006-10.449 0.039* 1.618 0.321-8.131 0.495 3.192 0.792-12.868 0.062** 
Resuscitation No need Ref    Ref    Ref    
 Resuscitated  2.906 0.937-9.011 0.065** 5.717 1.370-23.845 0.017*     1.819 0.393-8.409 0.444 
NICU admission No need  Ref    Ref       
 Admitted  0.512 0.063-4.141 0.530 0.688 0.078-6.068 0.736 - - - 
Perinatal death   Survived  Ref    Ref       
 Died 2.382 0.211-26.824 0.482 1.247 0.153-10.169 0.837 - - - 
Statistically significant at *p<0.05 and **p<0.10. The blank space represents variables which were omitted from the model due to poor model fit.  
GA: gestational age at birth; PPH, postpartum hemorrhage; SGA, small for gestational age; LGA, large for gestational age. Model 1 summary: N = 385; Prob > chi2 = 0.035; Log 
likelihood = -51.317; Pseudo R2 = 0.1686. Model 2 summary: N = 399; Prob > chi2 = 0.034; Log likelihood = -28.959; Pseudo R2 = 0.1914. Model 3 summary: N = 393; Prob > 
chi2 = 0.035; Log likelihood = -23.921411; Pseudo R2 = 0.1910. a GDM defined as fasting plasma glucose ≥5.6 mmol/L (National Institute for Health and Care Excellence, 2015) 
and/or 2-hour OGTT ≥8.5 mmol/L (World Health Organization, 2013). b Fasting glucose ≥5.6 mmol/L (National Institute for Health and Care Excellence, 2015) irrespective of 2-
h OGTT values. c 2-h OGTT ≥8.5 mmol/L (World Health Organization, 2013) irrespective of fasting glucose values. d Small for gestational age is birth weight <10th percentile for 
gestational age and large for gestational age large is large birth weight >90th percentile for gestational age. 
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3.5 Postpartum Glycemic Status  
At 12 weeks postpartum, 100 of the study participants who tested for GDM during pregnancy 
could be traced out of which 20 were diagnosed with GDM during pregnancy. Mean fasting 
plasma glucose of the GDM group in the second trimester of pregnancy was 5.70 mmol/L 
(SD=0.79). At 12 weeks postpartum, mean fasting plasma glucose of the GDM group had 
reduced by 1.3 mmol/L to 4.39 mmol/L (SD=0.83). Difference between the prenatal and 
postpartum fasting glucose was statistically significant (p=0.01). Out of the 20 GDM cases, 
14 (70%) achieved euglycemia at 12 weeks postpartum while fasting plasma glucose of the 
remaining 6 (30%) of the women diagnosed with GDM was persistently above 5.6 mmol/L 
at 12 weeks postpartum. Presented in Table 21 is a comparison of health indicators of woman 
who were euglycemic at 12 weeks postpartum and those who were persistently 
hyperglycemic. It was observed that the hyperglycemic women were significantly shorter in 
stature than the euglycemic woman while other indicators assessed were statistically similar.  
 
 
Table 21. Comparison of profile of diagnosed women who had resolved and 
unresolved GDM at 12 weeks postpartum 
 
Variables   
GDM unsolved 12 
weeks postpartum 
(n=6) 
GDM resolved at 12 
weeks postpartum 
(n=14) 
P-
value a 
 Mean (SD) Mean (SD) 
Maternal age (years) 32.67 (6.28) 32.38 (8.64) 0.944 
Parity  2.50 (1.92) 1.18 (0.87) 0.082** 
Gravida  4.75 (0.96) 3.45 (1.57) 0.151 
Systolic blood pressure (mmHg)  129.50 (16.94) 122.69 (20.26) 0.486 
Diastolic blood pressure (mmHg)  86.00 (11.88) 78.85 (14.39) 0.305 
Maternal height (cm)  153.25 (3.95) 159.01 (3.81) 0.007* 
Maternal weight (kg) 73.57 (3.97) 71.09 (17.49) 0.739 
MUACa (cm) 33.48 (2.11) 31.40 (6.02) 0.427 
Child’s birthweight (kg) 3.20 (0.39) 3.20 (0.54) >0.999 
Statistically significant at *p<0.05 and **p<0.10.  
a Difference determined by students t-test  
MUAC: mid-upper arm circumference; SD: standard deviation
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4 DISCUSSION 
_______________________________________________________________________________________________________________ 
Note: The doctoral student has published some aspects of this chapter in the underlisted publications. For details, see pages 109-111.  
• Prevalence of low birth weight, macrosomia and stillbirth and their relationship to associated maternal risk factors in Hohoe 
Municipality, Ghana http://dx.doi.org/10.1016/j.midw.2016.06.016  
• Accuracy of glycosuria, random blood glucose and risk factors as selective screening tools for gestational diabetes mellitus in 
comparison with universal diagnosing. http://dx.doi:10.1136/bmjdrc-2017-000493  
• Gestational diabetes using diverse diagnostic criteria, risk factors including dietary intakes, pregnancy outcomes and postpartum 
glycemic status: a nested case-control study in Ghana. https://doi.org/10.1101/582239  
 
This study is among the few in Sub-Saharan Africa that investigated gestational diabetes, 
validity of screening tests and diagnostic cut-offs and used restrictive diagnostic criteria to 
assess prevalence, risks and pregnancy outcomes. Key findings include the following 
1. Reference to 2-hour OGTT, fasting glucose had the highest diagnostic validity 
compared to all the screening (dipstick glycosuria, random blood glucose, glycated 
hemoglobin and risk factors) and diagnostic (HbA1c and 1-hour OGTT) instruments 
validated. Fasting glucose could be used both as a screening and diagnostic test as the 
screening tests were insensitive, diagnostically poor and missed majority of cases.  
2. In terms of cut-off, the lower cut-off (≥5.1 mmol/L) for fasting glucose recommended 
by WHO had more false positives but higher discriminatory properties and is 
preferable for screening purposes. The higher cut-off (≥5.6 mmol/L) recommended 
by NICE had fewer false positives and higher disease prediction and is preferable for 
diagnostic purposes. 
3. Depending on the diagnostic test and cut-off used, up to a quarter of participants in 
primary and secondary hospitals were diagnosed with GDM, similar as reported in 
most tertiary hospitals suggesting a rising trend in the general population. 
4. The most important risk factors were excess intake of high glycemic index foods, 
maternal adiposity and history of perinatal death, spontaneous abortion and cesarean 
delivery and pre-eclampsia. This necessitates intensifying education on lifestyle 
modifications throughout the reproductive life cycle and improving obstetric care.  
5. Key maternal outcomes were perineal trauma and postpartum hemorrhage whereas 
the key neonatal outcomes were fetal macrosomia, birth asphyxia and resuscitation 
Regarding post-delivery glycemia, a third of GDM cases remained hyperglycemic at 
12 weeks postpartum calling for a structured postpartum monitoring of all GDM 
cases.  
This chapter is organized according to the key findings and closes with a reflection on the 
global perspectives, limitations of the study and implications of findings for health systems 
in low income settings. 
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4.1 GDM Screening and Diagnosis and the Cut-offs  
Over the years, there have been exhaustive and heated debates about whether screening of 
pregnant women for GDM is needed, whether only clinical risk factors should be used, 
whether all pregnant women be screened (universal screening) with OGTT directly and 
whether fasting plasma glucose and HbA1c should be considered as alternate screening 
methods (Agarwal, 2018). Short- and long-term adverse effects of gestational hyperglycemia 
are well documented (Metzger et al., 2008, Wendland et al., 2012, Damm et al., 2016). 
Prevention and management start with timely and accurate diagnosing. Aside clinical risk 
factors evaluated through history taking and physical assessment, dipstick glycosuria and 
random glucose are used for screening purposes particularly in resource-constraint settings 
and serve as basis for diagnostic testing (National Institute for Health and Care Excellence, 
2015).  
It is crucial that these screening tests are diagnostically valid, have clinically useful cut-offs, 
adequately sensitive (at least 70%) to rule out GDM and be specific enough for disease 
confirmation after a positive screening (Glas et al., 2003). Not only is the ideal method for 
screening of GDM not established or agreed upon, the evidence to make decision on the 
benefits and harms of screening for GDM is insufficient and therefore not justified (Agarwal, 
2018, Hod et al., 2015). The IADPSG recommends using OGTT both for screening and 
diagnosis of GDM (IADPSG Consensus Panel, 2010). However, this would be a ‘wide goose 
chase’ in low resource settings.  
 
4.1.1 Dipstick Glycosuria 
Like in most low- and middle-income healthcare settings, dipstick glycosuria testing is a 
routine ANC practice in Ghana and diagnostic decision is made based on its outcome. The 
NICE recommends glycosuria of ≥1+ on more than one occasion or ≥2+ on one occasion as 
indication to conduct the ‘one-step’ 2-h OGTT (National Institute for Health and Care 
Excellence, 2015). In Ghana, glycosuria values of 1+/2+ on two occasions or 3+/4+ on one 
occasion are indication for OGTT (Ghana Ministry of Health, 2010). In this study, women 
with glycosuria of 1+ and above at any one point during pregnancy was less than one percent. 
Only 3% of clients had positive glycosuria and the test sensitivity was below 5%. With the 
prevalence of GDM based on the 2-h OGTT and fasting glucose being much higher, it is not 
surprising that NICE recommends a re-evaluation of use of glycosuria in pregnancy (National 
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Institute for Health and Care Excellence, 2015) while others have discredited its continued 
use (Alto, 2005, Hanna and Peters, 2002).  
It is established that during pregnancy, renal glucose threshold is highly variable. Reduction 
in glycemic thresholds is needed for GDM diagnosis (Hanna and Peters, 2002) but there is 
possibility of hyperglycemia without detectable glycosuria (Cersosimo et al., 1997). 
Diagnostic decision for GDM should not rely on dipstick glycosuria as it is diagnostically 
poor. But often, glycosuria and proteinuria are checked simultaneously using a single test 
strip and provides vital basis for detecting pre-eclampsia as well. The test is cost-effective 
despite its associated limitations. Universal screening is recommended using fasting or 
OGTT. However, in primary healthcare settings where glycosuria testing is predominant, 
clients with trace results should be closely monitored and booked for diagnostic testing if 
trace result is obtained on more than one occasion.  
 
4.1.2 Random Blood Glucose 
Although diagnostic accuracy of random glucose was poor, it was better than glycosuria and 
HbA1c. Interestingly, mean random glucose was only 0.3 mmol/L-point higher than mean 
fasting glucose. In our study setting, care seekers typically attend healthcare facilities in 
fasting state in anticipation of service providers unexpectedly requesting a biochemical test 
that might require overnight fasting. Also, long waiting times and high clientele turn-out often 
compel clients to skip breakfast or eat meals typically smaller than usual in order to arrive 
early at the hospital and thus minimize delays. Meanwhile, the effect of pregnancy-related 
physiological changes altering dietary patterns and preferences cannot be ruled out (Moya et 
al., 2014), likewise the cultural practices which cause some pregnant women to over-indulge 
in food during pregnancy. No wonder the highest sensitivity and specificity for random 
glucose was at the 5.2 mmol/L threshold.  
Random glucose using capillary finger prick checked on the spot using a glucose meter is not 
only cheap but can be done by low cadre health workers with minimum training in remote 
areas. This therefore makes it the test of choice in primary healthcare care settings where 
laboratory facilities are often unavailable. However, none of the health regulating bodies have 
established a diagnostic threshold for this test although the NICE recommends RBG >7.0 
mmol/L as indication for OGTT while the WHO/IADPSG recommends >11.1 mmol/L as 
diagnostic criteria for pre-existing (overt) diabetes. This >11.1 mmol/L cut-off would have 
yielded only one positive case in this study. Due to non-consensus on diagnostic threshold 
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for random glucose and the fact that the test is not sufficiently sensitive to detect GDM, 
effectiveness of RBG needs to be further explored with emphasis on the reference threshold 
and optimum postprandial conditions under which the test would be most accurate. 
Considering difficulty faced by pregnant women in adhering to overnight fasting regulations 
(Hod et al., 2015), postprandial conditions like effect of the last meal time prior to testing, 
type and quantity of the meal on the random glycemic levels might be worth investigating.  
 
4.1.3 Clinical Risk Factors as a Screening Tool 
Even though the increasing prevalence has been attributed to increasing diabetes in the 
general population (Cho et al., 2018), maternal risk factors particular age, obesity, ethnicity, 
family history of type II diabetes and previous GDM miscarriages, stillbirths, fetal 
malformations, preeclampsia, and macrosomia, are increasingly becoming a significant 
predictor for GDM (Damm et al., 2016, Anand et al., 2017). These risk profile vary widely 
from one study to another. A third of the pregnant women in this study had at least one risk 
factor for GDM. In a similar study in South Africa, almost half (45.8%) had at least one risk 
factor and only 26.0% of those ‘at risk’ developed GDM compared to 54.3% in our study 
(Adam and Rheeder, 2017). Presence of clinical risk factors was a better screening tool for 
GDM compared to glycosuria and random glucose because whereas risk factors missed 
approximately half of the true positive rate, glycosuria and random glucose missed 
approximately 90%. Risk factors had higher sensitivity (54%) compared to glycosuria (5%) 
and random glucose (13%) but had the least (73%) specificity compared to all the other tests 
which had over 90% specificity.  
A third (Agbozo et al., 2018) to half (Hod et al., 2015) of women diagnosed with GDM have 
one or more risk factors but some asymptomatic women develop GDM thus making 
diagnostic decision based on risk could miss half of all cases. The ideal method to screen 
GDM is debatable (Agarwal, 2018). Even though meta-analysis suggests that women with 
prior GDM have 17.92‐fold adjusted risk for GDM in subsequent pregnancies (Song et al., 
2018), use of risk factors do not identify women with GDM well as the high sensitivity of 
diverse risk factor combinations results in low specificities (Farrar et al., 2017). This supports 
universal screening where all pregnant women are tested using a recommended diagnostic 
criterion instead of selective screening via risk factors and other screening methods. However, 
universal screening requires health-system preparedness to screen all pregnant women and to 
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manage the 10-25% who might need some additional non-pharmacological and/or 
pharmacological support.  
 
4.1.4 Glycated Hemoglobin 
Glycated hemoglobin test had the highest number of false negative, least diagnostic odds ratio 
and the test performance was diagnostically invaluable. As pregnancy progresses, HbA1c 
levels decreases (Moya et al., 2014) as a result of factors such as increased red cell turnover, 
hemoglobin variations and iron deficiency anemia  (Narayan and Pettitt, 1996) which is 
known to be a major public health problem affecting almost half of all pregnant women 
globally (WHO, 2015). Isolated use of HbA1c as a screening test has been shown to miss a 
significant number of GDM cases (Hanna et al., 2017). Nonetheless, HbA1c values provide 
useful information about glycemic control in the preceding three months. Like this present 
study were HbA1c coordinates of 5.0% was the most clinically useful sensitivity and 
specificity, 5.05% cut-off was found to be good to rule out women who did not have GDM 
(Kwon et al., 2015). Values >6.5% at first prenatal care visit are suggestive of overt diabetes 
(National Institute for Health and Care Excellence, 2015). However, in deprived populations 
where over 90% of pregnant women are unaware of their pre-pregnancy glycemic status and 
half make their first ANC visit after the first trimester, it is difficult to delineate pre-existing 
hyperglycemia from pregnancy-induced diabetes. Considering the limited availability of 
HbA1c testing in many primary and secondary facilities, the high cost of the test 
(approximately 15 Dollar equivalent in Ghana), the lack of correlation between HbA1c and 
average blood glucose due to gestational metabolic alterations (Berggren et al., 2017) and the 
risk of missing GDM patients and wrongly labeling women as having GDM (Ye et al., 2016), 
use of HbA1c as a routine GDM detection tool in resource-constraint settings is non-
beneficial at the population level.  
 
4.1.5 Oral Glucose Tolerance Test  
Ironically, there is no contention on the fact that the OGTT remains the cornerstone for 
diagnosis of GDM and one abnormal plasma glucose value is sufficient to make a diagnosis 
(Hod et al., 2015, National Institute for Health and Care Excellence, 2015, IADPSG 
Consensus Panel, 2010, World Health Organization, 2013). However, use of 2-h OGTT as 
the ‘gold standard’ test is supported by some health regulatory bodies (National Institute for 
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Health and Care Excellence, 2015) while others focuse on prognostic accuracy rather than 
diagnostic accuracy and do not endorse any gold standard test per se (World Health 
Organization, 2013). Meanwhile, there are wide variations in cut-off values needed in making 
a diagnosis of GDM ranging from 7.8 mmol/L (National Institute for Health and Care 
Excellence, 2015), 8.5 mmol/L (World Health Organization, 2013, IADPSG Consensus 
Panel, 2010, American Diabetes Association, 2013), 8.6 mmol/L (ACOG Practice Bulletin, 
2018) to 9.0 mmol/L (Diabetes Canada Clinical Practice Guidelines Expert Committee, 
2018b). Also, there are disagreements regarding the diagnostic approach, that is, whether one-
step screening using 75-g glucose (IADPSG Consensus Panel, 2010, World Health 
Organization, 2013, National Institute for Health and Care Excellence, 2015) or two-step 
screening using 50-g glucose challenge test, followed, if abnormal, with a 75-g OGTT 
(Diabetes Canada Clinical Practice Guidelines Expert Committee, 2018b). Regarding when 
postprandial glucose should be measured, although many advisory bodies recommend 2-hour 
OGTT, a few recommend 3-h OGTT (ACOG Practice Bulletin, 2018). Most guidelines 
recommend the timing for testing to be restricted to early pregnancy (24–28 weeks). Although 
the WHO recommends this timing, the guideline is flexible on the timing of the test during 
pregnancy (World Health Organization, 2013). More recently, there are considerations to 
perform OGTT in a non-fasting state (Hod et al., 2015).  
Interesting some regulatory bodies have lower thresholds for fasting glucose and higher 
thresholds for 2-h OGTT and vice versa. For instance, the NICE cut-off for fasting glucose is 
5.6 mmol/L but that for 2-h OGTT is 7.8 mmol/L whereas the WHO cut-off for fasting 
glucose is 5.1 mmol/L but that for 2-h OGTT is 8.5 mmol/L. Amid the controversies and 
chaos surrounding aspects of GDM screening despite five decades of research on GDM, what 
is clear for health systems in low income settings is the need for simplicity and flexibility in 
GDM testing. Ghana for example is battling with budgetary constraints to the health sector 
and lack of political will to invest into healthcare; inequities in the human resource, 
infrastructure and equipment allocation across different levels of healthcare delivery in rural 
and urban areas; and socio-cultural practices, economic and geographic constraints that affect 
health seeking behaviors, thus the need for a simple and flexible test cannot be 
overemphasized. Simple, flexible and less expensive GDM test approaches will facilitate 
compliance by clients and motivate health insurances providers to make payments.  
The OGTT is poorly reproducible, expensive, requires preparation, not physiologic, ethnicity-
dependent, given without consideration to body weight, unpleasant, causes nausea and 
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vomiting in pregnant women and compliance with follow-up appointments for testing is poor 
(Cundy et al., 2014, Agarwal, 2018, Utz et al., 2018, Njete et al., 2018). Besides, making a 
GDM diagnosis without providing management alternatives is unethical and as good as no 
diagnostic testing at all. Hence, as used in this present study for GDM case definition, higher 
restrictive cut-off for OGTT is recommended to be used to make GDM diagnosis and most 
importantly, to commence pharmacological management in low income settings. This study 
demonstrates that higher cut-offs limit false positives, better predicts GDM and classifies 
fewer women with the condition which can be managed by weaker health systems thereby 
addressing the concern of GDM been touted as one of the diseases discovered due to 
medicalization of obstetric care (Agarwal, 2018, Cundy et al., 2014, Twohig et al., 2018, 
Naaktgeboren et al., 2018). Going forward, studies are needed in low income resource settings 
to identify cut-offs that are based on mean glucose values at which odds of adverse pregnancy 
outcomes reach 1.75 times (IADPSG Consensus Panel, 2010) and that can form the basis to 
diagnose GDM. 
 
4.1.6 Fasting Plasma Glucose  
Unlike OGTT, use of fasting plasma glucose as a diagnostic test for GDM is not touted with 
so much controversies and chaos by advisory bodies. The test preparations are much simpler 
to accomplish by clients and can be done in many more health settings worldwide. However, 
there are varied diagnostic cut-offs needed to make a diagnosis of GDM ranging from 5.1 
mmol/L (World Health Organization, 2013, IADPSG Consensus Panel, 2010, American 
Diabetes Association, 2013), 5.3 mmol/L (Diabetes Canada Clinical Practice Guidelines 
Expert Committee, 2018b), 5.6 mmol/L (National Institute for Health and Care Excellence, 
2015) to 5.8 mmol/L (ACOG Practice Bulletin, 2018). Fasting glucose is not a first-line 
diagnostic test for GDM although an abnormal value can be used to make a diagnosis 
irrespective of OGTT outcomes (World Health Organization, 2013, IADPSG Consensus 
Panel, 2010, American Diabetes Association, 2013). In recent times, there are suggestions to 
consider fasting plasma glucose as alternate screening method (Agarwal, 2018). In this 
present study, fasting plasma glucose was found to have the highest true positive rate and the 
test performance was very good thereby making it a useful test for ruling out GDM and 
minimizing missed cases. The test has an added advantage of being readily available, easy to 
perform, relatively inexpensive and requiring minimal client preparation. It has a better 
diagnostic property thereby making it applicable for use as both a GDM screening and a 
diagnostic test.  
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When assessing diagnostic accuracy, tests with high discriminatory measures are helpful for 
screening and making health policy decisions whereas tests with highly predictive measures 
are useful for predicting probability of disease progression at the individual level in order to 
facilitate client-centered case management (Raslich et al., 2007). In the US, fasting glucose 
reduced 7% missed cases when used as a screening tool (Herrera et al., 2015). Similarly, in 
South Africa, use of lower cut-off for fasting glucose (≥5.1 mmol/L) mis-diagnosed 54% of 
pregnant women but was reduced to 31% when the NICE cut-off was used (≥5.6 mmol/L) 
(Adam and Rheeder, 2017).  
In was noted in this present study that the higher cut-off (≥5.6 mmol/L) recommended by 
NICE had fewer false positives and higher predictive properties making it the test and cut-off 
option for predicting the probability of an individual developing GDM and making a GDM 
diagnosis. As advocacy increases to adhere to the universal screening approach of testing all 
pregnant women for GDM, screening tests will become obsolete. However, in situations 
where selective screening is preferred or the only feasible alternative, the lower cut-off (≥5.1 
mmol/L) recommended by the WHO which was found to be the most sensitive and had higher 
discriminatory properties could be used even though this cut-off over-diagnosed due to the 
high number of false positives detected. This lower cut-off is preferred if prevention of missed 
cases is the focus; screen-positive cases detected can then proceed to do OGTT. 
 
4.2 What are the Key Drivers of GDM in Low-Income Settings? 
4.2.1 Obesity Associated with Excess Caloric Intake  
Despite the diverse risk profiles observed in this study, adiposity and excess intake of high 
glycemic index (GI) foods are striking. Changes in lifestyle have contributed to the increasing 
risk of obesity. Maternal diets were monotonous and energy-dense resulting in over one-third 
neither meeting the minimum dietary diversity indicator or eating healthily. Excess energy 
that is not expended is stored as fat leading to adiposity. Obesity is associated with an 
increased likelihood of GDM and a meta-analysis shows an increasing cumulative incidence 
of type II diabetes from 2.1% to 35.7% within 5.5 months to 15 years of follow-up after the 
index pregnancy complicated by GDM (Zhu and Zhang, 2016). High carbohydrate intake has 
been associated with GDM in South Africa where pregnant women believe that controlling 
for sugar and sweetener cravings during pregnancy is difficult to achieve (Krige et al., 2018). 
Concentrating efforts at addressing modifiable risk factors is central to the prevention and 
management of GDM (Utz et al., 2018). Intensifying education on lifestyle modifications 
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focusing on reduced intake of high GI foods, lower pregnancy weight gain in obese women 
and monitoring and intervening to ensure optimum glycemic control are crucial (Hod et al., 
2015). Midwives at the forefront of ANC care need training on approaches to engage pregnant 
women in order to give family-centered nutrition counseling that is acceptable and fits the 
socio-cultural context. Also, capacity of other frontier health workers needs to be enhanced 
to provide tailored dietary counselling considering socioeconomic status, food security 
including availability, food preferences, processing, cooking and storage methods. Owing to 
obesity being associated with higher risk for GDM, it is crucial not to fuel the obesity 
epidemic by promoting healthy diversified intakes while limiting excess energy intake during 
pregnancy. Further studies are needed to identify locally available carbohydrate-based food 
sources that have low glycemic index.  
 
4.2.2 Poor Access to Healthcare Leading to Bad Obstetric History  
Most studies on GDM in Africa are conducted in urban tertiary hospitals where prevalence is 
expectedly high. Interestingly, similar prevalence was noticed among secondary and primary 
facility users in this study who are peri-urban and rural dwellers. This could be explained in 
the context of rural dwellers having more children compared to urban dwellers (Ghana 
Statistical Service, 2013) culminating in longer childbearing years and advance age at 
childbirth. In settings where fertility and abortion rates are high, reducing childbearing 
especially in older women is crucial. Also, primary healthcare users often have lower 
education and are more unlikely to afford healthcare. Adhering to treatment regimen and 
making healthy dietary choices could also be problematic. Besides, primary facilities are 
limited to receiving basic Emergency Obstetric and Newborn Care (EmONC) services that 
often excludes emergency services like removal of retained products, neonatal resuscitation, 
blood transfusion and cesarean section. Traveling longer distances for emergency EmONC 
increases risks for complications and bad obstetric outcomes. But undoubtfully, the nutrition 
transition poses risk for urban dwellers (Cho et al., 2018, Mwanri et al., 2014, Hod et al., 
2015) who are significantly more obese (4.3% vs 13.5%), have higher triglycerides (35.0% 
vs 64.4%) (Agbozo et al., 2018) and double odds for obesity (Oppong et al., 2015, Njete et 
al., 2018). Bridging access to healthcare and improving equity at all levels could be central 
to reducing the GDM surge. 
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4.3 What are the Effects of GDM?  
4.3.1 Compromised Perinatal Survival  
Despite the diverse factors that are associated with increased risk for GDM, its effects on 
maternal and fetal outcomes are inconsistent (Metzger et al., 2008, Wendland et al., 2012). It 
was observed that a unit rise in glucose significantly increased birth weight and blood loss 
whereas hyperglycemia in pregnancy was associated with perineal tear, large-for-gestational 
age and birth asphyxia. In many low-resource settings postpartum hemorrhage and birth 
asphyxia are common causes of maternal and neonatal deaths respectively. With 85% of 
annual global deliveries occurring in low- and middle-income countries coupled with the 
surge in GDM, efforts at reducing near-miss events and maternal mortality especially in weak 
health systems could be derailed if GDM detection, management and follow-up efforts are 
not intensified. Few studies in Africa have assessed the effect of GDM on pregnancy 
outcomes. In Morocco for instance, larger birth weight was the only significant effect (Utz et 
al., 2018). Macrosomic babies have two-fold odds for cesarean birth and stillbirth in Ghana 
(Agbozo et al., 2016). Women who deliver macrosomic babies per vaginal have higher risk 
for prolonged labour, perineal tear and shoulder dystocia (Wendland et al., 2012, O’Sullivan 
et al., 2011, Metzger et al., 2008). The newborns whose lungs are not fully developed, are 
often hypoxic and require resuscitation and admission to NICU to establish extra-uterine 
breathing (Agbozo et al., 2016). In primary facilities where emergency obstetric and neonatal 
services are unavailable, perinatal death becomes inevitable.  
 
 
4.3.2 Fetal Macrosomia Leading to Labour Complications  
Fetal adiposity particularly macrosomia and large for gestational age are pregnancy outcomes 
associated with increased risk of adverse maternal and perinatal outcomes (Wendland et al., 
2012). Vaginal delivery of macrosomic babies increases risk for prolong/obstructed labour, 
perineal trauma and postpartum hemorrhage. Yet, unlike low birth weight, little attention is 
paid to macrosomic births in most developing countries. Prevalence of macrosomia in 
developed countries is between 5% and 20% although an increase of 15%-25% has been 
reported in the past decades. This is driven by an increase of maternal obesity and diabetes 
(Henriksen T., 2008). In developing countries however, data on the changing prevalence of 
macrosomia are rare. Macrosomia could lead to complicated delivery and is linked to obesity 
in later life. This can pose additional threat to mother-newborn pairs especially in resource-
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limited settings such as Ghana because of the challenges associated with emergency obstetric 
and other essential care. Until recently, there was no data on the overall prevalence of 
macrosomia in Ghana. A cross-sectional survey on macrosomic births in Northern Ghana 
identified a prevalence of 10.5% (Abubakari et al., 2015). The prevalence of macrosomia in 
the secondary data analyzed was low (3.03%) (Agbozo et al., 2016), similar as the 3.3% 
macrosomic births recorded in among the pregnant cohort empathizing the low rates of 
macrosomia in the study area. Considering that 16% GDM prevalence was found in this study, 
if macrosomia was to be used as a proxy for GDM, GDM would have been underestimated 
by over 10%.  
 
4.3.3 Progression to Type II Diabetes  
Significant associations have been found between fasting and post-prandial glucose levels 
during pregnancy and future risk of diabetes. Uncontrolled GDM is known to increase short- 
and long-term cardio-metabolic risk especially for type 2 diabetes (Eades et al., 2015, 
Kampmann et al., 2015, Hod et al., 2015). A third of the GDM cases in this study were 
persistently hyperglycemic at 12 weeks postpartum. If lower cut-off criteria, say fasting 
glucose ≥5.1 mmol/L was used, over half of the women would still be hyperglycemic at 12 
weeks postpartum. In Morocco where nutritional counselling and pharmacology intervention 
were given, 93.2% attained glycemic control (Utz et al., 2018) but at 8 weeks postpartum, 
50% of the intervention group had fasting glucose values indicative of type 2 diabetes (Utz 
et al., 2018). A 2.6-70% cumulative incidence of diabetes has been observed after following-
up on diagnosed with GDM women from 6 weeks to 28 years post-gravidity (Kim et al., 
2002). In a Scottish study, quarter of GDM women progressed to diabetes from 4 months to 
16 years after GDM diagnosis (Eades et al., 2015).  
Evidence shows an increasing risk for type II diabetes with increasing post-gravidity follow-
up period. Risk of developing diabetes among women diagnosed with GDM was 6.9% at 5 
years and increased to 21.1% at 10 years following the initial GDM diagnosis (Sivaraman et 
al., 2013). This implies that the 30% of women who were hyperglycemic at 12 weeks 
postpartum in this present study could increase if the no control measures are provided. This 
situation is worrying and necessitates proper transition of the continuum of care from 
obstetricians and midwives to cadres of health professional who are versatile with diabetes 
care after the routine postpartum phase ends. By so doing, mother-offspring pairs who 
experience diabetogenic conditions during pregnancy would be handed over to an appropriate 
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care provider to be monitored and supported to avert long-term complications. Risk of 
diabetes following GDM is not found to be associated with maternal age, gestational age at 
diagnosis, and numbers of previous and subsequent pregnancies (Sivaraman et al., 2013). 
Other than maternal height, no significant associated risks were found in this present study. 
However, this is a novel finding worth further research to determine the effect of low maternal 
stature on risk for diabetes following diagnosis of GDM.  
 
4.4 How Does Findings Relate to the Burden of GDM Globally?  
It was observed in this cohort study that prevalence of GDM according to 2-h OGTT was 
9.0%, and was similar to the 9.3% recorded in a tertiary facility in Ghana in 2015 (Oppong et 
al., 2015). However, overall, findings show a GDM prevalence of 15.9% when test results 
from 2-h OGTT and fasting glucose were combined using restrictive higher diagnostic cut-
offs for both tests. Generally, glycemic values of primary healthcare users tended to be higher, 
which could be an indication of poor access to healthcare and non-adherence to test 
preparations like overnight fasting. Evidence shows an increasing burden of GDM globally 
with majority of cases occurring in low- and middle-income countries (Cho et al., 2018). 
GDM prevalence in Africa is relatively lower (9.5%), but investments into diabetes healthcare 
is not commensurate with the current rising trends (Cho et al., 2018).  
Lower prevalence has been reported in African countries including South African (9.1%) 
(Macaulay et al., 2018) and Nigeria (8.6%) (Olagbuji et al., 2015) compared with developed 
regions like North America (12%) and Europe (14%) (Cho et al., 2018). But Africa is 
catching-up fast as pockets of high cases have recently been reported in Tanzania (19.5%) 
(Njete et al., 2018), South Africa (25.8%) (Adam and Rheeder, 2017) and Morocco (23.7%) 
(Utz et al., 2018). However, diverse algorithms for testing and diagnosing pose challenges in 
comparing prevalence, risks, treatment effects, pregnancy outcomes, and harmonizing 
clinical practice (Agarwal, 2018).  
Comparing a study conducted in South Africa to this present GDM, prevalence based on the 
fasting glucose per WHO guideline ≥5.1 mmol/L was similar (26% vs 24%), prevalence per 
the NICE guideline ≥5.6 mmol/L was slightly different (17% vs 11%) whereas using the 1999 
WHO guideline (fasting glucose ≥7.0 mmol/L) yielded much lower prevalence (7% vs 3%) 
(Adam and Rheeder, 2017). In Tanzania, large variation was found between GDM prevalence 
per fasting glucose (18.3%) and 2-h OGTT (4.3%) (Njete et al., 2018). Whether this is a 
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situation of over or underdiagnosing is uncertain but certainly calls for harmonization of 
diagnostic tests and cut-offs globally. Irrespective of the test modalities, there is an obvious 
trend of a rising prevalence of GDM in line with the epidemiological and nutrition transition. 
The implications might be detrimental for primary health systems in rural communities and 
low-income settings if such facilities are not resourced with health professionals and 
equipment to enhance screening, testing and management of cases or clear algorithms 
instituted for referral. 
 
4.5 Limitations and Strengths of the Study  
There are some limitations with this study worth highlighting. Although HbA1c was 
performed in the fasting state (n=445), few non-fasting pregnant women (n=35) were 
included. Nonetheless prandial state has been shown not to affect HbA1c levels. Whereas 
random blood glucose was checked using capillary finger prick before 20 gestational weeks, 
fasting plasma glucose was checked from venous blood from 20-34 weeks. Variability in 
sampling collection procedures and testing times poses a challenge when equating these two 
glucose values. Because pregnant women also receive antenatal care in primary facilities 
where laboratory services could be unavailable, accuracy of point-of-care testing using 
fasting whole blood glucose obtained from a capillary finger prick should have been 
investigated as well. 
In determining BMI, first trimester weight was used instead of pre-pregnancy weight as that 
was the only possibility. But in the first trimester, substantial weight changes are not expected 
(Institute of Medicine, 2009). MUAC was useful in assessing maternal adiposity as a GDM 
risk and could be used when pregnancy is advanced, and BMI is no longer useful. As a result 
of the global non-consensus on diagnostic thresholds for GDM, (Agarwal, 2018, Hod et al., 
2015), the study team restricted to using higher thresholds for 2-h OGTT (IADPSG/WHO: 
≥8.5 mmol/L) and fasting glucose (NICE: ≥5.6 mmol/L (Metzger et al., 2010a, World Health 
Organization, 2013) as the case definition. Higher diagnostic cut-offs are known to have 
higher sensitivity, better disease prediction (Agbozo et al., 2018) better within-patient 
correlation (Metzger et al., 2008) and less likelihood for overdiagnosis (Cundy et al., 2014). 
Slightly different estimates could have been obtained if other diagnostic thresholds were used. 
The call for countries to develop national guidelines for screening and diagnosis considering 
resource availability (Hod et al., 2015) could facilitate context-specific diagnoses and care.  
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A key challenge in GDM testing is the ‘no show’ syndrome. While 23% of the pregnant 
women booked for GDM testing in Tanzania failed to attend their appointments (Njete et al., 
2018), 45% was observed in this present study. However, this did not affect the estimates as 
50% attribution was accounted for in the design. Establishing postpartum contact with 
participants was difficult due to poor house addresses and relocations out of the study area. 
Out of the 70 GDM cases, only 20 (representing 28.6%) could be traced at 12 weeks 
postpartum. Hence the postpartum hyperglycemic estimates need to be interpreted in the 
context of the study population and cautiously generalized.  
Having observed elevated fasting glucose among participants less than 20 years, and the 
underweight group, poor adherence to fasting requirements cannot be rule-out. The Indian 
strategy of performing 2-h OGTT irrespective of fasting state (Hod et al., 2015) could be 
considered in settings where adherence to overnight fasting and antenatal schedules are 
problematic. Encouraging partner support could improve diagnostic outcomes as higher 
partner education was found to reduce GDM risk significantly. 
Routine delivery data recorded by health professionals was used for the initial secondary data 
analysis. Therefore, measurements errors including inappropriate measurements, readings or 
recordings of parameters such as birth weight and other indices were likely to occur. 
However, the effect of these errors was random and unlikely to affect the results due to the 
large sample size used (n=4,262). Also, association of gestational age at birth on pregnancy 
outcomes could not be assessed because this information was unavailable in the secondary 
records reviewed.   
Despite these limitations, unlike in most diagnostic accuracy studies where retrospective data 
sources were used, our study was conducted prospectively using the blind comparison to a 
gold standard design, a type of randomized controlled trial design that compares accuracy of 
diagnostic procedures in the same individual. This design increases probability of the test 
outcomes being close to the true values. In low- and middle-income countries, studies of this 
nature are mostly concentrated in tertiary hospitals. Our study shows higher glycemic values 
among primary healthcare users. This provides evidence of obstetric transition even in rural 
communities and highlights the need to enhance access to quality maternal healthcare at 
primary healthcare levels. A key strength is the follow-up to assess short-term birth outcomes 
and glycemic status. As previous obstetric outcomes of the multiparous women were 
extracted from the ANC booklet, recall biases were minimized.  
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Dietary data was collected using the food frequency questionnaire which was validated 
against the 24-hour recall method generating information on both current and habitual food 
habits. Assessing anthropometry by BMI, mid-upper arm circumference and pregnancy 
weight change provided alternatives of monitoring adiposity and nutritional status as 
pregnancy progressed. Study participants were recruited from primary, secondary and referral 
facilitates providing overview of the disease burden in peri-urban and rural populations. 
Unlike in similar epidemiological studies where retrospective data are used, data was 
collected prospectively allowing the ease to explore the role of diverse and interesting risk 
factors. The main strength of the secondary data analysis was the large sample size of over 
4,200 delivery records used.  
 
4.6 Clinical, Public Health and Policy Implications of Findings  
Fasting glucose had the highest diagnostic validity. None of the screening tests was clinically 
useful thus making selective screening diagnostically non-beneficial. In settings where 
screening is the first step to diagnostic testing, fasting plasma glucose should be used both as 
a screening and a diagnostic test. Lower diagnostic cut-offs should be used to detect screen-
positive cases whereas higher cut-off should be used to make a GDM diagnosis. Prevalence 
of GDM ranged from 5-27% depending on the diagnostic test and cut-off used. Main adverse 
birth outcomes were perineal tear and birth asphyxia. A third of the sample were unable to 
achieve euglycemia at 12 weeks postpartum. Findings highlight the need for timely universal 
testing, integration of diagnostic testing into routine antenatal care at all levels of healthcare 
and monitoring of blood glucose after routine postpartum care ends. 
 
4.6.1 Commence Pharmacological Treatment if Fasting Glucose ≥5.6 mmol/L 
Even though the WHO (World Health Organization, 2013), IADPSG (Metzger et al., 2010a), 
and NICE (National Institute for Health and Care Excellence, 2015) have recommended 
fasting glucose as a diagnostic test for GDM, the preferred test is the ‘gold standard’ 2-h 
OGTT. Criteria for diagnosing diabetes in pregnancy based on the 1-h post-load value have 
not been fully established (World Health Organization, 2013) and this study has shown that 
this test has a low sensitivity (<50%). Therefore, in settings where 2-h postprandial glucose-
load testing is unavailable or difficult to obtain for confirmation of diagnosis, GDM diagnosis 
and decision to commence pharmacological treatment should be established based on pre-
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prandial glucose values ≥5.6 mmol/L as substitute for an OGTT due to the high predictive 
properties of this cut-off. This could be complemented with presence of maternal risk factors 
which, although has least specificity, has a higher sensitivity than most of the tests assessed 
and collectively, serve as basis to commence treatment. The lower cut-off (≥5.1 mmol/L) for 
fasting glucose has high discriminatory properties and is therefore useful for screening 
purposes. This cut-off could be used as basis to initiate non-pharmacological management 
such as dietary counseling, exercise programmes and pregnancy weight control.  
 
4.6.2 Integrate Fasting Glucose Monitoring into All GDM Screening Procedures  
Because fasting plasma glucose was the most sensitive test with minimal false negatives 
diagnoses, its integration into all GDM detection procedures through universal testing of all 
pregnant women is recommended as the test is much more readily available, less expensive, 
the procedure is less cumbersome and therefore easier to accomplish for many women 
compared to OGTT. At the population level, the WHO diagnostic criteria ≥5.1 mmol/L could 
be useful for screening purposes because of its discriminatory properties, which is key for 
making health policy decisions. At the individual level, the NICE diagnostic criteria ≥5.6 
mmol/L which has higher GDM prediction properties could be useful for making diagnostic 
and therapeutic decision.  
 
4.6.3 Apply Universal Screening – Test All Pregnant Women  
In the wake of updated guidelines for detecting hyperglycemia in pregnancy whereby 
diagnostic thresholds have reduced (World Health Organization, 2013, National Institute for 
Health and Care Excellence, 2015, Metzger et al., 2010a, American Diabetes Association, 
2015), there are widespread concerns about over-diagnosing and the associated implications 
particularly for fragile health systems. In as much as over-diagnoses (false positive) will 
increase costs, under-diagnoses (false negative) have adverse public health implications. 
Selective screening using risk factors is better when compared with glycosuria and random 
blood glucose because these tests missed majority of cases thereby decreasing opportunities 
for diagnostic testing. However, selective screening using risk factors also missed over half 
of all GDM positive women who could otherwise have missed the chance to be tested and 
subsequently managed. Universal screening is the only strategy by which majority of women 
with GDM will be diagnosed. Hence all pregnant women should be tested for GDM 
irrespective of the risk profile or obstetric history. GDM prevalence in Ghana might increase 
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substantially by virtue of using the universal screening approach. To minimize the impact that 
the surge in prevalence could have on the health system in Ghana, there is need to develop 
screening algorithms specific to the Ghanaian context and to establish diagnostic cut-offs that 
would balance obstetric and long-term health risks and benefits unique to socioeconomic and 
clinical context. 
 
 
4.6.4 Strengthen Primary Healthcare Systems to Screen and Diagnose GDM 
Gestational diabetes is common in the study population. Prevalence ranged from 5-27% 
depending on the test and diagnostic criteria. But prevalence based on 2-h OGTT was 9.0%, 
same as the 9.3% observed in the largest tertiary hospital in Ghana indicating an increase 
even in peri-urban and rural communities. Prevalence was high among primary healthcare 
users who often have poor access to healthcare. Evidence of increasing prevalence of 
pregnancy-triggered diabetes from negligible rates to almost 30% in certain settings in 
African (Macaulay et al., 2014, Hall et al., 2011, Adam and Rheeder, 2017) necessitate a 
critical review of diagnostic strategies by health systems if adverse outcomes such as newborn 
macrosomia, hypoglycemia, hyperinsulinemia, respiratory distress, perinatal mortality, 
maternal pre-eclampsia, caesarean delivery  (Metzger et al., 2008) and risk for long-term 
metabolic conditions (Damm et al., 2016) are to be reduced. This highlights the need to tackle 
rural-urban inequities in access to healthcare by equipping primary facilities with basic 
amenities to test, provide non-pharmacological management and refer non-responsive cases. 
While this study supports testing all pregnant women using fasting plasma followed by 2-
hour OGTT if available, consensus is needed on the diagnostic criteria which could be 
applicable for health systems in low resource settings who are the least prepared to handle 
implications of the surge in GDM prevalence. 
 
4.6.5 Tackle Modifiable Risks and Monitor GDM Women beyond Postpartum  
The manifold risk factors identified necessitate a wide range of holistic and integrated facility 
and community-based interventions. Concentrating on the modifiable risks through 
interventions that focus on lifestyle modification is crucial. Nutrition education tailored 
towards moderate intake of high glycemic index foods and dietary diversification, glycemic 
control and weight management in overweight/obese women is crucial. Owing to multiple 
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micronutrients derived from diversified diets, investing efforts into dietary diversification 
might be more sustainable at improving dietary intakes across the pregnancy continuum.  
 
4.6.6 Monitor all GDM Women After Routine Postpartum Care Ends 
Access to adequate and comprehensive Emergency Obstetric and Newborn Care and prompt 
referral is important to reduce adverse maternal and fetal complications during birth. To avert 
long-term metabolic effects, there should be transition of care when the routine postpartum 
phase ends to ensure follow-up and monitoring of glycemic control among women who 
experience gestational diabetes. Referral to community health nurses and general 
practitioners is recommended. Where possible, GDM-affected women can be educated to do 
self-glycemic monitoring at home. Where possible, mother-to-mother peer support, 
community-based and telemedicine monitoring strategies could be explored. 
 
4.6.7 Areas for Further Research   
Physiologic interactions between fasting plasma glucose and 2-h postprandial glucose during 
pregnancy needs further research because even though some overlap effect was seen for birth 
outcomes associated with high fasting glucose and high 2-h OGTT, there seems to be some 
distinctive outcome profiles as well. To facilitate management for women diagnosed with 
GDM, glucose cut-off values for African populations and health systems in low resource 
settings that would balance the risks and benefits of adverse pregnancy outcomes and long-
term complications that are applicable to the health systems context is needed. To improve 
access to GDM diagnosing in primary facilities, correlation profile of venous versus capillary 
blood glucose and the correlation of point-of-care device versus laboratory analysis needs to 
be researched to assess the extent to which findings from the Ghanaian population would 
compare with current global evidence. Finally, effective monitoring strategies for GDM 
women is needed. 
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5 SUMMARY 
_______________________________________________________________________________________________________________ 
Background: Gestational diabetes is increasing globally. Studies from Sub-Saharan Africa 
have investigated the risk factors but reported prevalence is often based on one diagnostic test 
while short-term outcomes have scarcely been explored. In primary settings, gestational 
diabetes is tested after screen-positive glycosuria and/or presence of clinical risk factors. 
There is suspicion of missing cases due to likelihood of active hyperglycemia without 
detectable glycosuria and the wide profile of risk facts associated with gestational diabetes. 
Despite recent updates of diagnostic guidelines with lowered diagnostic cut-off in most cases, 
opinions are divided on the screening methods diagnostic cut-offs to apply, and whether to 
do selective screening followed by diagnostic testing of screen-positive cases vis-à-vis 
universal testing of all pregnant women. 
Objective: This study was conducted to address three overarching objectives:  
(1) validate the diagnostic validity of screening tests for gestational diabetes and estimate 
the proportion of cases that could be missed if selective screening is applied;  
(2) estimate the prevalence of gestational diabetes and assess the risk factors; and  
(3) assess the pregnancy outcomes including the extent of attainment of euglycemia at 12 
weeks postpartum. 
Materials and methods: This study employed blind-comparison-to-the-gold-standard and 
case-control designs embedded in a prospective cohort study. Singleton non-diabetic 
singleton pregnant women (n=807) were recruited in the first trimester from five state-owned 
hospitals serving rural and peri-urban communities in Ghana. They were all screened for 
gestational diabetes from 13-20 weeks using dipstick glycosuria, random glucose and clinical 
risk factor assessment. Between 20-34 weeks, 491 pregnant women were tested for 
gestational diabetes using glycated hemoglobin, fasting glucose, 1-hour and the ‘gold 
standard’ 2-hour oral glucose tolerance test following the universal ‘one-step’ approach. 
Dietary and obstetric history were assessed retrospectively while physiologic measurements 
were repeated throughout pregnancy. Case definition was fasting ≥5.6 mmol/L and/or 2-hour 
postprandial glucose ≥8.5 mmol/L. Short-term outcomes of 403 and 100 women were traced 
at delivery and 12 weeks postpartum respectively. Validity of test instruments were estimated 
using standard disease measures. Adjusted odds ratio for gestational diabetes and relative risk 
for adverse birth outcomes were estimated by logistic regressions.   
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Results: Fasting plasma glucose had the highest diagnostic validity among all the screening 
and diagnostic tests evaluated. Fasting glucose cut-off ≥5.1 mmol/L threshold had the highest 
clinically relevant sensitivity and specificity but the ≥5.6 mmol/L threshold had higher 
disease prediction. Selective screening using glycosuria, random glucose and risk factors 
missed 97.4%, 87.2% and 45.7% of cases respectively. Using the area under the curve to 
determine the diagnostic accuracy and test performance, fasting and 1-hour postprandial 
glucose tests were found to be very good, random glucose was poor whereas glycated 
hemoglobin was not diagnostically useful. Depending on the diagnostic test and cut-off used, 
5-27% of participants were diagnosed with gestational diabetes. Overall 15.9% met the case 
definition; prevalence per 2-hour postprandial glucose ≥8.5 mmol/L was 9.0% and per fasting 
glucose ≥5.6 mmol/L was 10.8%; 3.9% were positive in both tests. Adjusted risk factors for 
gestational diabetes included high glycemic intake, obesity, previous Cesarean section and 
antenatal care in a primary facility. In terms of outcomes, a unit rise in blood glucose 
significantly increased maternal blood loss and fetal birthweight. Associated adverse birth 
outcomes were perineal tear and birth asphyxia. At 12 weeks postpartum, 30% of the 
diagnosed women did not achieve euglycemia.  
Conclusions and recommendations: Findings show rising gestational diabetes in the general 
population. Selective screening using glycosuria, random glucose and clinical risk factors are 
unnecessary due to their low diagnostic validity. Fasting glucose monitoring need to be 
integrated into all gestational diabetes detection protocols. Cut-off ≥5.1 mmol/L could be 
applicable for screening at the population level but to make therapeutic decision, cut-off ≥5.6 
mmol/L is recommended where 2-hour oral glucose tolerance test is unavailable. Primary 
facilities need strengthening to test and refer cases. Diet and adiposity are key risk factors that 
necessitate lifestyle modifications with focus on nutrition education and weight control. 
Fetuses exposed to hyperglycemia uterine environment require quality obstetric care as birth 
asphyxia which is a key outcome is likely to compromise their survival. Follow-up on women 
diagnosed with gestational diabetes is crucial to avert transition into active diabetes. Cut-off 
values that would balance risks and benefits of adverse pregnancy and long-term outcomes is 
needed for the Ghanaian population. Physiologic interactions between fasting and oral 
glucose tolerance tests need further research. 
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5 ZUSAMMENFASSUNG 
_______________________________________________________ 
Hintergrund: Gestationsdiabetes steigt weltweit an. Studien aus Subsahara-Afrika 
untersuchen die Risikofaktoren; es gibt aber wenig Studien zur Prävalenz und diese basieren 
oft nur auf einem einzigen diagnostischen Test. Es gibt auch kaum Studien zur 
Nachverfolgung post partum. In primären Gesundheitseinrichtungen in Ghana beruht die 
Diagnose Gestationsdiabetes auf einem positiven Glykosurie-Test oder dem Vorhandensein 
klinischer Risikofaktoren. Vermutlich werden aber viele Fälle übersehen, bei denen eine 
aktive Hyperglykämie ohne feststellbare Glykosurie besteht. Trotz kürzlich angepasster 
internationaler Richtlinien für das Screening und die Diagnostik, mit in den meisten Fällen 
gesenkten Grenzwerten, sind die Meinungen bezüglich der Screening-Möglichkeiten nach 
wie vor gespalten zwischen einem universellen Screening aller schwangeren Frauen und 
einem selektiven Screening nach Risikobelastung. Darüber hinaus gibt es unterschiedliche 
Vorschläge für diagnostische Tests und deren Grenzwerte.  
Zielsetzung: Diese Studie wurde durchgeführt, um die folgenden drei Ziele zu erreichen:  
(1) die Validität  von Tests zum Screening und zur Diagnose von Gestationsdiabetes in 
Ghana zu ermitteln,  sowie den Anteil von Fällen einzuschätzen, die bei selektivem 
Screening übersehen werden;  
(2) (2) die Prävalenz von Gestationsdiabetes in Ghana zu ermitteln, sowie Risikofaktoren 
zu identifizieren und  
(3) (3) die kindlichen und mütterlichen Schwangerschaftsergebnisse, einschließlich der 
mütterlichen glykämischen Situation 12 Wochen postpartum zu untersuchen. 
Material und Methoden: Die vorliegende Studie ist eine Kohortenstudie mit eingebetteter 
Fall-Kontroll-Studie die Schwangere während der Schwangerschaft und bis zu 12 Wochen 
post partum einschließt. Nicht-diabetische Frauen mit einer Einlings-Schwangerschaft 
(n=807) wurden in ihrem ersten Trimester in fünf staatlichen Krankenhäusern, welche 
ländliche und halb-städtische Gemeinden in Ghana versorgen, rekrutiert. Sie wurden alle 
zwischen der 13. und 20. Schwangerschaftswoche auf Gestationsdiabetes untersucht, und 
zwar mittels Tests auf Glucosurie und Blutzucker. Ebenso wurde ein klinisches 
Risikoassessment gemacht. Zwischen der 20. und 34. Schwangerschaftswoche, wurden 491 
schwangere Frauen nach dem „single-step“ Verfahren untersucht. Dabei wurden 
glykosyliertes Hämoglobin, Nüchtern-Blutzucker, oraler Glukosebelastungstest 1-Stunden-
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Wert und als „Goldstandard“ der 2-Stunden-Wert erhoben. Ernährungs- und geburtshilfliche 
Anamnesen wurden retrospektiv erhoben und bewertet. Die Falldefinition für 
Gestationsdiabetes lautete: Nüchtern-Blutzucker  ≥ 5,6 mmol/L und/ oder 2-Stunden Wert 
nach oralem Glukosebelastungstest  ≥ 8,5 mmol/L. Von 403 Frauen wurden die 
Geburtsergebnisse erfasst; 100 Frauen aus dieser Gruppe wurden zusätzlich nach 12 Wochen 
postpartum untersucht.  Die adjustierten Odds Ratios für Gestationsdiabetes und für weitere 
Schwangerschaftskomplikationen wurden mittels logistischen Regression ermittelt. 
Ergebnisse: Nüchtern-Blutzucker im Plasma hatte die höchste diagnostische Validität von 
allen getesteten Screening- und Diagnostik-Tests. Nüchtern-Blutzucker-Grenzwerte von ≥5,1 
mmol/L hatte die höchste klinisch relevante Spezifität, aber der Schwellenwert ≥5,6 mmol/L 
hatte einen höheren Krankheitsvorhersagewert. Selektive Screenings, welche mit Testen von 
Glykosurie, spontanen Blutzuckermessungen und Risikoprofilen durchgeführt wurden, 
verfehlten 97,4%, 87,2% beziehungsweise 45,7% der Fälle. Benutzt man die „area under the 
curve“, um die diagnostische Genauigkeit und die Leistung eines Tests zu bestimmen, 
ergaben der Nüchtern-Blutzucker und der 1-Stunde-Wert des Glukosebelastungstests die 
besten Ergebnisse. Spontane Blutzuckermessungen hingegen schnitten schlecht ab, während 
das glykolisierte Hämoglobin diagnostisch nicht brauchbar war. Abhängig davon, welcher 
diagnostische Test und welcher Grenzwert verwendet wurde, ergaben sich Prävalenzen von 
5-27%. Unter Verwendung des eingangs genannten Goldstandards für diese Studie 
(Nüchtern-Blutzucker  ≥ 5,6 mmol/L und/ oder 2-Stunden Wert nach oralem 
Glukosebelastungstest  ≥ 8,5 mmol/L)  ergab sich eine Prävalenz für Gestationsdiabetes von 
15,9%: Die Prävalenz für den 2-Stundenwert des Glukosebelastungstests von  ≥8,5 mmol/L 
war 9,0% und für den Nüchtern-Blutzucker ≥5,6 mmol/L war 10,8%; bei 3,9 % waren beide 
Tests positive. Die Risikofaktoren für Gestationsdiabetes beinhalteten großen Zuckerkonsum, 
Adipositas und vorhergehenden Sectio caesarea. Ein Anstieg der Glukose im Blut um eine 
Einheit hatte einen signifikanten Anstieg des mütterlichen Blutverlusts sowie des 
Geburtsgewichts des Neugeborenen zur Folge. Assoziierte ungünstige Geburtenergebnisse 
beinhalteten perineale Geburtsverletzungen und kindliche Asphyxie. Zwölf Wochen post 
partum hatten 30% der Frauen mit Gestationsdiabetes noch keine Euglykämie erreicht. 
Schlussfolgerung und Empfehlungen: Die Ergebnisse zeigen, dass die Prävalenz des 
Gestationsdiabetes in der Ghana zunimmt. Selektive Screening-Verfahren wie Glykosurie 
und spontane Blutzuckermessung sind wenig valide und unnötig. Die Nüchtern-Blutzucker-
Überwachung sollte jedoch routinemäßig in die Schwangerenvorsorge integriert werden. Die 
Zusammenfassung 
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Nüchtern-Blutzucker-Obergrenze von ≥5,1 mmol/L sollte in Ghana für Screenings der aller 
Schwangeren benutzt werden, um jedoch therapeutische Entscheidungen zu treffen, soll ein 
diagnostischer Grenzwert von ≥5,6 mmol/L gelten, falls kein oraler Glukosetoleranztest 
durchführbar ist. Primäre Gesundheitseinrichtungen sollten beim Screening und in der 
Überweisung von Gestationsdiabetes-Fällen unterstützt werden. Diabetogene Ernährung und 
Adipositas sind Hauptrisiken, welche eine Änderung des Lebensstils benötigen. Der Fokus 
der Beratung sollte in der Ernährung und der Gewichtskontrolle liegen. Feten welche 
intrauterinen Hyperglykämien ausgesetzt waren, brauchen eine spezialisierte Geburtshilfe, da 
Geburts-Asphyxien eine häufige Folge von Gestationsdiabetes sind und diese das 
Sterberisiko erhöhen. Es ist wichtig, Frauen mit Gestationsdiabetes nachzubetreuen, um zu 
verhindern bzw. zu erkennen, ob ein Gestationsdiabetes in einen manifesten Diabetes mellitus 
übergeht. Die spezifische klinische Wertigkeit von erhöhtem Nüchternblutzucker und 
pathologischem oralem Glukosetoleranztest im Kontext der Situation in Ghana sollte weiter 
untersucht werden.  
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8 ANNEX  
_______________________________________________________ 
 
8.1 Data Collection Tools and Questionnaires 
8.1.1 Form 1. Prenatal Data Collection Form  
Interviewer’s name:  
Name of facility:  
Date of Interview:  
 
Section A: Participant Identification 
Client’s study ID no:  
Client’s hospital registration no.  
Name of client:  
Primary phone no:  
Secondary phone no.  
Exact 
Home 
address:  
 
 
 
Common name by which client 
is known in her neighborhood:   
 
After delivery, exactly where do you intend 
to attend postnatal clinic?  
 
After delivery, exactly where do you intend 
to attend child welfare clinic (weighing)? 
 
 
Section B: Socio-Demographic Information (Please tick where appropriate) 
Client’s completed age (years): Date of birth:  
Marital status (1) Married   (2) Cohabitating   
(3) Single   (4) Other (specify):  
Client’s 
highest 
educational 
level  
(0) None  (1) Primary   
(2) Junior high school  (3) Middle school  
(4) Senior high school  (5) Technical/vocational school  
(6) College/Polytechnic   (7) University   
 
 
Client’s 
occupation  
Unemployed   Student   
Housewife  Teacher  
Petty trader  Sales attendant   
Business woman   Micro-finance staff  
Farmer  Banker  
Fisher folk  Civil/public servant  
Hairdresser  Health worker (specify)  
Seamstress    
Others (specify)  Others (specify)  
Partner’s  
highest 
(0) None  (1) Primary   
(2) Junior high school  (3) Middle school  
(4) Senior high school  (5) Technical/vocational school  
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educational 
level 
(6) College/Polytechnic   (7) University   
Partner’s 
occupation  
Unemployed   Student   
Farmer  Teacher  
Fisher man  Health worker  
Driver   Micro-finance staff  
Mechanic   Banker  
Carpenter   Civil/public servant  
Mason   Sales attendant   
Tailor   Security man   
Trader    
Others (specify)  Others (specify)  
Clients 
hometown: 
Name of town: 
 _________________________ 
District: ___________________________ 
Region: ___________________________ 
 
Ethnicity 
(1) Ewe  (2) Akan  
(3) Ga/Ga Ademgbe  (4) Guan   
(5) Northern tribe 
(Specify) ____________ 
 (6) Others (Specify) 
_____________________________ 
 
Religious 
affiliation  
(1) Christian   (2) Moslem  
(3) Other (specify) ________________________________  
Total household size   
Did you plan for this pregnancy  No  Yes  
Are you happy being pregnant? No  Yes  
 
 
Section C: Obstetric History 
Gestational age at first ANC registration   
Gestational age at first contact with field worker   
Date of Last menstrual period  
Expected date of delivery 
(from Last Menstrual Period):  
 Expected date of delivery 
(from ultrasound scan): 
 
Gravida (number of pregnancies): 
 
Parity (number of live births): 
Abortions:___________________ Spontaneous:_________________ Induced:_________ 
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Past Six Pregnancies (including miscarriages and abortions) 
 Child 1 Child 2 Child 3 Child 4 Child 5 Child 6 
Date        
Sex        
Home or 
hospital 
delivery  
      
If hospital, 
specify name  
      
Problems during 
pregnancy  
      
Mode of 
delivery  
      
Live or dead        
Singleton or 
multiple birth  
      
Preterm, term or 
post-term  
      
Birth weight        
Labour 
complications  
      
Postpartum 
complications 
      
Condition of 
child under 5y  
      
 
 
Section D: Medical & Surgical History (Please tick where appropriate) 
Does the client have any of the 
following? 
Does client’s family have any of the 
following? 
If yes, who? 
 No   Yes    No   Yes    
Hypertension    Hypertension     
Heart disease   Heart disease    
Diabetes   Diabetes    
Prior gestational diabetes        
Sickle cell disease    Sickle cell disease     
Asthma   Asthma    
Tuberculosis    Tuberculosis    
Jaundice   Multiple pregnancies     
Epilepsy   Birth defects     
Mental illness   Mental illness    
STIs (specify) 
_________________  
  Renal disease     
Previous operations 
(specify) 
____________________ 
  Others (specify) 
__________________ 
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Section E: Anthropometric Data 
Type Measurement Date  Gest. Age 
(weeks)  
Pre-pregnancy weight (if known) (kg)    
Body weight at at first ANC registration (kg)    
Height at first ANC registration (cm)    
MUAC (cm)    
Pregnancy body weight at 2nd ANC visit     
Pregnancy body weight at 3rd ANC visit     
Pregnancy body weight at 4th ANC visit    
Pregnancy body weight at 5th ANC visit    
Pregnancy body weight at 6th ANC visit    
Pregnancy body weight at 7th ANC visit    
Pregnancy body weight at 8th ANC visit    
Pregnancy body weight at 9th ANC visit    
 
 
Section F: Laboratory Investigations 
Test Result Date Gest. Age (wks)  
Haemoglobin 1    
Haemoglobin 2    
Haemoglobin 3    
Haemoglobin 4    
Hb-Electrophoresis    
G6PD    
Blood group     
Rhesus factor     
Antibody screen     
VDRL/PRP    
HBsAg    
Stool RE    
Urine RE    
HIV status     
For malaria test, indicate whether Rapid Diagnostic Test or Blood Film for Malaria Parasites 
Malaria test 1    
Malaria test 2    
Malaria test 3    
 
 
Lipid profile 
  
Measurement  Result Date Gest. Age (wks)  
Total cholesterol    
Triglycerides    
High density lipoprotein    
Low density lipoprotein    
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Screening & diagnosis tests for gestational diabetes & diabetes in pregnancy 
 
Test 
Result Date Gest.  Age (wks) 
when tested 
At first contact with client  
Urine dipstick test     
Random capillary 
blood glucose  
 
 
  
At the 2nd contact with client, that is between 24 to 32 weeks  
Urine dipstick test    
Fasting capillary 
blood glucose  
 
 
  
Fasting venous 
plasma glucose  
 
 
  
Oral glucose 
tolerance at 1 hour  
 
 
  
Oral glucose 
tolerance at 2 hours 
   
Glycosylated 
haemoglobin 
   
 
 
Ultra sound scan  
 Scan 1 Scan 2 Scan 3 
Date of scan     
Gestational age when scan was taken    
Expected date of delivery (EDD)    
Estimated fetal weight (EFW)    
Crown rump length (CRL)    
Fetal heart rate (FHR)    
Biparietal diameter (BPD)    
Femur length (FL)    
Head circumference (HC)    
Abdominal circumference (AC)    
Occipitofrontal diameter (OFD)    
Humerus length (HL)    
Liquor volume     
Presentation     
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Section G: Food Frequency Questionnaire 
 
 
 
Food 
Groups 
 
 
 
Food Items  
 
Frequency of consumption categories  
Please tick the appropriate response category 
  Monthly Weekly  Daily 
N
ev
er
 
R
a
rely
 
1
 p
er 
m
th
 
2
 p
er 
m
th
 
3
 p
er 
m
th
 
1
 p
er 
w
k
 
2
 p
er 
w
k
 
3
 p
er 
w
k
 
4
 p
er 
w
k
 
5
 p
er 
w
k
 
6
 p
er 
w
k
 
1
 d
a
ily
 
2
  d
a
ily
 
3
+
 
d
a
ily
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 
 
Cereals 
& grains 
Maize products                
Rice products                
Wheat products                
Millet                
Sorghum               
Oats                
Others                 
  
              
 
Roots, 
tubers & 
plantain 
Yam               
Cassava               
Plantain               
Cocoyam               
Potatoes               
Water yam               
Others                 
  
              
 
Legumes
, nuts & 
oily 
seeds 
White beans               
Red beans               
Black beans               
Bambara beans               
Soya beans               
Groundnuts               
Neri               
Agushie               
Dawadawa               
Soy milk               
Tiger nuts               
Cashew nuts                
Palm fruits               
Coconut               
Others                 
                
 
Animal 
source 
foods 
Fish               
Poultry               
Beef               
Goat                
Sheep               
Pork               
grasscutter               
Shellfish               
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Food 
Groups 
 
 
 
Food Items  
 
Frequency of consumption categories  
  Monthly Weekly  Daily 
N
e
v
e
r
 
R
a
r
e
l
y
 
1
 p
e
r
 
m
th
 
2
 p
e
r
 
m
th
 
3
 p
e
r
 
m
th
 
1
 p
e
r
 
w
k
 
2
 p
e
r
 
w
k
 
3
 p
e
r
 
w
k
 
4
 p
e
r
 
w
k
 
5
 p
e
r
 
w
k
 
6
 p
e
r
 
w
k
 
1
 
d
a
ily
 
2
 
d
a
ily
 
3
+
 
d
a
ily
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Animal 
source 
foods 
 
Snail               
Eggs               
Sausage               
Milk               
Yoghurt                
Others                 
  
              
 
 
Green 
leafy 
vegetabl
es 
Kontomire               
Gboma               
Ademe (ayoyo)               
Fotete (aleefu)               
Moringa leaves                
Cassava leaves                
Dandelion 
leave 
              
Spinach                
Lettuce               
Others                
  
              
 
Other 
vegetabl
es 
Tomatoes               
Okra               
Garden eggs               
Onion               
Garlic                
Pepper               
Abedru                
Mushroom               
Green pepper               
Cabbage               
Carrots               
Lettuce                
Green peas               
Cauliflower               
Cucumber               
Others                 
                
 
 
Fruits  
Pawpaw               
Orange                
Banana               
Pineapple               
Mango               
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Food 
Groups 
 
 
 
Food Items  
 
Frequency of consumption categories  
  Monthly Weekly  Daily 
N
e
v
e
r
 
R
a
r
e
l
y
 
1
 p
e
r
 
m
th
 
2
 p
e
r
 
m
th
 
3
 p
e
r
 
m
th
 
1
 p
e
r
 
w
k
 
2
 p
e
r
 
w
k
 
3
 p
e
r
 
w
k
 
4
 p
e
r
 
w
k
 
5
 p
e
r
 
w
k
 
6
 p
e
r
 
w
k
 
 d
a
ily
 
2
  
d
a
ily
 
3
+
 
d
a
ily
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Fruits Water melon               
Apple               
Guava               
Grapes                
Pear               
Others                 
                
 
Fats & 
oils 
Palm oil               
Coconut oil               
Palm kernel oil               
Groundnut oil               
Shea-butter                
Refined 
vegetable oil 
              
Olive oil                
Margarine               
Butter               
                
Miscella
neous 
 
Sweets, sugary 
foods/drinks 
Specific 
_____________ 
              
 Alcohol               
 Cigarette 
smoking 
              
Others                 
 
 
Food taboos, avoidances and cravings Please tick the appropriate response 
Is there any food that is forbidden for you to eat? [0] No  [1] Yes  
If yes, what food(s) is forbidden for you to eat?  
Is there any food you avoid eating as a result of 
your current pregnancy? 
[0] No  [1] Yes  
If yes, what food do you avoid eating as a result 
of this current pregnancy? 
 
Is there any food you eat uncontrollably as a 
result of this pregnancy? 
[0] No  [1] Yes  
If yes, what food(s) do you eat uncontrollably as 
a result of this pregnancy? 
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Section H: Health Education Topics at Antenatal Clinics  
Has client ever been educated on any of the under-listed topics at the ANC during this current 
pregnancy? 
Topic  N Y  If yes, 
how 
many 
times 
Ask client to mention any issues discussed under each 
topic 
Danger signs in 
pregnancy  
   ________________________________________________
________________________________________________
________________________________________________
___________________________ 
Diet, nutrition, 
anaemia, 
deworming  
   ________________________________________________
____________________________________________ 
Hygiene     ________________________________________________
________________________________________________
__________________ 
Rest / exercise     ________________________________________________
________________________________________________
__________________ 
Husband / 
support person 
involvement  
   ________________________________________________
____________________________________________ 
Medications or 
immunizations  
   ________________________________________________
________________________________________________
________________________________________________
___________________________ 
Birth 
preparedness & 
complication 
readiness 
   ________________________________________________
________________________________________________
__________________________________________ 
STI prevention / 
condom use / 
safer sex 
   ________________________________________________
________________________________________________
__________________________________________ 
Voluntary 
counselling & 
testing  
   ________________________________________________
________________________________________________
__________________________________________ 
Mother-to-child 
transmission of 
HIV 
    
________________________________________________
________________________________________________
__________________ 
Labour and 
delivery  
   ________________________________________________
________________________________________________
__________________________________________ 
Baby care    ________________________________________________
________________________________________________
__________________________________________ 
Breastfeeding & 
breast care  
   ________________________________________________
________________________________________________
__________________________________________ 
Family planning 
motivation  
 
 
 
  ________________________________________________
________________________________________________
________________________________________________
___________________________ 
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Promote use of 
insecticide 
treated materials  
   ________________________________________________
________________________________________________
________________________________________________
___________________________ 
Iron folate 
supplementation  
   ________________________________________________
________________________________________________
________________________________________________
___________________________ 
Others  
 
 
 
 
   ________________________________________________
________________________________________________
________________________________________________
________________________________________________
____________________________________ 
 
 
 
Assessment of intake of folic acid 
Are you taking folic acid, multivitamin or mineral supplements during this pregnancy? 
Yes No 
If yes, what are the benefits of taking these drugs? 
_________________________________________
_________________________________________
_________________________________________
_________________________________________
_________________________________________
_________________________________________ 
If no, why are you not taking these drugs? 
_____________________________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________
_____________________________________ 
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Section I: Screening for antepartum depression 
As you are pregnant, we would like to know how you are feeling. Please tick the answer that comes 
closest to how you have felt in the past 7 days, not just how you feel today 
No In the past 7 days:   
 
1. 
 
I have been able to laugh 
and see the funny side of 
things 
(a) As much as I always 
could 
 (b) Not quite so much 
now  
 
(c) Definitely not so much 
now 
 (d) Not at all  
 
 
2.  
I have looked forward with 
enjoyment to things  
(a) As much as I ever did  (b) Rather less than I used 
to  
 
(c) Definitely less than I 
used to 
 (d) Hardly at all  
 
 
3. 
I have blamed myself 
unnecessarily when things 
went wrong         
(a) Yes, most of the time   (b) Yes, some of the time  
(c) Not very often  (d) No, never  
 
 
4. 
I have been anxious or 
worried for no good reason  
(a) No, not at all  (b) Hardly ever  
(c) Yes, sometimes  (d) Yes, very often  
 
 
5. 
I have felt scared or panicky 
for no very good reason  
(a) Yes, quite a lot  (b) Yes, sometimes  
(c) No, not much  (d) No, not at all  
 
6.  
Things have been 
overwhelming me 
 
(a) Yes, most of the time I 
haven’t been able to cope at 
all  
 (b) Yes, sometimes I 
haven’t been coping as 
well as usual 
 
(c) No, most of the time I 
have coped quite well 
 (d) No, I have been 
coping as well as ever 
 
 
7.  I have been so unhappy that 
I have had difficulty 
sleeping  
(a) Yes, most of the time  (b) Yes, sometimes  
(c) Not very often  (d) No, not at all  
 
8. I have felt sad or miserable  (a) Yes, most of the time   (b) Yes, quite often  
(c) Not very often  (d) No, not at all  
 
9. 
I have been so unhappy that 
I have been crying  
(a) Yes, most of the time  (b) Yes, quite often  
(c) Only occasionally  (d) No, never  
 
10. The thought of harming 
myself has occurred to me  
(a) Yes, quite often  (b) Sometimes  
(c) Hardly ever  (d) Never  
 
  
Annex 
123 
 
Section J: Referral to Specialist  
Extract this information from referral records  
Has client been 
referred to see a 
specialist? 
No  Yes  
What type of 
specialist was she 
referred to? 
(tick) 
Obstetrical/gynaecologist  Physician specialist  
General doctor/medical 
assistant  
 Dietician/nutritionist   
Psychiatrist/mental health 
worker 
 Social worker  
Others (specify)  
 
If yes, date of 
referral 
 
  
To which facility 
was she referred? 
 
What is the reason 
for the referral? 
 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
_______________________________________________ 
 
Was client offered 
any treatment? 
No  Yes  
If offered treatment, 
specify treatment 
given?  
 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
____________________________________________ 
Any other 
comments  
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Section K: Participant’s Antenatal Progress Record 
 
No.  
 
Date 
body 
weight 
kg 
BP 
mmHg 
 
Urine 
Gest. 
Age 
(weeks) 
Fundal 
height 
(cm) 
Presen- 
tation 
 
Descent 
Foetal 
Heart 
No. of 
IFA 
given 
Intake of intermittent preventive 
treatment for malaria prevention 
    Protein  Sugar        Dose 1 Dose 2 Dose 3 
1               
2               
3               
4               
5               
6               
7               
8               
9               
10               
11               
12               
13               
15               
16               
17               
 
 
Take pictures of this page or make copies 
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8.1.2 Form 2. Intrapartum Perinatal Data Collection Form  
Name of Midwife:  
Name of hospital:  
Date:  
 
Section A: Participant Identification 
Name of client:  
Primary phone no:  
Home 
address:  
 
 
Date for 6 weeks postnatal 
clinic appointment:  
 
 
 
Section B: Maternal Pregnancy Outcomes 
Tick where appropriate Otherwise, please complete the sections  
Date & time of 
delivery 
Date:  
_____________________________ 
Time: 
________________________ 
 
Cord blood 
sample? 
Laboratory test Results 
Cord blood sample for malaria 
parasite microscopy 
 
Cord blood sample for plasma 
glucose concentrations 
 
Cord blood sample C-peptide test  
 
Placental weight 
(kg) 
                                              
Body weight 
after delivery 
(kg) 
 
 
Mode of delivery 
Spontaneous vaginal delivery  Forceps delivery   
Vaginal delivery with episiotomy   Caesarean section  
Others (specify) _____________ 
___________________________ 
 Others (specify) 
______________________ 
______________________ 
 
If caesarean 
delivery, what 
was the reason? 
 
 
 
 
Labour 
complications 
 
 
 
Labour 
complications 
Was there any labour complications? 
No   Yes   
If yes, what was the complication? 
Prolong labour  Obstructed labour  
Pre-eclampsia   Eclampsia   
Antepartum haemorrhage   Volume of blood 
loss  
______
____ml 
Postpartum haemorrhage   Volume of blood 
loss  
______
____ml 
Others (specify)  Others (specify) 
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___________________________ ________________________ 
Referral Was mother referred to another level facility? 
No   Yes   
 
If referred, what 
was the reason 
for the referral? 
 
 
 
 
 
Maternal death Was there a case of maternal death? 
No   Yes   
If yes, what was 
the cause of 
death? 
 
 
 
 
Referral status:  
 
1. Self-referral   2. Refereed for delivery                  3. Emergency referral  
 
 
Section C: Newborn Assessment   
Tick where appropriate Otherwise, please complete the sections 
Sex  Male:   Female:  
Gestational age at 
delivery (weeks) 
                                                         
 
Newborn 
measurements  
Birth weight   
_____________  Kg  
Birth length   
________ cm  
Head 
circumference  
 
_____________ cm 
Chest 
circumference  
 
_________cm 
 
Mid-upper arm circumference  
 
_____________    mm 
 
Birth outcome  
Live   Still  
If still, indicate whether fresh or lacerated 
Fresh   Lacerated  
APGAR score  At 1 minute: 
 
At 5 minute: 
 
Newborn blood sugar analysis (to be done between 1-2 hours hour after birth) 
Heel prick for blood 
random plasma 
glucose  
Result:  
 
------------------------------------------ mmol/L 
 
 
 
 
Birth injury  
Does newborn have any injury as a result of the delivery process? 
No  Yes  
If yes, specify the exact type of birth injury? 
Should dystocia   Bone fracture  
Specify: 
 
Nerve palsy  
Others (specify)  
 
 Others (specify)    
 
Congenital 
malformation  
Was neonate born with any congenital malformation? 
No  Yes  
Spinal bifida  Cleft lip  
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Down syndrome   Cleft palate   
Heart defect (specify) 
 
 Others (specify)  
 
 
 
Infant feeding   
How long after delivery was breastfeeding initiated? 
Less than 30 minutes   30 minutes to 1 hour   
1 hour to 12 hours   Above 12 hours   
Could newborn breastfeed well?  
No  Yes  
If no, what was the reason? 
 
 
 
In the absence of breastfeeding, how was newborn fed? 
Intravenous feeding  Formula feeding   
Sugar solution   Glucose solution   
Others (specify) 
  
 
If formula feeding, what type of formula was given? 
NAN  SMA  
Lactogen   Other (specify) 
 
 
 
Health 
problems 
Does newborn have any other health problems? 
  No   Yes  
If yes, specify the exact type of health problem: 
 
 
 
 
Has newborn admitted for intensive care? 
No  Yes  
If yes, what is 
the reason for 
admission into 
intensive care? 
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8.1.3 Form 3. Laboratory Form 
Name of lab personnel 
taking the blood sample: 
 
Name of client:  
Date:  Time:   
Client’s study ID no:  Study lab no.    
 
 
 Test  Checklist  Time of specimen 
collection 
 Test  Checklist  
1. Fasting plasma 
glucose  
  
 
_____________ 
5. Blood film for 
malaria 
parasite  
 
2. Oral glucose 
tolerance at 1 hour  
  
 
______________ 
 
6. 
 
Full blood 
count  
 
 
3. Oral glucose 
tolerance at 2 hours  
  
 
_____________ 
 
7. 
 
Lipid profile  
 
 
4. Glycosylated 
haemoglobin 
  
 
_______________ 
 
8. 
 
Ferritin 
 
 
 
________________________________________________________________________________ 
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8.1.4 Form 4. Postpartum/Postnatal Data Collection Form 
Data can be collected at postnatal clinic, child welfare clinic, or in the client’s home at 12 Weeks 
after delivery 
Interviewer’s name:  
Date of interview:  
 
Section A: Participant Identification 
Client’s study ID no:  
Client’s hospital registration no.  
Name of client:  
Primary phone no:  
Secondary phone no.  
Home 
address:  
 
 
 
 
Section B: Maternal Information  
Resting blood 
pressure 
 
Measurement 1 
 
________mmHg 
Take 2nd 
measurement after 
5 minutes  
 
_______
mmHg 
Body 
measurements  
Weight (kg)                    Height (cm)  
Triceps skinfold (mm)  MUAC (cm)  
 
Blood glucose  
Fasting plasma 
glucose 
 
 
Glycosylated 
haemoglobin 
 
 
If she has already eaten, then perform  Random plasma 
glucose 
 
  
Screening for postpartum depression  
As you have recently had a baby, we would like to know how you are feeling. Please tick the 
answer that comes closest to how you have felt in the past 7 days, not just how you feel today 
No In the past 7 days:  
 
1. 
 
I have been able to laugh 
and see the funny side of 
things 
(a) As much as I always 
could 
 (b) Not quite so much now  
(c) Definitely not so much 
now 
 (d) Not at all 
 
 
2.  
I have looked forward with 
enjoyment to things  
(a) As much as I ever did  (b) Rather less than I used 
to  
(c) Definitely less than I 
used to 
 (d) Hardly at all 
 
 
3. 
I have blamed myself 
unnecessarily when things 
went wrong         
(a) Yes, most of the time   (b) Yes, some of the time 
(c) Not very often  (d) No, never 
 
 
4. 
I have been anxious or 
worried for no good reason  
(a) No, not at all  (b) Hardly ever 
(c) Yes, sometimes  (d) Yes, very often 
 
 
5. 
I have felt scared or 
panicky for no very good 
reason  
(a) Yes, quite a lot  (b) Yes, sometimes 
(c) No, not much  (d) No, not at all 
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6.  
Things have been 
overwhelming me 
 
(a) Yes, most of the time I 
haven’t been able to cope 
at all  
 (b) Yes, sometimes I 
haven’t been coping as well 
as usual 
(c) No, most of the time I 
have coped quite well 
 (d) No, I have been coping 
as well as ever 
 
7.  I have been so unhappy 
that I have had difficulty 
sleeping  
(a) Yes, most of the time  (b) Yes, sometimes 
(c) Not very often  (d) No, not at all 
 
8. I have felt sad or miserable  (a) Yes, most of the time   (b) Yes, quite often 
(c) Not very often  (d) No, not at all 
 
9. 
I have been so unhappy 
that I have been crying  
(a) Yes, most of the time  (b) Yes, quite often 
(c) Only occasionally  (d) No, never 
 
10. The thought of harming 
myself has occurred to me  
(a) Yes, quite often  (b) Sometimes 
(c) Hardly ever  (d) Never 
 
 
Section C: Neonatal Information 
Age of neonate (weeks)    
 
 
 
Neonatal 
death  
Is infant alive (ask mother to bring baby for you to see) 
No  Yes  
If neonate is dead, what date did the infant die? 
  
What was the cause of death? 
 
 
 
 End the interview there if infant is dead  
 
Anthropometry 
Body weight  Kg  Baby’s length  cm  
Head 
circumference  
cm Chest circumference  Cm 
Mid-upper arm circumference  _______________________mm 
Blood glucose  Random blood 
glucose 
 
_______________
__ 
Fasting plasma 
glucose  
 
______________
_______ 
 
 
Neonatal 
conditions  
 
According to the mother or from the child health records, did infant suffer from 
any illness?  
No   Yes   
If yes, what was the health problem? 
Sepsis  Pneumonia  
Diarrhoea  Malaria  
Jaundice   Other (specify) 
_________________________________
_________________________________
_________________________________
_____________________ 
In case of jaundice, how 
many days old was baby 
when the jaundice occurred? 
 
 
Physical 
assessment 
Is the infant looking visibly healthy? 
No  Yes  
If no, what is the problem?: 
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Mothers 
opinion of 
child’s health 
status 
Ask mother if she happy with the baby’s health status  
No   Yes   
If yes, what is the problem?: 
 
 
 
 
 
 
 
Breastfeeding 
assessment  
Is baby breastfeeding? 
No  Yes  
If not breastfeeding, what is the reason?: 
 
 
 
 
 
Is baby exclusively breastfeeding? 
No   Yes   
If not exclusively breastfeeding, why?: 
 
 
 
 
 
Immunizations  
Tick the immunizations that the baby has completed 
BCG  OPV 0  
Puemo 1  OPV 1  
Penta 1    
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8.2 Participant Information and Consent 
Title: Gestational Diabetes Mellitus in Volta Region Ghana: Prevalence, Risk Factors 
and Pregnancy Outcomes  
Principal Investigator: Faith Agbozo; MPhil Nutrition, RN, cPHNs 
Principal supervisor:  Prof. Albrecht Jahn; PhD, MD (Obstetrician & Gynaecology 
specialist)  
Address: Institute of Public Health, University of Heidelberg in Germany. 
Mobile: +233 262 156005 ; +49 152 11054 5392 
E-mail: faith.agbozo@uni-heidelberg.de / faagbozo@uhas.edu.gh  
 
Introduction 
My name is Faith Agbozo, a lecturer at the University of Health and Allied Sciences. I am a 
registered nurse and a certified public health nutritionist and currently a doctoral student at 
the Institute of Public Health, University of Heidelberg in Germany under the supervision of 
Prof. Albrecht Jahn, a public health specialist and a medical doctor with specialization in 
obstetrics and gynaecology. I am conducting a research for my doctoral thesis on effect of 
diabetes in pregnancy and maternal nutrition on the health of mother-newborn pair at delivery. 
I want to use this opportunity to enlighten you on the research after which you will decide 
whether or not to participate.  
General information about the research  
Globally, evidence shows that just as the number of people suffering from chronic non-
communicable diseases such as hypertension, diabetes, stroke and cancer is rising, so are 
more cases of diabetes in pregnancy also on the ascendency. Babies born to mothers with 
diabetes in pregnancy receive more sugar from the mother than they ideally need. The primary 
effect is that, the baby may be too large for the age yet the vital organs such as the lungs may 
be immature. Consequently, the baby is likely to have several problems at birth such as 
difficulty breathing, low blood sugar due to detachment of supply from the mother at birth 
and need for intensive care. The mother may experience obstructed or prolonged labour and 
hence may require caesarean delivery. Apart from the risk of maternal and newborn death, 
the mother-child pair may develop diabetes in later years. Proper management has been 
shown to reduce the adverse pregnancy outcomes. But this is possible only when the mother 
is checked for diabetes in pregnancy during antenatal visits using accurate tests. Also, when 
factors that put a mother at risk of diabetes in pregnancy known, then interventions may be 
implemented to prevent or reduce the adverse effects in at risk mothers.  
 
Purpose of the study 
This research is being conducted in the entire Volta region and involves 840 pregnant women 
(and later, their babies) of whom you will potentially be one of them. Findings from this study 
might help in strengthening existing policies to improve maternal and child health in Ghana. 
It will also help policy makers and implementers such as the Ghana Health Service and the 
Ministry of Health to come out with interventions and strategies to prevent and manage 
diabetes in pregnancy which will lead to improvement in maternal and newborn health and 
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invariably reduction in maternal and child mortality not only in the Volta region but Ghana 
at large.  
 
Type of research intervention and expenditure of time  
This research will be conducted in three stages, that is, during your antenatal visits, at delivery 
and six weeks after delivery. If you agree to be part of the study, you will be requested to 
participate in all these three stages. For today, I will take information recorded in your ANC 
booklet and measure your blood glucose levels. During your next ANC visit, you will be 
informed not to eat before coming to ANC because your fasting blood sugar levels will be 
measured. Also, you will be required to do a lab test that will take two hours to complete. 
You will be given some glucose solution to drink. Then your blood sugar levels measured to 
assess how your body will tolerate the glucose drank.  
Although you wouldn’t have eaten overnight to the next morning, you wouldn’t feel too 
hungry because the glucose solution will give your needed energy. During the 2-hour test 
period, we will use the opportunity to enquire about you previous pregnancies (if any) and 
ask you some few questions such as what you usually you eat. By so doing, the time will be 
judiciously used. But as a study participant, you are free to decide whether or not you want 
your left-over blood sample to be stored or discarded after analysis. Instead of using your 
name, a number would be assigned to your blood sample that would be drawn and used for 
lab analysis such that it would be impossible for anyone to identify you with the test results. 
After the stipulated period, the specimen (stored blood sample) would be destroyed by 
incinerator (a burning type of waste disposal used in hospitals).  
During delivery, the midwives, nurses and doctors will keep an eye on the health status of 
you and your baby. Before discharge from the hospital after delivery, you will be informed 
on when to come back to the hospital for the six weeks postnatal visit. There the research 
team will meet you again and assess how you and your baby are doing. In case you are 
diagnosed with diabetes in pregnancy, you and your baby will be visited by the research team 
at the child welfare clinic (weighing) once every three months for 12 month (1 year) to 
monitor the blood sugar levels of you and your baby. You will be eligible to participate if 
only your pregnancy is 24 to 28 weeks old (6-7 months), you intend to deliver in this hospital 
and stay in this study area after delivery. If this is the case, you will be asked to indicate your 
willingness to participate in this study by signing the consent form.   
 
Discomforts/risks 
You would have to do without food 8 to 12 hours after meal the previous night before the lab 
test can be done in the morning. We appreciate how difficult it is for a pregnant woman to go 
without food sometimes. Therefore, the test will be conducted timely. The process of drawing 
blood samples also come with some pain and discomfort. But this is part of routine antenatal 
care and we will try and minimize the discomfort as much as possible. There is a slight risk 
that you may share some personal or confidential information by choice or chance. If at any 
point during the study you feel uncomfortable talking about or answering any question posed 
by the researcher, you may decline to answer. 
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Benefits 
This study will confer both direct and indirect befits to you. Should you be diagnosed with 
diabetes in pregnancy or any other disease, you will be referred to the appropriate specialist 
for treatment. You will be strictly monitored throughout the study period and given special 
attention at all the stages of the projects. On a wider scale, your participation is likely to help 
save lives of many children pregnant women and babies by using the knowledge given in the 
development of strategies that will improve maternal and new-born health. 
 
Voluntary participation and right to leave the research 
Your participation in this research is entirely voluntary. You may choose not to participate or 
leave the study at any time during any of the stages without any penalty, harassment or 
intimidation from the researchers, midwives, nurses or doctors. The choice that you make 
will have no bearing on the medical care that you will receive in this hospital. You can 
withdraw your consent at any time during the study, without specification of reasons and 
without any detriment to your medical care.  
 
Use of data collected after withdrawal  
When you withdraw from the study, the data collected on you will be destroyed if you make 
that intention known to us. Otherwise, we may continue to use your data but only for the 
intended research purpose.  
 
Confidentiality and privacy policy 
Any information you give us will be protected to the best of our ability. We will record your 
name during the interview process. This is to help us address you by your name should we 
contact you or follow-up up on you at the postnatal clinic or in your community if need be. 
However, you will not be named in any reports or documents regarding this study and any 
information about you will be anonymous. Your information will be collected and written 
down for our analysis purposes. It will be stored in a file that will not have your name written 
on it, but a number assigned to it instead. The information that we collect from your will be 
kept private. Your data will be secure from unauthorized access.  
 
Sharing the Results 
As the findings of this research can be useful to provide knowledge on accurate diagnosis of 
diabetes in pregnancy and improve maternal and child health delivery both locally and 
internationally, findings from this study will be disseminated in an aggregated data form with 
clinical staff and policy makers in Ghana. Results will be published in international journals 
and presented at scientific conferences. 
 
Compensation 
There will be no payments, either monetary or non-monetary as result of participation in this 
study. Women coming for the 2-hour laboratory test will be served with breakfast afterwards. 
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The breakfast will consist of hot milo or tea beverage with either meat pie or rock buns and 
boiled eggs. 
Conflict of interest  
We the researchers hereby declare that we do not have any conflict of interest whatsoever 
relating to the study.  
Contacts for additional information 
In case of any pertinent questions about the research, please ask them now for further 
clarification. If later, some issues arise that enquire explanation, feel free to contact Faith 
Agbozo on 0262 165005 or via email on faagbozo@uhas.edu.gh  
 
Your rights as a Participant 
This research has been reviewed and approved by the Ghana Health Service Ethics 
Committee. If you have any questions about your rights as a research participant you can 
contact the Administrator of the Ghana Health Service Ethics Committee, Madam Hannah 
Frimpong on any of the following telephone numbers 0302681109; 0244712919; 
0243235225 or 0507041223. You can also contact her through her email address at 
Hannah.Frimpong@ghsmail.org  
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Informed Consent Form 
Evidence of willingness of volunteer to participate on the study 
“I have read the foregoing information, or it has been read to me.  I have had the opportunity 
to ask questions about it and any question I have asked has been answered to my satisfaction.  
I consent voluntarily to participate as a subject in this study. I understand that I have the right 
to withdraw from the study at any time without it affecting my further medical care in any 
way. I have not waived any of my rights by signing this consent form. Upon signing this 
consent form, I will receive a copy for my personal records”. 
Name of participant: ____________________________            
Signature of participant: _________________________    
Date (Day/month/year): _________________________ 
                                                                      If unable to sign, thumb-print in the space above 
                                                                     
If participant is unable to read, the witness to the consent process should complete this section  
I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.  
A literate witness must sign (if possible, this person should be selected by the woman and should 
have no connection to the research team). Participants who are illiterate should include their 
thumb print as well. 
 
Name of witness: _____________________________          
Signature of witness: __________________________   
Date (Day/month/year): ________________________ 
                                                                                                If unable to sign, thumb-print in the space 
Name of field worker: ___________________________________           
Signature of field worker: ________________________________ 
Date (Day/month/year): _________________________________ 
 
Name of investigator: ___________________________________           
Signature of investigator: ________________________________ 
Date (Day/month/year): _________________________________ 
8.3 Referral and Feedback form 
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______/_______/20_____ 
Referral Letter 
Dear Specialist,   
Madam _____________________________________________ is a participant on our study 
which is primarily aimed to validate the screening and diagnostic tools for GDM, estimate 
prevalence of hyperglycaemia and malnutrition in pregnancy, assess risk factors, determine 
maternal and neonatal pregnancy outcomes associated with the condition and evaluate early 
postpartum glycemic changes and health status of mother-infant pairs. 
In the course of the study, the research team has made the following observations: 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________ 
As a result, we are referring our client to you for advice and management. We kindly request 
that you provide us feedback on treatment provided to her.  
Thank you for your kind cooperation  
 
___________________________ 
Ms Faith Agbozo (Principal Investigator - PhD Student in Public Health with specialization 
in Epidemiology/Biostatistics, and Reproductive/Child Health) 
On behalf of Prof Dr Albrecht Jahn (Academic Supervisor - PhD Public Health; MD, Specialist 
in Obstetrics and Gynaecology; MSc. in Community Health & Health Management; MSc. Biology, 
Dipl. Biol.) 
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Feedback from Specialist 
Name of Client: ____________________________________________________________ 
Folder Number: ____________________________________________________________ 
Name of Facility: ___________________________________________________________ 
__________________________________________________________________________ 
Date: _____________________________________________________________________ 
Primary diagnosis: __________________________________________________________ 
__________________________________________________________________________ 
Secondary diagnosis: ________________________________________________________ 
__________________________________________________________________________ 
Treatment given: ____________________________________________________________ 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________ 
Next Appointment Date (if any): _______________________________________________ 
Any Other Information or Comments: ___________________________________________ 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________ 
 
_______________________________________ 
Signed  
_______________________________________ 
Name of Physician  
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8.4 Supplementary Results 
 
Figure 16. Habitual dietary intakes according to the FAO minimum dietary diversity indicator for women and the frequency of 
consumption  
aEggs and dairy products are two separate groups but added to the fleshy food group due to similarity in nutrient content. bFats/oils is not part of the FAO food list for 
assessing dietary diversity. Dawadawa (African locust bean), agushi (melon seeds), ‘kontomire’ (cocoyam leaves), ‘gboma’ (African eggplant leaves), ayoyo (corchorus 
leaves), fotete (Amaranthus leaves), abedru (Turkey berries) and vegetable oil (includes all types commercially produced). 
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